A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis
Phase: PHASE2
Conditions: Shigella Sonnei Infection
Sponsor: GlaxoSmithKline

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 1 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
 
 
 
CLINICAL STUDY PROTOCOL H03_04TP 
Version 1.0 
 
A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate 
The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The SBVGH 
1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult 
Subjects From A Country Endemic For Shigellosis 
 
 
 
 
 
 
 
 
 
Property of Sclavo Behring Vaccines Institute for Global Health (hereafter referred 
to as SBVGH) 
Confidential 
May not be used, divulged, published or otherwise disclosed without written 
 consent of Sclavo Behring Vaccines Institute for Global Health.

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 2 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
TABLE OF CONTENTS 
TABLE OF CONTENTS ..................................................................................................... 2 
PROTOCOL SYNOPSIS H03_04TP .................................................................................. 8 
LIST OF ABBREVIATIONS ............................................................................................ 23 
1. 
BACKGROUND AND RATIONALE .................................................................... 25 
1.1 
Background .......................................................................................................... 26 
1.2 
Rationale .............................................................................................................. 27 
2. 
OBJECTIVES ........................................................................................................... 28 
2.1 
Primary Objective(s) ............................................................................................ 28 
2.2 
Secondary Objective(s) ........................................................................................ 28 
2.3 
Exploratory Objective(s)...................................................................................... 28 
3. 
STUDY DESIGN ..................................................................................................... 29 
3.1 
Overview of Study Design ................................................................................... 29 
3.2 
Study Period ......................................................................................................... 30 
3.3 
Blinding Procedures ............................................................................................. 30 
3.4 
Data Collection .................................................................................................... 31 
3.4.1  Data Collected from Subjects ....................................................................... 31 
3.4.2  Tools Used for Data Collection .................................................................... 31 
3.5 
Collection of Clinical Specimens ........................................................................ 32 
3.6 
Stopping/Pausing Guidelines ............................................................................... 33 
3.7 
Procedures related to neutropenia ........................................................................ 34 
3.8 
Data Monitoring Committee ................................................................................ 35 
3.9 
Premature Withdrawal from Study ...................................................................... 36 
3.10  End of Study ........................................................................................................ 39 
4. 
SELECTION OF STUDY POPULATION .............................................................. 40 
4.1 
Inclusion Criteria ................................................................................................. 40 
4.2 
Exclusion Criteria ................................................................................................ 40 
4.3 
Criteria for Delay of Vaccination ........................................................................ 42 
5. 
STUDY PROCEDURES .......................................................................................... 43 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 3 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
5.1 
Pre-vaccination Clinic Visit(s) ............................................................................ 43 
5.1.1  Informed Consent/Assent ............................................................................. 43 
5.1.2  Screening ...................................................................................................... 44 
5.1.3  Enrolment ..................................................................................................... 45 
5.1.4  Randomization .............................................................................................. 46 
5.2 
Vaccination Clinic Visit(s) .................................................................................. 46 
5.2.1  Post-vaccination Procedures ......................................................................... 47 
5.2.2  Post-vaccination Reminders ......................................................................... 47 
5.3 
Post-vaccination Visit(s) ...................................................................................... 47 
5.3.1  Follow-up Home Visit(s) .............................................................................. 47 
5.3.2  Follow-up Clinic Visit(s) .............................................................................. 48 
5.3.3  Safety Follow-up Calls ................................................................................. 49 
5.4 
Unscheduled Visits .............................................................................................. 49 
5.5 
Study Termination Visit ...................................................................................... 49 
5.5.1  Early Termination Visit ................................................................................ 50 
6. 
TREATMENT OF SUBJECTS ................................................................................ 52 
6.1 
Study Vaccine(s) .................................................................................................. 52 
6.2 
Non-Study Vaccines ............................................................................................ 53 
6.3 
Vaccine Preparation and Administration ............................................................. 53 
6.4 
Vaccine Administration Error or Overdose of Vaccine....................................... 54 
6.5 
Prior and Concomitant Medications and Vaccines .............................................. 54 
6.6 
Vaccine Supply, Labeling, Storage and Tracking ............................................... 55 
7. 
ASSESSMENTS ...................................................................................................... 57 
7.1 
Safety Assessment ............................................................................................... 57 
7.1.1  Solicited Adverse Events .............................................................................. 57 
7.1.2  Unsolicited Adverse Events .......................................................................... 60 
7.1.3  Evaluation of Adverse Events ...................................................................... 60 
7.1.4  Serious Adverse Events ................................................................................ 62 
7.1.4.1  Adverse Events of Special Interest ........................................................ 63 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 4 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.1.5  Methods for Recording Adverse Events and Serious Adverse Events ......... 64 
7.1.5.1  Post-Study Events .................................................................................. 64 
7.1.6  Pregnancies ................................................................................................... 64 
7.1.7  Safety Laboratory Measurements ................................................................. 65 
7.2 
Efficacy Assessment ............................................................................................ 65 
7.3 
Immunogenicity Assessment ............................................................................... 66 
8. 
STATISTICAL CONSIDERATIONS ..................................................................... 67 
8.1 
Endpoints ............................................................................................................. 67 
8.1.1  Primary Endpoint(s) ...................................................................................... 67 
8.1.1.1  Primary Safety Endpoint(s) ................................................................... 67 
8.1.1.2  Primary Efficacy Endpoint(s) ................................................................ 67 
8.1.1.3  Primary Immunogenicity Endpoint(s) ................................................... 67 
8.1.2  Secondary Endpoint(s) .................................................................................. 67 
8.1.2.1  Secondary Safety Endpoint(s) ............................................................... 67 
8.1.2.2  Secondary Efficacy Endpoint(s) ............................................................ 67 
8.1.2.3  Secondary Immunogenicity Endpoint(s) ............................................... 68 
8.1.3  Exploratory Endpoint(s) ............................................................................... 69 
8.1.3.1  Exploratory Safety Endpoint(s) ............................................................. 69 
8.1.3.2  Exploratory Efficacy Endpoint(s) .......................................................... 69 
8.1.3.3  Exploratory Immunogenicity Endpoint(s) ............................................. 69 
8.2 
Success Criteria ................................................................................................... 69 
8.2.1  Success Criteria for Primary Objective(s) .................................................... 69 
8.2.1.1  Success Criteria for Primary Safety Objective(s) .................................. 69 
8.2.1.2  Success Criteria for Primary Efficacy Objective(s) .............................. 69 
8.2.1.3  Success Criteria for Primary Immunogenicity Objective(s) .................. 69 
8.2.2  Success Criteria for Secondary Objective(s) ................................................ 69 
8.2.2.1  Success Criteria for Secondary Safety Objective(s) .............................. 70 
8.2.2.2  Success Criteria for Secondary Efficacy Objective(s) .......................... 70 
8.2.2.3  Success Criteria for Secondary Immunogenicity Objective(s) .............. 70 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 5 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.3 
Analysis Sets ........................................................................................................ 70 
8.3.1  All Enrolled Set ............................................................................................ 70 
8.3.2  All Exposed Set ............................................................................................ 70 
8.3.3  Safety Set ...................................................................................................... 70 
8.3.4  Full Analysis Set (FAS) Immunogenicity Set .............................................. 71 
8.3.5  Per Protocol (PP) Set Immunogenicity Set ................................................... 71 
8.3.6  Other Analysis Sets....................................................................................... 71 
8.3.7  Subgroups ..................................................................................................... 72 
8.3.8  Protocol Deviations ...................................................................................... 72 
8.4 
Statistical Analysis Plan ...................................................................................... 72 
8.4.1  Analysis of Demographic and Baseline Characteristics ............................... 72 
8.4.2  Analysis of Primary Objective(s) ................................................................. 72 
8.4.2.1  Analysis of Primary Safety Objective(s) ............................................... 72 
8.4.2.1.1 
Analysis of Extent of Exposure ...................................................... 73 
8.4.2.1.2 
Analysis of Solicited Local, Systemic and Other Adverse Events . 73 
8.4.2.1.3 
Analysis of Unsolicited Adverse Events ........................................ 73 
8.4.2.1.4 
Analysis of Safety Laboratory Values ............................................ 74 
8.4.2.2  Analysis of Primary Efficacy Objective(s) ............................................ 74 
8.4.2.2.1 
Statistical Hypotheses ..................................................................... 74 
8.4.2.2.2 
Analysis Sets .................................................................................. 74 
8.4.2.2.3 
Statistical Methods ......................................................................... 75 
8.4.2.3  Analysis of Primary Immunogenicity Objective(s) ............................... 75 
8.4.2.3.1 
Statistical Hypotheses ..................................................................... 75 
8.4.2.3.2 
Analysis Sets .................................................................................. 75 
8.4.2.3.3 
Statistical Methods ......................................................................... 75 
8.4.3  Analysis of Secondary Objective(s) ............................................................. 75 
8.4.3.1  Analysis of Secondary Safety Objective(s) ........................................... 75 
8.4.3.1.1 
Analysis of Extent of Exposure ...................................................... 75 
8.4.3.1.2 
Analysis of Solicited Local, Systemic and Other Adverse Events . 75 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 6 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.4.3.1.3 
Analysis of Unsolicited Adverse Events ........................................ 75 
8.4.3.1.4 
Statistical Hypotheses ..................................................................... 75 
8.4.3.1.5 
Analysis Sets .................................................................................. 76 
8.4.3.1.6 
Statistical Methods ......................................................................... 76 
8.4.3.2  Analysis of Secondary Efficacy Objective(s) ........................................ 76 
8.4.3.2.1 
Statistical Hypotheses ..................................................................... 76 
8.4.3.2.2 
Analysis Sets .................................................................................. 76 
8.4.3.2.3 
Statistical Methods ......................................................................... 76 
8.4.3.3  Analysis of Secondary Immunogenicity Objective(s) ........................... 76 
8.4.3.3.1 
Statistical Hypotheses ..................................................................... 76 
8.4.3.3.2 
Analysis Sets .................................................................................. 76 
8.4.3.3.3 
Statistical Methods ......................................................................... 76 
8.4.4  Analysis of Exploratory Objectives .............................................................. 77 
8.4.4.1  Analysis of Exploratory Safety Objective(s) ......................................... 77 
8.4.4.2  Analysis of Exploratory Efficacy Objective(s) ..................................... 77 
8.4.4.3  Analysis of Exploratory Immunogenicity Objective(s) ......................... 77 
8.5 
Sample Size and Power Considerations of Primary Objectives .......................... 77 
8.6 
Interim Analysis ................................................................................................... 77 
9. 
SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING ...... 78 
9.1 
Source Documentation ......................................................................................... 78 
9.2 
Study Monitoring, Auditing and Source Data Verification ................................. 79 
10. 
DATA MANAGEMENT ......................................................................................... 80 
10.1  Data Entry and Management ............................................................................... 80 
10.2  Data Clarification ................................................................................................. 80 
10.3  Data Protection .................................................................................................... 80 
11. 
RECORD RETENTION .......................................................................................... 81 
12. 
USE OF INFORMATION AND PUBLICATION .................................................. 82 
13. 
ETHICAL CONSIDERATIONS ............................................................................. 83 
13.1  Regulatory and Ethical Compliance .................................................................... 83 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 7 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
13.2  Informed Consent Procedures .............................................................................. 83 
13.3  Responsibilities of the Investigator and IRB/EC ................................................. 84 
13.4  Protocol Amendments ......................................................................................... 85 
14. 
REFERENCE LIST .................................................................................................. 86 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 8 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
PROTOCOL SYNOPSIS H03_04TP 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
Title of Study:  
A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate 
The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The SBVGH 
1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult 
Subjects From A Country Endemic For Shigellosis. 
Study Period:  
Each subject will be followed up for 
approximately 1 month after last 
vaccination.  Following the screening 
period, the total study duration will be 
approximately 2 months for each subject. 
Clinical Phase:  
Phase 2a 
Background and Rationale:  
Shigellosis remains a major health problem in developing countries with approximately 
100 million cases per year mostly in children ≤5 years. Antibiotic resistance of Shigella 
is increasing and no vaccine is currently available against shigellosis. Among the 
Shigella serotypes that are epidemiologically more relevant, the investigators of the 
recently published GEMS study, aimed to identify the main causes of moderate to 
severe diarrhea (MSD) in Africa and Asia (Livio et al., 2014) have concluded that a 
quadrivalent vaccine containing S. sonnei and 3 serotype/subserotypes of S. flexneri (S. 
flexneri 2a, S. flexneri 3a, and S. flexneri 6) can provide broad coverage against Shigella 
serotypes (up to 65%), which cause shigellosis in the developing world, and can also 
provide broad coverage for travelers.  
The SBVGH candidate vaccine against shigellosis caused by Shigella sonnei 
(1790GAHB) has been developed with a novel technology based on high yield 
production of Generalized Modules for Membrane Antigens (GMMA) from S. sonnei. 
GMMA are outer membrane particles naturally released from the S. sonnei during 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 9 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
growth.  
The candidate S. sonnei 1790GAHB vaccine was chosen as a prototype Shigella vaccine 
based on the GMMA technology since S. sonnei is among the most common serotypes 
causing dysentery in humans.  
This SBVGH S. sonnei 1790GAHB vaccine has been tested in two parallel Phase 1 
trials in European adult population: H03_01TP looking at the intramuscular (IM) 
administration and H03_02TP looking at the intradermal (ID), intranasal (IN) and IM 
administration. Based on the preliminary results from these phase 1 studies, it has been 
decided to proceed with further development using only the IM route of immunization 
and to test in the proposed H03_04TP study two doses selected based on the results 
from H03_01TP study.  
The two doses have been selected as follows: 25 µg is the lowest dose that in phase 1 
consistently induced antibody titers comparable to antibodies in a population of 
convalescent subjects after natural infection while 100 µg is tested for two reasons i.e.1) 
a higher dosage may be needed to induce high antibody titers in endemic population and 
2) there is a need to test in African populations the tolerability of  a higher dose of 
GMMA that will be ultimately needed  in the multivalent vaccine against Shigellosis. 
The purpose of H03_04TP study is to evaluate the safety and the immunogenicity of 
two different doses (25 µg and 100 µg) of the SBVGH S. sonnei 1790GAHB vaccine in 
healthy adults and represents the first step towards testing of the GMMA vaccine in the 
vaccine target population of children from developing countries where shigellosis is 
endemic. 
Study Objectives:  
Primary Objective:  
To evaluate the safety profile of two injections of S. sonnei 1790GAHB vaccine in 
healthy adults in a Shigella endemic country 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 10 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
Secondary Objective:  
To evaluate the immunogenicity profile of two injections of S. sonnei 1790GAHB 
vaccine in healthy adults by measuring the anti-LPS S. sonnei serum IgG. 
Study Design:  
This is a phase 2a, randomized, controlled, single center, observer blind trial that will 
enroll approximately 72 healthy adult subjects, 18-45 years of age inclusive. 
As currently there is no vaccine available against shigellosis, the safety of the 
1790GAHB vaccine will be evaluated against two licensed control vaccines: one dose 
of Menveo as 1st injection and one dose of Boostrix as 2nd injection.  
Subjects will be randomized to one of the three parallel treatment arms in a 1:1:1 ratio 
to receive either the study vaccine dose A (25 µg), the study vaccine dose B (100 µg) or 
the control vaccines as follows: 
Table 1 Overview of the Study Groups 
 
No. Subjects 
Group A (25 µg) 
24 
Group B (100 µg) 
24 
Group C (Control) 
24 
Total 
72 
Two injections of the study vaccine or the two control vaccines will be administered 28 
days apart.  
The study includes a screening visit (performed at study Days -28/-1), five Clinical 
Visits (performed at study Day 1, 7, and 28 days after 1st injection and 7 and 28 days 
after 2nd injection) and daily home visits performed for 6 days after the 1st and 2nd 
injection. 
During the screening period before 1st vaccination, subjects providing informed consent 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 11 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
will be screened for general health status.  
Blood (approximately 10 mL) will be drawn from all subjects before the first injection 
(visit 1), 28 days after the first injection (visit 3), and 28 days after the second injection 
(visit 5) for immunogenicity evaluation. 
Appropriately trained study staff will be instructed to complete the subject’s diary card 
during daily home visits following discussion with the subject to (i) describe solicited 
local (i.e. injection site erythema, induration and pain) and systemic (i.e. fever 
[temperature ≥ 38.0°C measured axillary], fatigue, malaise, myalgia, chills, arthralgia 
and headache) adverse events (AEs) occurring during the day of each injection visit 
(visit 1 and 3) and for the following 6 days; (ii) indicate if any analgesic/antipyretic to 
prevent or treat pain/fever was taken after injection.  
In addition to the solicited adverse events data, from study visit 1 through visit 5 (i.e. 
study termination visit) any unsolicited AE, all serious adverse events (SAEs), all AEs 
leading to vaccine/study withdrawal, all Adverse Events of Special Interest (AESI, see 
below) and all concomitant medications associated with those events, will be collected 
and recorded in the subject's source document and on an Adverse Events CRF(s). In 
case of such events, subjects will be instructed to contact the site as soon as possible to 
report the event(s).  
Reactive arthritis will be collected and analyzed as an AESI for this study.  
Number of Subjects planned:  
A total of 24 subjects per group will be enrolled in each of the three study groups in 
order to have 20 evaluable subjects in each group. This allows for a drop-out rate of 
15% during the course of the trial. Thus a total of approximately 72 subjects will be 
enrolled in the trial.  
Study Population and Subject Characteristics:  
Subjects, who meet all inclusion criteria and none of the exclusion criteria (refer to 
section 4. Selection Of Study Population), will be eligible for enrollment. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 12 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
Study Procedures: 
Before any study procedure is performed, informed consent will be obtained and 
subjects will be enrolled only after their eligibility for participation is confirmed by the 
investigator.  
Study will be explained in either Swahili or in English where prospective participants 
express a preference.  For subjects who are illiterate the whole informed consent 
document will be explained in the presence of an impartial witness.   
For all women of childbearing potential the screening will include the evaluation of 
human chorionic gonadotropin (hCG) in blood to exclude pregnancy and women 
refusing to perform the test or with positive test will be immediately excluded from the 
study. Informed consent process will include counseling about pregnancy and family 
planning. hCG in urine will then be evaluated (using a dipstick) at visit 1 before 
randomization; it will be repeated on visit 3 before 2nd vaccination and on the day of the 
last study visit (visit 5). The pregnancy test should be negative prior to each injection. 
All pregnancies that occur during the study will be recorded into the Pregnancy CRF 
appropriate pages and followed until delivery or abortion, as applicable. 
Female subjects of child-bearing potential must use acceptable birth control measures 
(defined as oral, injected or implantable contraceptives) for the two months preceding 
1st vaccination and during entire study participation.  
Vaccination Procedure: Subjects will receive the study vaccines at study Day 1 (visit 1) 
and at study Day 29 (visit 3) in accordance with group assignment in a blinded fashion. 
Vaccines should be administered by unblinded study personnel by deep IM injection 
into the deltoid area of the non-dominant arm unless there is a reason to vaccinate 
elsewhere which should be documented. After receiving the vaccination, subjects will 
be observed for at least 1 hour for any immediate reactions.  
Procedure for collection of solicited AE: appropriately trained study staff will record 
solicited local and systemic adverse events and medications/vaccinations taken/received 
by the subject into a Diary Card and following discussion with the subject. Beginning in 
the evening  following study vaccine administration (approximately 6 hours), and daily 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 13 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
thereafter through the following 6 days, solicited local and systemic adverse events 
including other reactions (i.e. body temperature measurements and use of 
analgesics/antipyretics) will be reported daily by field workers on a Diary Card. For this 
purpose daily home visits will be performed for 6 days after each injection and a 
consultation at the vaccination clinic will be performed at 7 days after each injection 
(clinic Visits 2 and 4). 
Any unsolicited AE occurring during the day of injection with study vaccines and for 
the following 28 days, solicited local and systemic AE that continue beyond 7 days after 
study vaccination, all SAEs, AEs leading to vaccine/ study withdrawal, AESI and 
concomitant medications associated with those events will be collected and recorded 
from Visit 1 to Visit 5 in the subject's records and on the Adverse Events CRF. The 
information obtained by study personnel will be recorded on the appropriate web based 
system, referred to as Electronic Data Capture (EDC). 
Safety procedures: All subjects providing informed consent will undergo a general 
physical examination at the screening visit (study Day -28/-1) and at visit 1 (Day 1) for 
evaluation of the general health status by clinical assessment, verification of inclusion 
and exclusion criteria and review of medical history. On visit 3, prior to 2nd injection 
with the investigational vaccine or control, subjects will be assessed for continued 
eligibility with regard to the inclusion and exclusion criteria and physical examination. 
A brief symptom-directed physical examination (if necessary according to symptoms 
the subject has reported) will be performed at Clinic visits 2, 4 and 5.  
Blood Draw Procedure: Approximately 10 mL of blood will be obtained as part of the 
initial screening for hematology, renal, and liver function tests, and serological tests for 
hepatitis B and HIV. In addition, an analysis of the urine will be performed. Each 
randomized subject will have 10 mL of blood drawn before the 1st and 2nd vaccination, 
and 28 days after the 2nd vaccination for immunological studies. Additional blood draws 
of 10 mL for hematology, renal and liver panels will be obtained 7 and 28 days after 1st 
and 2nd vaccination, urinalysis will be conducted at the same time points. 
All subjects will undergo study termination procedures on visit 5 (28 days after 2nd 
injection visit). 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 14 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
Study Vaccines:  
SBVGH S. sonnei (1790GAHB) vaccine 
The investigational agent is the SBVGH S. sonnei vaccine. The vaccine consists of S. 
sonnei 1790-GMMA (approximately 200 µg/mL, measured by protein content) 
adsorbed to Alhydrogel (0.7 mg Al3+/mL) in Tris-buffered saline. The vaccine does not 
contain any preservative and is available as a liquid formulation in single dose vials 
with 0.7 mL of injectable solution containing approximately 140 µg of GMMA (as 
protein content), adsorbed onto 0.49 mg Al3+.  
The vaccine will be used at two different antigen doses obtained by bed-side mixing. 
Following dilution with Alhdyrogel (0.7 mg Al3+/mL) in Tris–buffered saline, the 
volume administered will be 0.5 mL for both doses: 
Group A: Each 0.5 mL dose of 1790GAHB will contain approximately 25 μg of 
GMMA total protein and 0.35 mg of Al3+.  
Group B: Each 0.5 mL dose of 1790GAHB will contain approximately 100 μg of 
GMMA total protein and 0.35 mg of Al3+.  
Control vaccines 
Menveo: vaccine indicated for active immunization to prevent invasive meningococcal 
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. The vaccine 
contains no preservative or adjuvant. Each 0.5 mL dose of vaccine contains 10 μg 
MenA oligosaccharide, 5 μg of each of MenC, MenY and MenW-135 oligosaccharides 
conjugated to 32.7 to 64.1 μg of CRM197 protein. 
Boostrix: Vaccine indicated for active booster immunization against tetanus, diphtheria, 
and pertussis. It contains tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis antigens (inactivated pertussis toxin [PT], formaldehyde-treated filamentous 
hemagglutinin [FHA] and pertactin). Each antigen is individually adsorbed onto 
aluminum hydroxide.  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 15 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
No other concomitant vaccines or treatments will be used as part of study procedures. 
Primary Endpoint(s):  
The safety profile of the two injections of the investigational vaccine and control(s) will 
be assessed through measurement of the following:  
a. Number and percentage of subjects with solicited local and systemic adverse 
reactions during 7 days following each vaccination. 
b. Numbers and percentage of subjects with deviations from normal ranges of safety 
laboratory data after each vaccination.  
c. Number and percentage of subjects with reported unsolicited adverse events during 
28 days following each vaccination.  
d. Number and percentage of subjects with reported SAEs throughout the study 
duration. 
e. Number and percentage of subjects with reported reactive arthritis (AESIs). 
Secondary Endpoint(s):  
The measures of the immunogenicity outcome, (i.e., the anti-LPS S. sonnei serum IgG), 
will include: 
a. IgG geometric mean concentrations (GMCs) pre-vaccination (Day 1), 28 days after 
1st vaccination and 28 days after 2nd vaccination, as determined by Enzyme-linked 
Immunosorbent Assay (ELISA), and applicable geometric mean ratios between post- 
and pre-vaccination samples. 
b. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination 
Seroresponse is aimed to define a significant increase in post vaccination samples based 
on the biological performance of this specific serology assay and it is defined as:  
- 
If the baseline value is greater than 50 ELISA Units (EU) then an increase of at 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 16 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
least 50% in the post-vaccination sample as compared to baseline [i.e. ((Post-vac 
minus baseline)/baseline)100% ≥ 50%] 
- 
If the baseline value is less or equal to 50 EU then an increase of at least 25 EU in 
the post-vaccination sample as compared to baseline [i.e. (post-vac minus baseline) 
≥ 25 EU] 
c. Number and percentage of subjects with titers post vaccination concentration ≥ 121 
for anti-LPS S. sonnei at 28 days after 1st vaccination and 28 days after 2nd vaccination 
d. IgG GMCs pre-vaccination (Day 1), 28 days after 1st vaccination and 28 days after 
2nd vaccination by antibody titer at baseline (i.e., above vs. below the assay detection 
limit), as determined by ELISA, and applicable geometric mean ratios between post- 
and pre-vaccination samples. 
e. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination by antibody titer at baseline 
(i.e., above vs. below the assay detection limit).  
A post vaccination concentration ≥ 121 anti-LPS serum IgG units in the SBVGH ELISA 
corresponds to a titer of 1:800 in the ELISA method used by Cohen et al. (1989 J. Clin. 
Microbiol. 27:162). This antibody level is the median antibody concentration of a set of 
87 convalescent subjects previously infected by S. sonnei. The value of 121 anti-LPS 
serum IgG units in the SBVGH ELISA was determined by calibration against the Cohen 
ELISA (i.e., the SBVGH standard serum was tested in Cohen’s lab using the Cohen’s 
methodology). 
Exploratory endpoints 
Other assays, including serum secretory IgA, might be done to further characterize the 
immune response to the study vaccine. 
Statistical Analyses:  
This Phase 2a safety and immunogenicity study is aimed to descriptively evaluate the 
safety and immunogenicity profiles of the study vaccines. No specific hypotheses are 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 17 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
Sclavo Behring 
Vaccines Institute 
for Global Health 
(SBVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
tested in this trial. A total of 72 subjects will be enrolled in this study: 24 subjects per 
group will be enrolled in order to have 20 evaluable subjects in each group (15% drop-
out rate). With 20 evaluable subjects in each vaccine group, the probability of observing 
at least one adverse event per group is 87%, if the actual rate of the event is 10%.  
Interim Analysis:  
No interim analysis will be performed. 
Data Monitoring Committee:  
An independent data safety monitoring board (DSMB) will receive a summary of all 
safety data (solicited local and systemic AE, unsolicited AE and SAEs) and listings of 
clinically significant modifications in hematology, blood chemistry and urine 
dipstick/urinalysis test values obtained during one week follow-up post-first vaccination 
of the initial 18 subjects. Further recruitment will be put on hold until the DSMB 
opinion is received.  
Throughout the entire study the DSMB will be consulted for any safety issue that might 
be reported during the trial. 
See section 3.8 of the protocol for more details. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 18 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Table 2 
Time and Events Table 
Study Periods 
Screening 
Treatment 
Visit Type 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Visit Number 
n/a 
1 
Daily for 6 
days 
2 
3 
Daily for 6 days 
4 
5 
Study Day* 
n/a 
1 
 
V1+7 
V1+28 
 
V3+7 
V3+28 
Time Window (days) (min/max) 
-28/-1 
0 
0 
0/+1 
0/+7 
0 
0/+1 
0/+7 
Study Event 
References 
 
Study Treatment 
Vaccination  
Section 5.2 
 
X 
 
 
X 
 
 
 
Screening and Safety 
Informed Consent[a] 
Section 5.1.1 
X 
 
 
 
 
 
 
 
Medical History 
Section 5.1.2 
X 
 
 
 
 
 
 
 
Physical Examination[b] 
Sections 5.1.2 and 5.3.1 
X 
X 
 
X 
X 
 
X 
X 
Pregnancy Test  
Sections 5.5.2 and 5.1.2 
X 
(blood) 
X 
(urine) 
 
 
X 
(urine) 
 
 
X 
(urine) 
Inclusion/Exclusion Criteria[c] 
Section 4.0 
X 
X 
 
 
X 
 
 
 
Randomization 
Section 5.1.4 
 
X 
 
 
 
 
 
 
Blood draw for Serology for HIV, 
HBV 
Section 5.1.2 
X 
 
 
 
 
 
 
 
Safety blood draw[d] 
Sections 3.5 and 5.1.2 
X 
 
 
X 
X 
 
X 
X 
Urine dipstick (urinalysis as 
required) 
Sections 3.5 and 5.1.2 
X 
 
 
X 
X 
 
X 
X 
Post Injection Assessment[e] 
Sections 5.1.2 
 
X 
 
 
X 
 
 
 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 19 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Study Periods 
Screening 
Treatment 
Visit Type 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Visit Number 
n/a 
1 
Daily for 6 
days 
2 
3 
Daily for 6 days 
4 
5 
Study Day* 
n/a 
1 
 
V1+7 
V1+28 
 
V3+7 
V3+28 
Time Window (days) (min/max) 
-28/-1 
0 
0 
0/+1 
0/+7 
0 
0/+1 
0/+7 
Study Event 
References 
 
Post Injection Assessment[f] 
Sections 5.2.1 and 5.3.1 
and 5.3.2 
 
X 
X 
X 
X 
X 
X 
 
Assess all AEs[g] 
Section 7.1 
 
X 
X 
X 
X 
X 
X 
X 
Assess/ Inquire about AE leading 
to withdrawal, all SAE and AESI[h] 
Sections 7.1.4.1 and 
7.1.3 
 
X 
X 
X 
X 
X 
X 
X 
Assess Medications and 
Vaccinations 
Sections 5.1.2 and 6.5 
X 
X 
X 
X 
X 
X 
X 
X 
Study Termination 
Section 5.5 
 
X 
Immunogenicity 
Serology blood draw 
Sections 3.5 and 7.3 
 
X 
 
 
X 
 
 
X 
* Study days should be calculated based on the actual date of the previous visit (as to comply with requested Study Visit Time Window) 
a. 
Informed Consent to be obtained before any study procedure 
b. Physical examination must be performed by a qualified health professional in accordance with local regulations and licensing requirements designated 
within the Site Responsibility Delegation Log.  
c. 
Compliance with Exclusion/Inclusion criteria should be verified.  
d. In case of neutropenia, Complete Blood Count to be repeated on a weekly basis until resolution. If neutropenia occurs at the last study visit, Complete 
Blood Count to be repeated on a regular basis until resolution.  
e. 
A post-injection local and system adverse event and body temperature measurement will be performed approximately 30 and 60 minutes after each 
vaccination during the clinic visit.   

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 20 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
f. 
Beginning in the evening  following study vaccine administration (approximately 6 hours), and daily thereafter through the following 6 days, solicited 
local and systemic adverse events including body temperature measurements and use of analgesics/antipyretics will be reported by field workers in a 
diary card based on subject’s observation and interview.  
g. All unsolicited adverse events will be captured through 28 days following each vaccination.  
h. SAEs, AESI and AEs leading to study or vaccine withdrawal will be collected through entire study duration. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 21 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Table 3  
Safety Tests Table  
HEMATOLOGY 
White Blood Cells (WBC) 
Red Blood Cells (RBC) 
Haemoglobin 
Haematocrit 
Platelets 
Eosinophils 
Basophils 
Neutrophils 
Monocytes 
Lymphocytes 
Prothrombin time* 
CLINICAL CHEMISTRY 
Total bilirubin 
Aspartic Aminotransferase (ASAT/GOT) 
Alanine Aminotransferase (ALAT/GPT) 
γ-Glutamyl Transferase (γ-GT) 
Lactic Dehydrogenase (LDH) 
Alkaline Phosphatase (AP) 
Total Proteins* 
Glucose (random glucose) 
Blood Urea Nitrogen (BUN) 
Creatinine 
Sodium 
Potassium 
SEROLOGY for VIROLOGY 
HbsAg* 
HIV antibodies* 
PREGNANCY TEST 
Human chorionic gonadotropin (hCG) in blood * 
Human chorionic gonadotropin (hCG) in urine 
* Performed at screening only 
 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 22 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
URINE DIPSTICK 
Glucose 
Proteins 
pH 
Ketones 
Nitrites 
Blood 
URINALYSIS: Microscopic test on urine 
(performed if urine dipstick shows deviations from normal values) 
Leucocytes (WBC) 
Erythrocytes (RBC) 
Epithelial Cells 
Casts 
Bacteria 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 23 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
LIST OF ABBREVIATIONS 
AE 
 
Adverse Event
AESI 
 
Adverse Events of Special Interest
AP 
 
(Statistical) Analysis Plan
ANC 
 
Absolute Neutrophil Count
BMI 
 
Body mass index
BUN 
 
Blood Urea Nitrogen 
CBC 
 
Complete Blood Count
CI 
 
Confidence Interval
CRF 
 
Case Report Form
CRO 
 
Contract Research Organization
DSMB 
 
Data Safety Monitoring Board 
EC 
 
Ethics Committee
eCRF 
 
Electronic Case Report Form
EDC 
 
Electronic Data Capture
EDT 
 
Electronic Data Transfer
ELISA 
 
Enzyme-linked Immunosorbent Assay
EMA 
 
European Medicines Agency
FAS 
 
Full Analysis Set
FDA 
 
Food and Drug Administration
GCP 
 
Good Clinical Practices
GMC 
 
Geometric Mean Concentration
GMMA 
 
Generalized Modules for Membrane Antigens 
GMR 
 
Geometric Mean Ratio
GMT 
 
Geometric Mean Titer
HIV 
 
Human Immunodeficiency Virus 
IB 
 
Investigator’s Brochure
ICF 
 
Informed Consent Form
ICH 
 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use
ID 
 
Intradermal 
IM 
 
Intramuscular
IN 
 
Intranasal 
IV 
 
Intravenous 
IRB 
 
Institutional Review Board
ITT 
 
Intention-To-Treat
MITT 
 
Modified Intention-To-Treat
MSD 
 
Moderate to Severe Diarrhea 
LPS 
 
Lipopolysaccharide 
LSLV 
 
Last Subject Last Visit

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 24 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
MedDRA 
 
Medical Dictionary for Regulatory Activities
NOCD 
 
New onsets of chronic diseases 
OAg 
 
O antigen (of Shigella sonnei) 
OMV 
 
Outer Membrane Vesicles 
PO 
 
Per Os (orally) 
PP 
 
Per Protocol
PSB 
 
Product Stewardship Board 
ReA 
 
Reactive arthritis 
SAE 
 
Serious Adverse Event
SBVGH 
 
Sclavo Behring Vaccines Institute for Global Health 
SDA 
 
Source Data Agreement
SOC 
 
System Organ Class
SOP 
 
Standard Operating Procedure
SPC 
 
Summary of Product Characteristics
WHO 
 
World Health Organization

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 25 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
1. 
BACKGROUND AND RATIONALE 
Shigella spp. are Gram-negative bacteria that infect the intestinal epithelium and are 
major causes of diarrhea, including dysentery. Shigella is transmitted by the fecal-oral 
route and taken up by contaminated food or water. It is endemic throughout the world but 
the main burden of disease is in developing countries. In 2009, the World Health 
Organization (WHO) estimated approximately 125 million cases of shigellosis per year in 
Asia alone (Bardhan et al., 2010).  Ninety-nine percent of all cases occur in developing 
countries and approximately 70% in children younger than 5 years of age (Kotloff et al., 
1999). Current estimates of mortality vary between 108,000 worldwide 
(http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index6.html) and 14,000 in Asia where 
previously 80% of all deaths were estimated to occur. Sixteen serotypes (all 14 S. flexneri, 
S. sonnei, and S. dysenteriae type I) are considered to be of global importance (Zhang et 
al., 2011) with Shigella sonnei being the most common serotype worldwide. 
Among the Shigella serotypes that are epidemiologically more relevant, the investigators 
of the recently published GEMS study, aimed to identify the main causes of moderate to 
severe diarrhea (MSD) in Africa and Asia (Livio et al., 2014) have shown that 8 Shigella 
serotypes are approximately responsible for 87% of the disease. However, they concluded 
that a quadrivalent vaccine containing S. sonnei and 3 serotype/subserotypes of S. flexneri 
(S. flexneri 2a, S. flexneri 3a, and S. flexneri 6) can provide a sufficiently broad coverage 
against Shigella serotypes (up to 65%), which cause the majority of endemic pediatric 
shigellosis in the developing world, and can also provide broad coverage for travelers. 
In target populations, treatment options for shigellosis are limited. Shigellosis can be 
treated with appropriate antibiotics. However, antibiotic resistance is increasing and many 
Shigella isolates are resistant to two or more of the common antibiotics ampicillin, 
chloramphenicol, nalidixic acid, co-trimoxasole. Resistance to third generation 
antibiotics, especially ciprofloxacin, has been reported to be emerging (Zhang et al., 
2011). Still effective antibiotics include ceftriaxone that is administered intramuscularly 
or intravenously and is not easily accessible for people in impoverished communities. 
No vaccine is available. Natural infection (experimental infection or vaccination with 
attenuated Shigella), leads to good protective immunity, but despite the generally high 
genetic conservation between serotypes, the protection is highly specific for the infecting 
serotype. This suggests that the dominant protective antigen is the O antigen (OAg) of the 
lipopolysaccharide (LPS). There have been many attempts to make a Shigella vaccine, 
using inactivated whole cell bacteria either orally or parentally (low efficacy, high 
reactogenicity for parenteral), attenuated live oral vaccines (no vaccine has yet obtained a 
useful balance between attenuation and efficacy), recombinant surface proteins (several 
projects at an early stage), O antigen conjugates (Levine et al., 2007). The latter have 
been the most successful to date with a parenteral S. sonnei and S. flexeneri type 2OAg 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 26 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
conjugates tested in field trials in Israel that achieved 74% efficacy in adults (Cohen et al., 
1997) with one immunization and 71% efficacy in children 3 years of age and older with 
2 vaccinations (Passwell et al., 2003, Passwell et al., 2010). No significant efficacy was 
achieved in younger children in accordance with a very low immunogenicity in the young 
children. As expected for an OAg vaccine, this was highly serotype specific and the S. 
sonnei OAg afforded no protection against infection with S. flexneri nor did a S. flexneri 
2a based OAg conjugate protect against S. sonnei. In addition, to achieve broad-spectrum 
protection against the 16 serotypes that are currently considered to be globally important, 
a multivalent OAg-vaccine will be needed. Therefore, new vaccine development 
approaches are needed. 
Sclavo Behring Vaccines Institute for Global Health (SBVGH) candidate vaccine against 
shigellosis caused by Shigella sonnei (1790GAHB) is based on a parenteral vaccine 
targeting the OAg but using a new platform technology called Generalized Modules for 
Membrane Antigens (GMMA) as a novel delivery system which may be applicable also 
for other vaccines against Gram-negative pathogens. GMMA are naturally shed from the 
surface of Gram-negative bacteria and consist of outer membrane proteins, outer 
membrane lipids, including phospholipids and LPS, and enclosed periplasmic proteins 
(Beveridge, 1999). In the previous literature, GMMA are called outer membrane vesicles 
(OMV). However, this term has also been used for vesicles derived by detergent-
extraction of homogenized bacteria which are used as vaccines, e.g. to control Neisseria 
meningitidis type B infections in New Zealand (MeNZB) or other broader coverage 
MenB vaccines (Bexsero). In order to clearly differentiate these different types of 
particles, the name ‘GMMA’ was introduced for the blebs spontaneously released from 
the cell surface (Berlanda Scorza et al., 2012). The natural arrangement of the outer 
membrane is preserved during the release of GMMA and therefore GMMA allow an 
optimal exposure of the antigens of the outer membrane for recognition by the host 
immune system. SBVGH has developed an economic process to purify GMMA in large 
quantities from high density cultures of bacteria genetically modified to increase GMMA 
production and generate a LPS with low endotoxicity, suitable for use in humans. S. 
sonnei was chosen as the proof of concept for the GMMA technology and as a prototype 
Shigella GMMA vaccine since S. sonnei is among the most common serotypes causing 
dysentery in humans.  
A comprehensive review of SBVGH 1790GAHB vaccine is contained in the 
Investigator’s Brochure (IB) supplied by SBVGH; this document should be reviewed 
prior to initiating the study. 
1.1 
Background 
This SBVGH S. sonnei 1790GAHB vaccine has been tested in two Phase 1 trials in 
European adult population: H03_01TP, looking at the intramuscular (IM) administration, 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 27 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
and H03_02TP, looking at the intradermal (ID), intranasal (IN) and IM administration. 
Based on the results from these phase 1 studies, it has been decided to proceed with 
further development using only the IM route of immunization and to test in the proposed 
H03_04TP study two doses selected based on the results from H03_01TP study. The two 
doses have been selected as follows: 25 µg is the lowest dose that in phase 1 induced 
antibody titers comparable to antibodies in a population of convalescent subjects after 
natural infection already after the first vaccination, while 100 µg is tested for two reasons 
i.e.1) a higher dose may be needed to induce high antibody titers in endemic population 
and 2) there is a need to test in African populations the tolerability of a higher dose of 
GMMA that will be ultimately needed in the multivalent vaccine against Shigellosis. 
The proposed H03_04TP trial is the logical continuation of the two Phase 1 studies and is 
aimed to evaluate the safety and immunogenicity profile of 1790GAHB in adults from an 
African country, where shigellosis remains a major health problem.  
The dose regimen tested in phase 1 studies (three doses given 1 month apart) did not 
show any significant benefit from the third dose in terms of immunogenicity, therefore a 
two dose schedule was selected for the current trial. The two dose schedule will allow 
evaluation of the immunogenicity in the endemic population where one dose may be not 
enough to induce the same immunogenicity observed in European population.  
During the two phase 1 trials three subjects of African descent experienced a transient and 
clinically asymptomatic decrease of circulating neutrophils (two episodes were graded as 
severe and one as moderate) that was finally classified as "benign ethnic neutropenia". 
Although this finding was not associated with any clinical illness, some precautionary 
procedures for enrollment and monitoring of trial subjects have been introduced to protect 
the safety of study subjects (refer to Section 3.7, Procedures Related to Neutropenia).  
The trial will be conducted in compliance with the protocol, GCP and applicable 
regulatory requirement(s). 
1.2 
Rationale 
The purpose of H03_04TP study is to evaluate the safety and the immunogenicity of two 
different doses (25 µg and 100 µg) of the SBVGH S. sonnei 1790GAHB vaccine in 
healthy adults in Africa and represents the first step towards testing of the GMMA 
vaccine in the vaccine target population of children from developing countries where 
Shigellosis is endemic. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 28 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2. 
OBJECTIVES 
2.1 
Primary Objective(s) 
Primary Safety Objective(s) 
To evaluate the safety profile of two injections of S. sonnei 1790GAHB vaccine in 
healthy adults in a Shigella endemic country 
2.2 
Secondary Objective(s) 
Secondary Immunogenicity Objective(s) 
To evaluate the immunogenicity profile of two injections of S. sonnei 1790GAHB 
vaccine in healthy adults at 28 days after 1st vaccination and 28 days after 2nd vaccination, 
by measuring the anti-LPS S. sonnei serum IgG. 
2.3 
Exploratory Objective(s) 
This study has no exploratory objectives.

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 29 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
3. 
STUDY DESIGN 
3.1 
Overview of Study Design 
This is a phase 2a, randomized, observer blind, controlled single center study in healthy 
adult women and men healthy volunteers evaluating the safety and immunogenicity of 
two doses of the SBVGH vaccine against Shigella sonnei infections (1790GAHB). As no 
vaccine is currently available against shigellosis, the safety profile of the 1790GAHB 
vaccine will be evaluated in comparison to that of two control vaccines, Menveo as 1st 
vaccination and Boostrix as 2nd vaccination. All subjects and blinded study personnel will 
be blinded to treatment throughout the study.  
This clinical trial has been designed to minimize pain, discomfort, fear and any other 
foreseeable risks. During the screening period, subjects giving informed consent will be 
screened for general health status. No pharmacokinetic tests will be performed as 
evaluation of pharmacokinetic properties is not required for vaccines unless new delivery 
systems are employed or when the vaccine contains novel adjuvants or excipients 
(Berlanda Scorza et al., 2012). Subjects who meet all inclusion criteria and none of the 
exclusion criteria, with screening tests within normal values and women of child bearing 
potential with negative pregnancy test will be eligible for enrollment. Female subjects of 
child bearing potential must use birth control measures during study participation. 
A total of 72 eligible subjects will be assigned to one of the three parallel treatment arms 
in a 1:1:1 ratio to receive either the study vaccine dose A (25 µg), the study vaccine dose 
B (100 µg) or the control vaccines as follows: 
Table 3.1-1 Overview of the Study Groups 
 
No. Subjects 
Group A (25 µg) 
24 
Group B (100 µg) 
24 
Group C (Control) 
24 
Total 
72 
Within each group, in an observer-blind fashion, subjects will be randomized to receive 
two intramuscular vaccinations, four weeks apart.  
Screening/baseline clinical safety labs will take place before Visit 1 (from -28 up to -1 
day). Blood will be obtained as part of the initial screening for hematology, renal, and 
liver function tests, and serological tests for hepatitis B and HIV. In addition, an analysis 
of the urine will be performed. Each randomized subject will have blood collected before 
the 1st and 2nd vaccination, and 28 days after the 2nd vaccination for immunological 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 30 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
testing. Additional blood draws for hematology, renal and liver panels will be obtained 7 
and 28 days after 1st and 2nd vaccination, urine dipstick/urinalysis will be conducted at the 
same time points. All individuals with a neutropenia occurring at any time during the 
study will have additional blood draws to repeat complete blood count on a weekly basis 
until the neutropenia resolves (for classification of neutropenia during the trial, refer to 
Section 3.7, Procedures Related to Neutropenia). 
Subjects will be observed at the clinic for at least 1 hour after each vaccination. In order 
to avoid excluding participants who cannot read and write, safety information (solicited 
local and systemic AE including body temperature measurements and use of 
analgesics/antipyretics) and medications/ vaccinations received beginning in the evening  
following study vaccine administration and daily thereafter through the following 6 days, 
will be recorded by appropriately trained study staff in a Diary Card, following discussion 
with the subject. For this purpose daily home visits will be performed on the day of the 
injection and for 6 days after each injection and a consultation at the vaccination clinic 
will be performed at 7 days after each injection (clinic Visits 2 and 4). 
Any unsolicited AE, serious adverse events (SAEs), all AEs leading to vaccine/study 
withdrawal, and reactive arthritis (adverse event of special interest (AESI)) and all 
concomitant medications associated with those events, will be collected for the entire 
study and recorded in the subject’s source document.  
3.2 
Study Period 
Each subject should expect to participate in the study for 2 months, from the time of 
enrolment through the last study visit. 
3.3 
Blinding Procedures 
The identity of the study vaccine and control cannot be concealed as presentations are 
different. 
Therefore an observer blind study design has been chosen: during the study, designated 
unblinded trained and qualified site staff (please see section 5.3) will be responsible for 
preparing the study vaccine or controls out of view of the subject and an unblinded 
nurse(s) or clinician(s) will be responsible for administering the study vaccines to the 
subjects. The unblinded staff will be instructed not to reveal the identity of the study 
vaccines either to the subject or the other investigative site personnel involved in the 
conduct of the trial. The designated unblinded pharmacists, nurse(s) or clinician(s) will 
not take part in evaluating the subject(s) for safety or collect study data after the 
administration of the study vaccine.  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 31 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Study vaccines allocations will not be available to the investigator or blinded personnel 
monitoring the trial until after the completion of the trial and final data review. Adherence 
to the randomization list will be verified by a designated and unblinded Study Monitor, 
independent of the staff involved in the regular monitoring of the study, by checking the 
randomization list against the vaccination records maintained at the study site. 
Except in the case of medical necessity, a subject’s treatment should not be unblinded 
without the approval of the Sponsor. In such instance of medical emergency, every effort 
should be made to contact the Sponsor prior to unblinding. If unblinding should occur (by 
either accidental unblinding or emergency unblinding for a serious adverse event) prior to 
completion of the study, the investigator must promptly contact the Sponsor and 
document the circumstances on the appropriate forms. Instructions regarding emergency 
unblinding will be provided to the investigator. 
3.4 
Data Collection 
3.4.1 Data Collected from Subjects 
The following data will be collected from each subject over the duration of their study 
participation: 
 Demographic Information. 
 Post-vaccination immediate reactions. 
 Body temperature. 
 Adverse Events. 
 Medical History. 
 Concomitant Medications. 
All data collected must only be identified using the SBVGH Subject ID and Subject code, 
as described in section 5.1.4, Randomization. 
3.4.2 Tools Used for Data Collection 
Data will be recorded in a Subject Diary Card by appropriately trained study staff and 
entered on Case Report Forms (CRFs). 
The subject Diary Card will be the only source document allowed for solicited local and 
systemic adverse events (including body temperature measurements), starting after the 
initial 60 minute post-vaccination period at the clinic. The following additional rules 
apply to documentation of safety information collected in the Diary Card. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 32 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
The Investigator or delegated staff should monitor the Diary Card status throughout the 
study for compliance and any solicited local and systemic adverse events that were of 
concern to the subject. 
1. No corrections or additions to the information recorded by the trained study staff 
within the Diary Card will be allowed after it is delivered to the site. 
2. Any blank or illegible fields on the Diary Card must be described as missing in the 
CRF. 
Case Report Forms 
This study utilizes Case Report Forms (CRFs) to collect study-related data from each 
subject. A qualified site staff member(s) is required to enter subject data in the CRFs in 
English based on the medical information available in each subject’s source record. 
Data should be entered into the CRF in a timely fashion following each subject’s clinic 
visit, study procedure, or home visit. Each subject’s CRF casebook will be compared with 
the subject’s source records by a SBVGH-approved study monitor (or designee) over the 
duration of the study in order to ensure data collection accuracy. 
3.5 
Collection of Clinical Specimens 
The following clinical specimens are required to be collected from each subject in this 
study: 
 Blood 
 Urine 
Blood Specimens 
A maximum of 10 mL of blood will be obtained as part of the initial screening. The blood 
will be used for pregnancy testing in females of child bearing potential and for 
hematology, renal and liver function tests, and serological tests for hepatitis B and HIV in 
all subjects as described in synopsis Table 3, Hematological, Haematochemical Blood 
Tests and Urinalysis Table. The safety laboratory assays will be conducted at the Clinical 
Trials Laboratory, Kilifi, Kenya. 
Each randomized subject will have blood collected before the 1st and 2nd vaccination, and 
28 days after the 2nd vaccination for immunological assays. The blood volume will not 
exceed 10 mL at each time point in order to provide the necessary serum volume 
(approximately half of the blood draw volume) for the serology assays.  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 33 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Serum samples will be stored frozen below -20ºC. Shipment to the laboratories for 
analysis will be performed according to sites guidelines provided by the sponsor. The 
serologic assays will be conducted at the GSK Clinical Serology Laboratory, Marburg, 
(Germany) or a delegated laboratory. 
Complete instructions for processing, labeling, storage and shipping of samples are 
included in the Clinical Specimen Laboratory Manual provided by sponsor and available 
in the Investigator Site File. 
Additional blood draws of 10 mL for hematology, renal and liver function tests will be 
obtained 7 and 28 days after 1st and 2nd vaccination.  
See section 7, Assessments for additional details. 
The total amount of blood collected over the study period (including the screening) per 
subject will be 80 mL. 
Blood samples must be collected in the appropriate manner, using exclusively materials 
and guidelines supplied by the sponsor. The investigator must ensure that his/her 
personnel and the laboratory(ies) under his/her supervision comply with this requirement. 
The results of safety testing will be recorded in the source document and CRF. 
Urine Specimens 
Urine will be collected for urine dipstick/urinalysis as part of the initial screening, before 
the 2nd vaccination, and 7 and 28 days after the 1st and 2nd vaccination. Urine samples will 
be also used for pregnancy testing in females of child bearing potential before the 1st and 
2nd vaccination, and 28 days after the 2nd vaccination.  
The results of urine dipstick/urinalysis will be recorded in the source document and CRF. 
3.6 
Stopping/Pausing Guidelines 
At the end of the 7 days observation period following 1st vaccination of the initial 18 
subjects, a summary of all safety data (solicited local and systemic AE, unsolicited AE 
and SAE), listings of hematology, blood chemistry and urine dipstick/ urinalysis test 
values and respective clinically significant modifications, if any, will be provided to the 
DSMB. Based on evaluation of the safety data, the DSMB will make a recommendation, 
as to whether the enrollment can be completed or not. Additionally, DSMB will make a 
recommendation, as to whether the enrollment of further subjects could be done using the 
published local normal ranges for neutrophils in Africa (Karita et al., 2009) or should 
instead be continued using the western normal ranges adopted for the first 18 subjects. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 34 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Enrollment for the subsequent subjects will be started immediately after DSMB review 
and confirmation in writing. 
During the course of the study, the occurrence of two cases of marked neutropenia (i.e. < 
0.5 x 109/L), or of febrile neutropenia (i.e., ANC <1.0x109/L associated with fever) will 
result in study hold, unblinding of data by DSMB (but not by the investigators in the site), 
discussion of results with safety management team (i.e., Pharmacovigilance) and final 
decision made in consultation with DSMB, IRB and PI. For additional information, 
please refer to Section 3.7, Procedures Related To Neutropenia 
Independent of the DSMB, SBVGH, as a sponsor, retains the right to halt the study at any 
time if there is a safety concern. If the study is prematurely terminated, the sponsor will 
promptly inform Regulatory Authorities and Ethic Committees on the decision of 
stopping the trial and no further enrollment or study immunizations will occur until 
written authorization is provided by the sponsor in conjunction with a recommendation to 
proceed by the DSMB and in consultation with Regulatory Authorities and Ethic 
Committees, as appropriate. 
3.7 
Procedures related to neutropenia 
During the two phase 1 trials with 1790GAHB, three subjects of African descent 
experienced a transient and clinically asymptomatic decrease of circulating neutrophils 
(two graded as severe and one as moderate) that was finally classified as "benign ethnic 
neutropenia". Although this finding was not associated with any clinical illness, some 
precautionary procedures for enrollment and monitoring of trial subjects were introduced 
to protect the safety of study subjects, including selection of subjects with baseline ANC 
above 1.8x109/L.  
In order to maintain a prudent approach, but, at the same time, to not compromise the 
scientific validity of the clinical trial by selecting participants that are not entirely 
representative of the local healthy population ( if non-local laboratory reference intervals 
are used) a step-wise approach will be adopted for the present trial H03_04TP. More 
specifically, same as in Phase 1 trials, the more conservative western normal ranges will 
be adopted for ANC collected up to 7 days after 1st vaccination of the initial 18 subjects. .  
Subsequently, all safety data from these 18 subjects will be evaluated by the DSMB 
which will make a recommendation as to whether the enrollment and assessment of 
neutropenia during the study of further subjects could be done using the local normal 
ranges published for neutrophils (Karita et al., 2009) and for which a consensus interval 
of 1.0 to 5.3x109/L has been reached, or should be continued using the western normal 
ranges adopted for the first 18 subjects. This is also in consideration of the clinically 
benign nature of the events reported in the phase 1 studies and of the documented lower 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 35 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
absolute neutrophils counts in healthy African populations (one of the key targets for this 
vaccine) compared to western populations (Badenhorst et al., 1995, Ezeilo, 1972, Lugada 
et al., 2004),     
Therefore, study procedures will be as follows: 
 First subset of 18 subjects (prior to DSMB evaluation of data): 
Subjects with ANC less than 1.8x109/L at screening will not be enrolled in the study. 
All individuals with ANC <1.8x109/L, occurring at 7 days after the first dose, will 
have additional blood draws for complete blood count to be repeated on a weekly 
basis until the neutropenia resolves (ANC ≥ 1.8x109/L). In case the ANC is less than 
0.5x109/L after 1st vaccination, the subject will be immediately discontinued from 2nd 
vaccination and will have the test repeated on a weekly basis until the neutropenia 
resolves. 
 All subjects (after DSMB evaluation of safety data from the initial 18 subjects with 
recommendation to switch to local normal ranges published for neutrophils): 
Subjects with neutropenia defined as ANC less than 1.0x109/L at screening will not be 
enrolled in the study. All individuals with a neutropenia (ANC <1.0x109/L), occurring 
at any time during the study 7 days after the first dose, will have additional blood 
draws for complete blood count to be repeated on a weekly basis until the neutropenia 
resolves (ANC ≥ 1.0x109/L). In case the ANC is less than 0.5x109/L after 1st 
vaccination, the subject will be immediately discontinued from 2nd vaccination and 
will have the test repeated on a weekly basis until the neutropenia resolves. 
All individuals with neutropenia either ongoing or with onset at visit 5 (or last study visit) 
will have additional blood draws for complete blood count to be repeated on a regular 
basis until the neutropenia resolves (ANC ≥ 1.0 x109/L or ANC ≥ 1.8x109/L, depending 
on recommendations given by DSMB after evaluation of safety data from the initial 18  
subjects).  
3.8 
Data Monitoring Committee 
A DSMB will be in place to receive from SBVGH a summary of all safety data (solicited 
local and systemic AEs, unsolicited AEs and SAEs) and listings of clinically significant 
modifications in hematology, blood chemistry and urine dipstick/ urinalysis test values 
obtained during one week follow-up post-first vaccination of the initial 18 subjects. Based 
on evaluation of the safety data, the DSMB will make a recommendation to SBVGH, as 
to whether the enrollment can be completed or not. Additionally, DSMB will make a 
recommendation to SBVGH, as to whether the enrollment of further subjects could be 
done using the published local normal ranges for neutrophils in Africa (Karita et al., 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 36 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2009) or should instead be continued using the western normal ranges adopted for the 
first 18 subjects. 
In addition to the evaluation of the safety data from the initial 18 subjects, DSMB will be 
consulted for any safety issue that might be reported during the trial. 
The composition of DSMB and the details of all relevant procedures will be documented 
in the DSMB Charter. 
3.9 
Premature Withdrawal from Study 
Subjects may withdraw at any time, or be dropped from the study at the discretion of the 
investigator should any untoward effects occur and/or for safety reasons. In addition, a 
subject may be withdrawn by the investigator or the Sponsor if he/she violates the study 
plan or for administrative reasons. The investigator or study coordinator must notify the 
Sponsor immediately when a subject has been withdrawn due to an adverse event. 
The circumstances above are referred to as premature withdrawal from the study, and the 
reason for premature withdrawal should be clearly documented and detailed in the source 
documentation. The investigator should make every attempt to evaluate the subject’s 
safety, including resolution of ongoing AEs, at the time of premature withdrawal. If a 
subject wants to withdraw from the study before all doses are administered or prior to the 
last planned study visit, the subject will be asked to be followed for safety for the duration 
of the study. When a subject withdraws, or is withdrawn, from the study, the procedures 
described in section 5.5.1, Early Termination Visit should be completed if possible. 
The reasons for premature withdrawal from the study include: Adverse event, death, 
withdrawal of consent, lost to follow-up, administrative reason, and protocol deviation. 
These reasons are described in greater detail below. 
Adverse Event 
For any subject withdrawn from study participation prior to the planned Study 
Termination Visit, it is important to determine if an AE was associated with the reason for 
discontinuing the study. This AE must be identified on the AE CRF page by indicating 
“Withdrawn from study due to AE”. Any ongoing AEs at the time of study withdrawal 
must be followed until resolution or stabilization. 
Subjects who develop a serious adverse event (SAE) judged to be possibly or probably 
related to the study vaccine, including hypersensitivity reactions, should not receive 
subsequent vaccination. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 37 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Death 
For any subject withdrawn from study participation due to death, this should be noted on 
the Study Termination CRF page and the associated SAE that led to the death must be 
reported. 
Withdrawal of consent 
The subject can withdraw consent for participation in the study at any time without 
penalty or loss of benefit to which the subject is otherwise entitled. Reason for early 
termination should be deemed as “withdrawal of consent” if the subject withdraws from 
participation due to a non-medical reason (i.e., reason other than AE). If the subject 
intends to withdraw consent from the study, the investigator should clarify if the subject 
will withdraw completely from the study or if the subject will continue study participation 
for safety, or a subset of other study procedures. If the subject requests complete 
withdrawal from the study, no further study interventions will be performed with the 
subject. 
Lost to Follow-Up 
For subjects who fail to show up for final visits (clinic or home visits), or for three 
consecutive visits, study staff are encouraged to make at least three documented attempts 
to contact the subject to encourage the completion of study termination procedures. These 
efforts to contact the subject should be recorded in the source document. The termination 
date for the subject to be captured on the Study Termination CRF page is the date of the 
last successful contact (clinic visit or home visits) with the subject. 
Administrative Reason 
Examples for subjects withdrawn from the study due to administrative reason can include: 
Sponsor decision to terminate the study, subject meeting a pre-specified withdrawal 
criterion, subject discontinuation for insurance issues, moving, no time, etc. This reason 
should be noted in the Study Termination CRF page and any ongoing AEs at the time of 
study withdrawal must be followed until resolution/stabilization. 
If the clinical study is prematurely terminated by the Sponsor, the investigator is to 
promptly inform the study subjects and local EC/IRB and should assure appropriate 
therapy and follow up for the subjects. All procedures and requirements pertaining to the 
archiving of study documents should be followed. All other study materials (study 
medication/vaccines, etc.) must be returned to the Sponsor. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 38 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
For subjects who are withdrawn from the study due to receipt of an excluded 
medication/vaccination or due to significant protocol non-compliance, this reason should 
be noted in the Study Termination CRF page. 
In studies that involve more than 1 consecutive dose of study vaccine, a separate event is 
“withdrawal of study vaccination”. This event may occur if subjects are expected to 
receive more than 1 consecutive dose of vaccine as part of study participation. The act of 
withholding additional study vaccinations is referred to as withdrawal of study 
vaccination. Subjects may be withdrawn from study vaccination for several reasons 
including but not limited to: AE related to earlier vaccinations, failure to meet inclusion 
or exclusion criteria for revaccination (see section 4.0, Selection Of Study Population), or 
pregnancy. Subjects who are withdrawn from study vaccination should be 
encouraged to continue in the study for safety follow-up and other procedures as 
appropriate until the scheduled termination visit. If the subject is withdrawn from 
study vaccination(s) due to adverse event, this event must be linked to the withdrawal 
from vaccination on the AE CRF page 
Protocol Deviation 
A protocol deviation is any change, divergence, or departure from the study design or 
procedures of a study protocol. In general, subjects associated with protocol deviations 
may remain in the study unless continuation in the study jeopardizes the subject’s health, 
safety, or rights. 
Investigators will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact SBVGH or its agents, if any, monitoring the 
study to request approval of a protocol deviation, as no authorized deviations are 
permitted. If the investigator feels a change to the protocol would improve the conduct of 
the study this must be considered a protocol amendment, and unless such an amendment 
is agreed upon by SBVGH and approved by the IRB/EC and health authorities it cannot 
be implemented.  
Any subject who becomes pregnant during the study, despite the protocol requirement for 
adequate contraception, will not receive further vaccination but should be encouraged to 
continue participating in the study for safety follow-up. The site must complete a paper 
Pregnancy Report CRF (initial report) as soon as possible after learning of pregnancy 
occurrence (see section 7.1.6, Pregnancies for further details). If the subject withdraws 
from the study for any of the above categories except death, the site will obtain 
permission from the subject to continue to remain in contact with her until the outcome of 
the pregnancy is known, even if the outcome is not known until after the subject reaches 
the end of follow-up period. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 39 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Refer to section 3.6, Stopping/Pausing Guidelines and to section 3.7 Procedures related to 
neutropenia for further details in case of neutropenia. 
3.10 
End of Study 
Most clinical trials intended to support the efficacy/immunogenicity and safety of an 
Investigational Product proceed to full completion of planned sample size accrual. 
Evaluation of the primary and/or secondary immunogenicity/efficacy objectives requires 
the testing of biological samples from the study subjects, which can only be completed 
after all samples are collected. The last samples for the analysis of the primary and/or 
secondary objectives will be taken at visit 5. For the purpose of this protocol, end of study 
is defined as the completion of the testing of such biological samples, to be achieved no 
later than 8 months after collection of the last biological sample visit 5. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 40 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
4. 
SELECTION OF STUDY POPULATION 
4.1 
Inclusion Criteria 
1. Individuals ≥18 years to ≤45 years of age on the day of informed consent who are 
resident in the study area and are not planning to leave during the study period. 
2. Individuals who, after the nature of the study has been explained, have voluntarily 
given written consent according to local regulatory requirements, prior to study entry. 
3. Individuals who can comply with study procedures including follow-up1. 
4. Individuals in good health as determined by the outcome of medical history, physical 
examination, hematology, renal function, and liver function tests, urine 
dipstick/urinalysis and the clinical judgment of the investigator.  
5. Males 
Or 
Females of childbearing potential who are using an effective birth control method2 
which they intend to use for the duration of the study 
Or 
Females without childbearing potential (i.e. irrespective of birth control method) 
Prior to receipt of second study vaccination, subjects must be evaluated to confirm that 
they are eligible for subsequent vaccination. If subjects do not meet any of the original 
inclusion criteria listed above, they should not receive additional vaccinations. 
4.2 
Exclusion Criteria 
1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the 
opinion of the investigator, may interfere with the subject's ability to participate in the 
study. 
2. Individuals with any progressive or severe neurological disorder, seizure disorder or 
previous Guillain-Barré syndrome. 
                                                 
1 A subject is considered to be compliant if the Investigator judges that the subject will return for all the 
follow-up visits as scheduled in the study. 
2 The following birth control methods are considered effective: 
- 
Hormonal contraceptive (such as oral, injected or implantable contraceptives) if used for at least 2 
months prior to 1st vaccination 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 41 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
3. Individuals who, in the judgment of the investigator, may not be able to comply with 
all the required study procedures. 
4. Individuals with history of any illness that, in the opinion of the investigator, might 
interfere with the results of the study or pose additional risk to the subjects due to 
participation in the study. 
5. Individuals with history of reactive arthritis. 
6. Individuals with known HIV or hepatitis B virus infection or HIV related disease, 
history of an autoimmune disorder or any other known or suspected impairment 
/alteration of the immune system. Individuals under systemic administration of 
corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to 
screening. 
7. Individuals with a known bleeding diathesis, or any condition that may be associated 
with a prolonged bleeding time. 
8. Individuals with a neutrophil count lower than 1.8 x 109/L (applicable to the initial 18 
subjects) or lower than 1.0 x 109/L (applicable to the additional subjects if approved 
by DSMB) at screening 
9. Individuals with any serious chronic or progressive disease according to judgment of 
the investigator (e.g., neoplasm, insulin dependent diabetes, Type 2 diabetes mellitus, 
hypertension, cardiac, renal or hepatic disease and tuberculosis). 
10. Individuals who have any malignancy or lymphoproliferative disorder. 
11. Individuals with history of allergy to vaccines components or any other allergies 
deemed by the investigator to increase the risk of an adverse event if they were to 
participate in the trial. 
12. Individuals participating in any clinical trial with another investigational product 
within 28 days prior to the screening study visit or intent to participate in another 
clinical study at any time during the conduct of this study. 
13. Individuals who received vaccines containing meningococcal A, C, W, Y or tetanus, 
diphtheria or pertussis antigens within 12 months before screening, or any other 
vaccines within 4 weeks prior to screening in this study or who are planning to receive 
any vaccine within the entire study duration.  
14. Individuals who have received blood, blood products, and/or plasma derivatives 
including parenteral immunoglobulin preparations in the 12 weeks prior to the first 
dose of the study vaccine. 
15. Individuals who are study personnel or immediate family members (parents, children, 
spouse and brothers/sisters) to the personnel conducting this study. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 42 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
16. Individuals with body temperature > 38.0◦C within 3 days of intended study 
vaccination is a reason for delay of vaccination (see section 4.3 Criteria for Delay of 
Vaccination for further details). 
17. Individuals with Body Mass Index (BMI)> 30 kg/m2 
18. Individuals with history of substance or alcohol abuse within the past 2 years. 
19. Women who are pregnant or are breast-feeding, or are of childbearing age who have 
not used (for the two months preceding the 1st vaccination) and are not willing to use 
acceptable contraceptive measures, for the duration of the study. If subjects are 
women of childbearing potential, they must have a negative pregnancy test at 
screening visit and prior to enrollment (visit 1). For the purposes of this study 
acceptable methods of contraception are oral, injected or implantable contraceptives. 
20. Individuals who have a previously laboratory confirmed case of disease caused by S. 
sonnei. 
21. Any condition which, in the opinion of the investigator, may pose an increased and 
unreasonable safety risk to the subject if they participated in the study.  
Prior to receipt of second study vaccination, subjects must be evaluated to confirm that 
they are eligible for subsequent vaccination. If subjects meet any of the original exclusion 
criteria listed above, they should not receive additional vaccinations. 
4.3 
Criteria for Delay of Vaccination 
There may be instances when individuals meet all eligibility criteria for vaccination yet 
have a transient clinical circumstance which may warrant delay of vaccination:  
- body temperature elevation [≥38.0° C (≥ 100.4° F) within 3 days prior to intended 
study vaccination] 
- use of antipyretics and/or analgesic medications within 24 hours prior to 
vaccination.  
- Individuals who have received blood, blood products and/or plasma derivatives or 
any parenteral immunoglobulin preparation in the past 12 weeks. 
Under such circumstances, a subject may be considered eligible for study enrolment after 
the appropriate window for delay has passed and inclusion/exclusion criteria have been 
rechecked, and if the subject is confirmed to be eligible. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 43 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
5. 
STUDY PROCEDURES 
The sections that follow provide an overview of the procedures that are to be followed in 
enrolling, evaluating, and following subjects who participate in this clinical study. Visits 
can be either clinic visits or home visits, as specified in the Table below and in the Time 
and Events Table 2. 
Table 5-1 
Study Procedures 
Visit Category 
Procedures 
Pre-vaccination Clinic Visit(s) 
Section 5.1 describes procedures to be followed prior to study 
vaccination: informed consent, screening, enrolment, and 
randomization 
Vaccination Clinic Visit(s) 
Section 5.2 describes procedures to be followed during each 
clinic visit involving vaccination: vaccination, post-
vaccination procedures, and post-vaccination reminders  
Post-vaccination Visit(s)  
Section 5.3 describes follow-up clinic and home visits 
Unscheduled Visit(s) 
Section 5.4 describes possible procedures to be followed at 
unscheduled clinic visit 
Study Termination Visit 
Section 5.5 describes procedures to be followed at the last 
study visit for a subject (may include early termination visit) 
 
5.1 
Pre-vaccination Clinic Visit(s) 
This section describes the procedures that must be performed for each potential subject 
prior to vaccination, including obtaining informed consent, screening, enrolment and 
randomization. 
5.1.1 Informed Consent/Assent 
"Informed consent" is the voluntary agreement of an individual or his/her legal 
guardian(s) to participate in research. Consent must be given with free will of choice, and 
without undue inducement. The individual must have sufficient knowledge and 
understanding of the nature of the proposed research, the anticipated risks and potential 
benefits, and the requirements of the research to be able to make an informed decision. 
Informed consent following local IRB/EC guidance must be obtained before conducting 
any study-specific procedure (i.e., all of the procedures described in the protocol). The 
process of obtaining informed consent should be documented in the subject source 
document in addition to maintaining a copy of the signed and dated informed consent. 

Scla v o Be hri n g Vacci nes I nstit ute f or Gl o bal Healt h   
Pr ot oc ol H 0 3 _ 0 4 T P 
2 8 J U L 1 5 Versi o n 1. 0 
C o nfi de ntial 
Pa ge 4 4 of 8 7 
P R O- 0 1 T E M P 0 6 / Atlas N o. 2 9 3 6 2 0 
Versi o n N o. 4 / Versi o n Date: Ja n uar y 2 9, 2 0 1 5 
St u d y will be e x plai ne d i n eit her S wa hili or i n E n glis h, w here pr os pecti ve partici pa nts 
e x press a prefere nce. If a s u bj ect is u na ble t o rea d, a n i m pa rtial wit ness s h o ul d be prese nt 
d uri n g t he e ntire i nf or me d c o nse nt disc ussi o n. A n  i m partial wit ness is defi ne d as a pers o n 
w h o is i n de pe n de nt fr o m st u d y c o n d uct, w h o ca n n ot be u nfairl y i nfl ue nce d b y t h ose 
i n v ol ve d wit h t he st u d y, w h o atte n ds t he i nf or me d c o nse nt pr ocess if t he s u bject or t he 
s u bject's le gall y acce pta ble re prese ntati ve ca n n ot rea d, a n d w h o rea ds t he i nf or me d 
c o nse nt f or m a n d a n y ot her writte n i nf or mati o n s u p plie d t o t he s u bject. After t he writte n 
i nf or me d c o nse nt f or m a n d a n y ot her writte n i nf or mati o n t o be pr o vi de d t o s u bjects, is 
rea d a n d e x plai ne d t o t he s u bject a n d after t he s u bject has ver ball y c o nse nte d t o t he 
s u bject’s partici patio n i n t he st u d y a n d, if ca pa ble of d oi n g s o, has si g ne d a n d pers o nall y 
date d t he i nf or me d c o nse nt f or m, t he wit ness s h o ul d si g n a n d pers o nall y date t he c o nse nt 
f or m. B y si g ni n g t he c o nse nt f or m, t he wit ness attests t hat t he i nf or mati o n i n t he c o nse nt 
f or m a n d a n y ot her writte n i nf or mati o n was acc uratel y e x plai ne d t o, a n d a p pare ntl y 
u n derst o o d b y, t he s u bject a n d t hat i nf or me d c o nse nt was freel y gi ve n b y t he s u bject. 
Pre-test c o u nselli n g will be perf or me d f or i n di vi d uals w h o c o nse nt t o HI V testi n g. T h ose 
i n di vi d uals, w h o will be f o u n d t o be HI V p ositi ve, will be als o c o u nselle d p ost-test a n d 
referre d t o t he Mi nistr y of Healt h HI V care ser vices. 
5. 1. 2  Scree ni n g 
After a n i n di vi d ual has c o nse n te d t o partici pate i n t he stu d y a n d i nf or me d c o nse nt is 
si g ne d, t hat i n di vi d ual will be gi ve n a u ni q ue 5- di git Scree ni n g N u m ber (assi g ne d 
se q ue ntiall y b y t he site fr o m  
). T he s u bject’s u ni q ue Scree ni n g N u m ber will be 
d oc u me nte d i n t he Scree ni n g a n d E nr ol me nt l o g. T he eli gi bilit y of t he s u bject will be 
deter mi ne d base d o n t he i ncl usi o n a n d e xcl usi o n criteria liste d i n secti o n 4, Selecti o n of 
St u d y P o p ulati o n
P P D
 a n d e val uate d d uri n g t his scree ni n g pr oce d ure. 
Pri or t o st u d y e nr ol me nt, de m o gra p hic data will be c ollecte d fr o m t he s u bject, i ncl u di n g 
ge n der, race, b o d y mass i n de x. 
Me dical hist or y will als o be c ollecte d, i ncl u d i n g b ut n ot li mite d t o a n y me dical hist or y 
t hat ma y be rele va nt t o s u bject eli gi bilit y f or st u d y partici pati o n s uc h as pri or 
vacci nati o ns, c o nc o mita nt me dicati o ns, a n d pre vi o us a n d o n g oi n g ill nesses or i nj uries. 
Rele va nt me dical hist or y ca n als o i ncl u de a n y me dical hist or y t hat c o ntri b utes t o t he 
u n dersta n di n g of a n a d verse e v e nt t hat occ urs d uri n g st u d y pa rtici pati o n, if it re prese nts 
a n e xacer bati o n of a n u n derl yi n g disease/ pre-e xisti n g pr o ble m. 
Re vie w of s yste ms is a str uct ure d i nter vie w t h at q ueries t he s u bject as t o a n y c o m plai nts 
t he s u bject has e x perie nce d acr oss eac h or ga n s yste m. T his will be perf or me d bef ore 
e nr ol me nt a n d use d t o g ui de p h ysical e xa mi nati o n. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 45 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
If applicable, prior and concomitant medications or vaccinations taken prior to start of 
study should be collected (refer to section 6.5, Prior and Concomitant Medications and 
Vaccines for further details). 
Collect vital signs, heart rate, respiratory rate, blood pressure, and temperature. Measure 
height and weight. 
Perform pregnancy testing in women of childbearing age (refer to section 3.5, Collection 
of Clinical Specimens for guidance regarding the procedure). Informed consent process 
with any women of childbearing potential will include counseling about pregnancy and 
family planning, including discussion of their commitment to practice acceptable birth 
control measures (defined as oral, injected or implantable contraceptives).Women of 
childbearing potential are defined as a post onset of menarche and pre-menopausal female 
capable of becoming pregnant. This does not include females who meet any of the 
following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 
year earlier, (3) total hysterectomy or (4) post bilateral oophorectomy.    
A general physical examination is to be performed by a qualified health care practitioner. 
“Qualified health care practitioner” refers to any licensed health care professional who is 
permitted by national policy to perform physical examinations and who is identified 
within the Study Staff Signature Log. 
These data will be written in the source document (see section 9.1, Source 
Documentation). 
Approximately 10 mL of blood will be drawn from all subjects for the hematology, renal 
and liver function testing, serological tests for HBV and HIV and pregnancy test (Refer to 
section 3.5, Collection of Clinical Specimens and to synopsis Table 3, Hematological, 
Haematochemical Blood Tests and Urinalysis Table). 
In the event that the individual is determined ineligible for study participation, he/she is 
considered a screen failure. The reason for screen failure must be documented in the 
Screening and Enrolment log. If the individual is determined to be eligible for the study, 
he/she will be enrolled into the study. 
5.1.3 Enrolment 
If an individual is determined to be eligible for study participation, the investigator will 
enroll the subject 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 46 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
5.1.4 Randomization 
Enrolled subjects will be randomized and automatically assigned a unique Subject ID. 
The Subject ID will be the subject’s unique identification number for all CRFs and 
associated study documentation that will be used for duration of the study. After 
randomization, the Screening Number ceases to be used and remains in the Screening and 
Enrolment Log only. 
At randomization, the subject will be assigned also a unique subject code. The subject 
code consists of the 2 letters subject’s initials (the 1st letter of the surname name – 
followed by the 1st letter of the 1st name). 
If for any reason, after signing the informed consent form (ICF), the subject who is 
eligible and enrolled fails to be randomized, this is called a randomization failure and the 
early termination study procedures must be applied. The reason for all randomization 
failures should be recorded in the Screening and Enrolment Log and in the source 
document as specified in the Source Data Agreement (SDA). The information on subjects 
who are randomization failures should be kept distinct from subjects who are screen 
failures, as described in section 5.1.2, Screening. 
If for any reason, after randomization the subject fails to undergo treatment, this is an 
Early Termination and the reason should be recorded in source document as specified in 
the SDA. The information on these Early Termination subjects should be kept distinct in 
the source documentation from randomization failures. 
Screening phase will be performed until 72 subjects are randomized and vaccinated. 
Additional subjects may be randomized into the study at the discretion of the sponsor in 
the case of any subject who is randomized but does not receive any study vaccine. 
Subjects withdrawn or lost to follow up will not be replaced. 
5.2 
Vaccination Clinic Visit(s) 
Vaccination will be performed on day 1 and day 29. 
For studies which have visits for concomitant vaccinations or treatments, see section 6.5, 
Prior and Concomitant Medications and Vaccines for those visit procedures. 
Ensure all serology samples are taken prior to each vaccination. 
After completing the pre-vaccination procedures on day 1, administer the vaccine to the 
subject according to the procedures described in section 6.3, Vaccine Preparation and 
Administration. Observe the blinding procedures described in section 3.3, Blinding 
Procedures. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 47 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Prior to administration of each vaccination, confirm that the subject is eligible for 
additional study vaccinations and does not meet any criteria for delaying additional study 
vaccinations as described in section 4, Selection of Study Population. 
5.2.1 Post-vaccination Procedures 
The following post-vaccination procedures will be performed on day 1 and day 29. 
After vaccination, the subject will be observed for at least 1 hour including observation 
for unsolicited adverse events, solicited adverse events, and body temperature 
measurement. Record all safety data collected during this time in the subject’s source 
document. 
The site should schedule the next study activity (daily home visits) with the subject. 
The subject should be reminded of the next planned study activity. The subject will be 
reminded to contact the site if there are any questions, and to contact the site immediately 
(or as soon as the subject is medically stable) if the subject has a medical condition that 
leads to a hospitalization or an emergency room visit or to a visit to/by a doctor or is of 
concern. 
5.2.2 Post-vaccination Reminders  
Not Applicable 
5.3 
Post-vaccination Visit(s) 
5.3.1 Follow-up Home Visit(s) 
Post-vaccination home visits will be performed daily by a field worker from day 1 (6 
hours after vaccination) to day 7 to check solicited local and systemic adverse events and 
medications/vaccinations received, following discussion with the subject. 
A Diary Card collected in person by study personnel will be used in this study to 
document solicited adverse events. The Diary Card is the only source for collection of 
these data; therefore, it is critical that the trained site staff completes the subject’s Diary 
Card correctly. The appropriate site staff should be trained on how and when to complete 
each field of subject’s Diary Card. 
The appropriate site staff should be trained on how to measure local solicited adverse 
events and body temperature. The trained field workers who will perform the home visits 
will be instructed to direct the subject to the clinic if the event requires medical 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 48 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
supervision. The measurement of solicited local adverse events is to be performed using 
the ruler provided by the site. 
The appropriate site staff should be instructed how to perform body temperature 
measurement using the thermometer provided by the site. The temperature recorded in the 
Diary Card will be the one measured by the site staff during point of contact with subject 
at home. 
Appropriate training should be directed at the site staff who will perform the 
measurements of adverse events and who will enter the information into the subject’s 
Diary Card. The identity of the person who will enter the information into the Diary Card 
must be documented in the subject’s source record and in the study delegation log. Any 
individual that makes entries into the Diary Card must receive training on completion of 
the Diary Card. This training must be documented. 
Whenever possible, the same individual should complete the subject’s Diary Card 
throughout the course of the study. 
5.3.2 Follow-up Clinic Visit(s) 
Safety follow-up clinic visits will be performed 7 days after V1 and V3. 
During the follow-up clinic visit, the subject’s source document and Diary Card will be 
reviewed. No changes to the information recorded by the trained study staff within the 
section of the Diary Card are permissible. For details see sections 3.4.2, Tools Used for 
Data Collection and 5.2.1, Post-vaccination Procedures. The subject will be interviewed 
to determine if any unsolicited adverse events occurred and if any concomitant 
medications or vaccines were taken/received in the time since the last clinic visit. This 
interview will follow a script which will facilitate the collection of relevant safety 
information. The healthcare professional reviewing these data will discuss the symptoms 
(if any) reported by the subject and will determine if any additional diagnoses and/or 
adverse events are present. Adverse events reported by the subject at this follow-up clinic 
visit must be recorded in the subject's source document and on an Adverse Events CRF, 
as specified in section 7.1, Safety Assessment, and not written on the script used for the 
interview. 
Perform a brief symptom-directed physical examination if necessary according to 
symptoms the subject has reported. This is a physical examination that will include an 
examination of organ systems that are relevant to the investigator based on review of the 
subject’s reported adverse events, concomitant medication use. This assessment may 
include: measurement of vital signs, body temperature taken axillary and a check of 
general appearance. The physical assessment must be performed by the investigator or 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 49 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
designee of the investigator, who is qualified to perform a physical assessment in 
accordance with their institutional policy. Corresponding information is documented in 
the subject’s source document and CRF(s). 
At this visit blood sample for safety evaluation and urine sample for urine 
dipstick/urinalysis will be obtained as described in section 3.5, Collection of Clinical 
Specimens 
The site should schedule the next study clinic visit with the subject. The subject will 
receive a reminder of the next planned study activity. The subject will be reminded to 
contact the site if there are any questions and to contact the site immediately (or as soon 
as the subject is medically stable) if the subject has a medical condition that leads to a 
hospitalization or an emergency room visit. 
5.3.3 Safety Follow-up Calls 
Not Applicable 
5.4 
Unscheduled Visits 
An unscheduled visit describes a non-routine study visit triggered by a specific event. 
These could include anticipated or unanticipated adverse events or interventions. 
 All individuals with a neutropenia, occurring at any time during the study, will have 
additional blood draws for complete blood count to be repeated on a weekly basis until 
the neutropenia resolves. If neutropenia occurs at the subject’s last study visit, the 
complete blood count will be repeated on a regular basis until resolution. For 
classification of neutropenia during the trial, refer to Section 3.7, Procedures Related To 
Neutropenia. 
5.5 
Study Termination Visit 
The study termination visit 5 will occur 28 days after 2nd vaccination. The termination 
visit may be a clinic visit or a home visit. The date of termination is the date of the last 
contact (clinic visit or home visit) in which the subject’s health status was assessed or, in 
cases where the subject does not agree to any further safety follow-up, it is the date 
consent is withdrawn. This date should be recorded on the termination CRF page. For 
visit procedures to be performed for a subject whose planned study participation ends 
prematurely, please see section 5.5.1, Early Termination Visit. 
At the clinic visit, the following procedures will be performed:  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 50 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
- 
review of subject’s medical records and source document designed to collect 
solicited AE,  
- 
review of systems, interview of subject to collect unsolicited adverse events, 
medically attended adverse events, AEs leading to withdrawal, SAEs, AESIs, and 
new onset of chronic disease,  
- 
interview of subject to collect concomitant medications/vaccinations,  
- 
symptom-directed physical assessment including measurement of vital signs and a 
check of general appearance,  
- 
Blood sampling for immunogenicity and safety laboratory assessment,  
- 
Urine sample for urine dipstick/urinalysis and pregnancy testing. 
All individuals with neutropenia either ongoing or with onset at visit 5 (last study visit) 
will have additional blood draws for complete blood count to be repeated on a regular 
basis until the neutropenia resolves (for classification of neutropenia during the trial, refer 
to Section 3.7, Procedures Related To Neutropenia). Laboratory results obtained after 
study termination will be maintained in subject medical records and not entered in the 
CRF. 
When the clinical study report is completed, the investigators will share the summary 
results with the participating communities. Town hall and village meetings will be held to 
convey the information and to allow for questions and answers.   
The site will complete the termination CRF page and this will mark the completion of the 
subject’s participation in the study. 
5.5.1 Early Termination Visit 
When a subject is withdrawn from treatment or withdraws from the study, the investigator 
will notify the Sponsor and, when possible, will perform the procedures listed below. The 
reason(s) for the early termination will be included in the subject’s source documentation. 
Early Termination Visits include subjects who were randomized but not treated. 
At the clinic visit or during the home visit, the following procedures will be performed (if 
the Early Termination Visit is a home visit, collect as much information as possible):  
- 
review of subject’s medical records, source document and Diary Card,  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 51 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
- 
review of systems, interview of subject to collect unsolicited adverse events, 
medically attended adverse events, AEs leading to withdrawal, SAEs, AESIs, and 
new onset of chronic disease,  
- 
interview of subject to collect concomitant medications/vaccinations,  
- 
symptom-directed physical assessment including measurement of vital signs and a 
check of general appearance,  
- 
blood sampling for safety laboratory assessment (no blood for immunogenicity 
assessment should be obtained unless this is agreed in advance with the sponsor),  
- 
urine sample for urine dipstick/urinalysis and pregnancy testing. 
All individuals with neutropenia either ongoing or with onset at last study visit will have 
additional blood draws for complete blood count to be repeated on a regular basis until 
the neutropenia resolves (for classification of neutropenia during the trial, refer to Section 
3.7, Procedures Related To Neutropenia). Laboratory results obtained after study 
termination will be maintained in subject medical records and not entered in the eCRF. 
The site will complete the termination CRF page and this will mark the completion of the 
subject’s participation in the study. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 52 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
6. 
TREATMENT OF SUBJECTS 
All vaccines associated with this study are to be stored separately from other vaccines and 
medications in a secure location under appropriate storage conditions with temperature 
monitoring. All vaccines associated with this study must be checked for expiration 
date prior to use. Expired vaccines must not be administered to subjects. 
6.1 
Study Vaccine(s) 
The term ‘study vaccine’ refers to those vaccines provided by the Sponsor, which will be 
evaluated as part of the study objectives. The study vaccines specific to this study are 
described below. 
SBVGH S. sonnei (1790GAHB) vaccine 
The investigational agent is the SBVGH S. sonnei vaccine. The vaccine consists of S. 
sonnei 1790-GMMA (approximately 200 µg/mL, measured by protein content) adsorbed 
to Alhydrogel (0.7 mg Al3+/mL) in Tris-buffered saline. The vaccine does not contain any 
preservative and is available as a liquid formulation in single dose vials with 0.7 mL of 
injectable solution containing approximately 140 µg of GMMA (as protein content), 
adsorbed onto 0.49 mg Al3+.  
The vaccine will be used at two different antigen doses obtained by bed-side mixing. 
Following dilution with Alhdyrogel (0.7 mg Al3+/mL) in Tris–buffered saline, the volume 
administered will be 0.5 mL for both doses: 
Group A: Each 0.5 mL dose of 1790GAHB will contain approximately 25 μg of GMMA 
total protein and 0.35 mg of Al3+.  
Group B: Each 0.5 mL dose of 1790GAHB will contain approximately 100 μg of 
GMMA total protein and 0.35 mg of Al3+.  
In each group two vaccinations, 28 days apart, will be administered intramuscularly. 
Bed-side mixing instructions will be provided to the investigator and will be located in 
the investigator site file.  
Control vaccines 
Menveo: vaccine indicated for active immunization to prevent invasive meningococcal 
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. The vaccine 
contains no preservative or adjuvant.  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 53 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Each 0.5 mL dose of vaccine contains 10 μg MenA oligosaccharide, 5 μg of each of 
MenC, MenY and MenW-135 oligosaccharides conjugated to 32.7 to 64.1 μg CRM197 
protein. 
Boostrix: Vaccine indicated for active booster immunization against tetanus, diphtheria, 
and pertussis. It contains tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis 
antigens (inactivated pertussis toxin [PT], formaldehyde-treated filamentous 
hemagglutinin [FHA] and pertactin). Each antigen is individually adsorbed onto 
aluminum hydroxide.  
For both control vaccines, the Summary of Product Characteristics (SPC) will be 
provided to the investigator and will be located in the investigator site file. 
6.2 
Non-Study Vaccines 
The term ‘non-study vaccine’ refers to those vaccines which will be intentionally given to 
study subjects but not formally included in the analysis of study objectives.  
This protocol does not foresee the use of non-study vaccines. 
6.3 
Vaccine Preparation and Administration 
The investigator or designee will be responsible for oversight of the administration of 
vaccine to subjects enrolled in the study according to the procedures stipulated in this 
study protocol. All vaccines will be administered only by unblinded personnel who are 
qualified to perform that function under applicable local laws and regulations for the 
specific study site. 
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING STUDY VACCINE: 
Prior to vaccination, subjects must be determined to be eligible for study vaccination and 
it must be clinically appropriate in the judgment of the investigator to vaccinate. 
Eligibility for vaccination prior to first study vaccine administration is determined by 
evaluating the entry criteria outlined in protocol sections 4.1, Inclusion Criteria and 4.2, 
Exclusion Criteria. 
Eligibility for subsequent study vaccination is determined by following the criteria 
outlined in section 4.3, Criteria for Delay of Vaccination. 
Study vaccines should not be administered to individuals with known hypersensitivity to 
any component of the vaccines. Standard immunization practices are to be observed and 
care should be taken to administer the injection intramuscularly. Before administering 
vaccine, the vaccination site is to be disinfected with a skin disinfectant (e.g., 70% 
alcohol). Allow the skin to dry. DO NOT inject intravascularly. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 54 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
As with all injectable vaccines, trained medical personnel and appropriate medical 
treatment should be readily available in case of anaphylactic reactions following vaccine 
administration. For example, epinephrine 1:1000, diphenhydramine, and/or other 
medications for treating anaphylaxis should be available. 
6.4 
Vaccine Administration Error or Overdose of Vaccine 
Vaccine administration error is defined as receiving a dose of study vaccine that was not 
reconstituted as instructed or administered by a different route from the intended route of 
administration. An overdose of study vaccine (whether accidental or intentional) is 
defined when a dose higher than the recommended dose is administered in one dose of 
study vaccine. 
An overdose would also occur if two doses of the study vaccine are administered within 
half the time of the recommended interval between doses, as defined in the protocol i.e. 
for this protocol, both an overdose and vaccine administration error would occur if receipt 
of more than one dose takes place in a 12 day period. 
Any vaccine administration error or overdose of study vaccine detailed in this protocol 
must be reported as an adverse event, and if the vaccine administration error or overdose 
is associated with a serious adverse event, it must be reported as such within 24 hours to 
the Sponsor. 
6.5 
Prior and Concomitant Medications and Vaccines 
All medications, vaccines and blood products taken or received by the subject within 4 
weeks prior to the start of the study are to be recorded on the Prior and Concomitant 
Medications CRF. 
The use of antipyretics and/or analgesic medications within 24 hours prior to vaccination 
must be identified and the reason for their use (prophylaxis versus treatment) must be 
described in the source document and Concomitant Medications CRF. Use of 
antipyretics/analgesics within 24 hours prior to vaccine administration is a reason to delay 
study vaccination (see section 4.3, Criteria for Delay of Vaccination). 
Medications taken for prophylaxis are those intended to prevent the onset of symptoms. 
Medications taken for treatment are intended to reduce or eliminate the presence of 
symptoms that are present. 
Concomitant medications include all medications (including vaccines) taken 
by/administered to the subject at and after enrolment and must be documented on the 
Concomitant Medications CRF. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 55 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
When recording concomitant medications/vaccines, they should be checked against the 
study entry and continuation criteria in section 4, Selection of Study Population to ensure 
that the subject should be enrolled/continue in the study. 
6.6 
Vaccine Supply, Labeling, Storage and Tracking 
The Sponsor will ensure the following: 
 Supply the study vaccine(s). 
 Appropriate labeling of all study vaccines provided that complies with the legal 
requirements of each country where the study is to be performed. 
The investigator must ensure the following: 
 Acknowledge receipt of the study vaccines by a designated staff member at the site, 
including: 
- 
Confirmation that the vaccines were received in good condition 
- 
Confirmation to the Sponsor of the temperature range during shipment from the 
Sponsor to the investigator’s designated storage location 
- 
Confirmation by the Sponsor that the vaccines are authorized for use. 
 Proper storage of the study vaccines, including: 
- 
Storage in a secure, locked, temperature-controlled location. 
- 
Proper storage according to the instructions specified on the labels. 
- 
Appropriate record keeping and inventory of the study vaccines, including regular 
documentation of adequate storage temperature. 
 Appropriate use of the study vaccines, including: 
- 
Not use of vaccines prior to receipt of authorization for use from the Sponsor. 
- 
Use only in accordance with the approved protocol. 
- 
Dilution in accordance to bed-side mixing procedure and documentation 
- 
Proper handling, including confirmation that the vaccine has not expired prior to 
administration. 
- 
Appropriate documentation of administration of vaccines to study subjects 
including: 
▪ 
Date, dosage, batch/lot numbers, expiration dates, unique identifying numbers 
assigned to subjects and study vaccines, and time of vaccine administration. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 56 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
This information will be maintained in an accountability log that will be 
reviewed by the site monitor. 
▪ 
Reconciliation of all vaccines received from the Sponsor. Reconciliation is 
defined as maintaining records of which and how many vaccines were 
received, which vaccines (and dilution for S. sonnei vaccine) were 
administered to subjects, which vaccines were destroyed at the site, and which 
vaccines were returned to the Sponsor, as applicable. 
 Proper adherence to the local institutional policy with respect to destruction of study 
vaccines. 
 Complete record keeping of vaccine use, wastage, return or destruction, including 
documentation of: 
- 
Copy of the site’s procedure for destruction of hazardous material. 
- 
Number of doses destroyed, date of destruction, destruction code (if available), 
method of destruction, and name of individual performing destruction. 
Vaccines that have been stored differently from the manufacturer’s indications must not 
be used unless the Sponsor provides written authorization for use. In the event that the use 
cannot be authorized, the Sponsor will make every effort to replace the vaccine supply. 
All vaccines used in conjunction with this protocol must be stored separately from normal 
hospital/practice stocks to prevent unintentional use of study vaccines outside of the 
clinical study setting. 
Monitoring of vaccine accountability will be performed by the study monitor during site 
visits and at the completion of the study. 
At the conclusion of the study, and as appropriate during the course of the study, the 
investigator must ensure that all unused study vaccines, packaging and supplementary 
labels are destroyed locally (upon approval from Sponsor) or returned to the Sponsor. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 57 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7. 
ASSESSMENTS 
7.1 
Safety Assessment 
The measures of safety used in this study are based on previous study data. They include 
a close vigilance for, and stringent reporting of selected local and systemic adverse events 
routinely monitored in vaccine studies as indicators of reactogenicity. 
An adverse event (AE) is defined as any untoward medical occurrence in a subject or 
clinical investigation subject administered a pharmaceutical product at any dose that does 
not necessarily have to have a causal relationship with this treatment. Therefore, an AE 
can be any unfavorable and unintended sign (including an abnormal laboratory finding, 
for example), symptom, or disease temporally associated with the use of an 
investigational product, whether or not considered related to the investigational product. 
This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing 
conditions. 
The period of observation for AEs extends from the time the subject signs informed 
consent until he or she completes the specified safety follow-up period (28 days after each 
vaccination) or terminates the study early (whichever comes first). AEs occurring after 
the informed consent form is signed but prior to receiving study vaccine/product will be 
documented as an adverse event and recorded within source document. However, any 
AEs occurring prior to receipt of any study vaccine will be analyzed separately from 
“treatment emergent” AEs (AEs occurring after administration of the first study vaccine). 
Adverse events are collected as either solicited or unsolicited adverse events. Solicited 
events are derived from organized data collection systems, such as Subject interview. 
7.1.1 Solicited Adverse Events 
The term “reactogenicity” refers to solicited signs and symptoms (“solicited adverse 
events”) occurring in the hours and days following a vaccination, to be collected by the 
subject for 7 consecutive days. 
The following solicited adverse events are included in the Diary Card that will be used in 
this study to document solicited adverse events.  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 58 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Solicited local adverse events: erythema, induration and pain at injection site. 
Solicited systemic adverse events: headache, arthralgia, chills, fatigue, malaise, myalgia, 
and fever (body temperature measured axillary). 
Other solicited reactions: Use of analgesics/antipyretics, body temperature (measured 
axillary). 
Each adverse event is to be assessed using the scoring system reported below:  
Solicited Local Adverse Events 
Solicited local adverse 
events 
Grade 0 
Absent 
Present - Grading of Severity 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Injection site Erythema 
(Captured as 
measurements in 
millimeters) 
1-24 mm 
25-50 mm 
51-100 mm 
> 100 mm 
Injection site Induration 
(Captured as 
measurements in 
millimeters) 
1-24 mm 
25-50 mm 
51-100 mm 
> 100 mm 
Injection site Pain 
No pain 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Solicited Systemic Adverse Events 
Solicited systemic 
adverse events 
Grade 0 
Absent 
Present - Grading of Severity* 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Headache 
No headache 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Arthralgia 
No 
arthralgia 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Chills 
No chills 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Fatigue 
No fatigue 
No interference 
with activity 
Some 
interference 
Significant; 
prevents daily 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 59 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
with activity 
activity 
Malaise 
No malaise 
No interference 
with activity 
Some 
interference 
with activity 
Significant; 
prevents daily 
activity 
Myalgia  
No myalgia 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Fever as a 
Body temperature 
(Captured as 
measurements in degrees 
Celsius) 
≤ 37.9 °C 
≥ 38.0 – 38.9°C 
≥ 39.0 – 39.9°C 
≥ 40.0°C 
Axillary Temperature: <35.5 °C to ≥38.0 °C 
Other Solicited Adverse Events 
Other Solicited adverse 
events 
Grade 0 
Absent 
Present - Grading of Severity 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Use of 
analgesics/antipyretics 
Categorized as “yes” or “no”  
The study staff must review the data entered into the Diary Card as described in section 
3.4.2, Tools Used for Data Collection and section 5.3.1, Follow-up Clinic Visit(s). 
Note: Any solicited adverse event that meets any of the following criteria must be entered 
into subjects’ source document (see section 9.1, Source Documentation) and also as an 
adverse event on the Adverse Event CRF: 
 Solicited local or systemic adverse event that continues beyond day 7 after 
vaccination. 
 Solicited local or systemic adverse event that leads to a visit to a healthcare provider 
(medically attended adverse event, see section 7.1.3, Evaluation of Adverse Events). 
 Solicited local or systemic adverse event leading to the subject withdrawing from the 
study or the subject being withdrawn from the study by the investigator (adverse event 
leading to withdrawal, see section 7.1.3, Evaluation of Adverse Events). 
 Solicited local or systemic adverse event that otherwise meets the definition of a 
serious adverse event (see section 7.1.4, Serious Adverse Events). 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 60 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.1.2 Unsolicited Adverse Events 
An unsolicited adverse event is an adverse event that was not solicited using the Diary 
Card and that was spontaneously communicated by a subject who has signed the informed 
consent. 
Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses 
requiring hospitalization, or emergency room visit, or visit to/by a health care provider), 
or were of concern to the subject. In case of such events, subjects will be instructed to 
contact the site as soon as possible to report the event(s). The detailed information about 
the reported unsolicited AEs will be collected by the qualified site personnel during the 
interview and will be documented in the subject’s records. 
Unsolicited AEs that are not medically attended nor perceived as a concern by subjects 
will be collected during interview with the subject and by review of available medical 
records at the next visit (see section 5.3, Post-vaccination Visit(s)). 
7.1.3 Evaluation of Adverse Events 
Every effort should be made by the investigator to evaluate safety information reported by 
a subject for an underlying diagnosis and to capture this diagnosis as the event in the AE 
page. In other words, the practice of reporting only symptoms (e.g., “cough” or “ear 
pain”) are better reported according to the underlying cause (e.g., “asthma exacerbation” 
or “otitis media”). 
The severity of events reported on the Adverse Events CRF will be determined by the 
investigator as: 
Mild: 
transient with no limitation in normal daily activity. 
Moderate: 
some limitation in normal daily activity. 
Severe: 
unable to perform normal daily activity. 
The relationship of the study treatment to an AE will be determined by the investigator 
based on the following definitions: 
1. Not Related 
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates an alternative explanation. If the subject has not received the vaccine, the timing 
of the exposure to the vaccine and the onset of the AE are not reasonably related in time, 
or other facts, evidence or arguments exist that reasonably suggest an alternative 
explanation, then the AE is not related. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 61 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2. Possibly Related 
The administration of the investigational vaccine and AE are considered reasonably 
related in time and the AE could be explained by exposure to the investigational vaccine 
or by other causes. 
3. Probably Related 
Exposure to the investigational vaccine and AE are reasonably related in time and no 
alternative explanation has been identified. 
The relationship of the study treatment to an unsolicited AE will be determined by the 
investigator.  
Note: solicited AEs will not be evaluated for relationship to study treatment. Grading for 
severity of solicited local and systemic AEs is described in section 7.1.1, Solicited 
Adverse Events. 
Adverse events will also be evaluated by the investigator for the co-existence of any of 
the other following conditions: 
 “Medically attended adverse event”: an adverse event that leads to a visit to a 
healthcare provider. 
 “New onset of chronic disease” (NOCD): an adverse event that represents a new 
diagnosis of a chronic medical condition that was not present or suspected in a subject 
prior to study enrolment. 
 AEs leading to withdrawal: adverse events leading to study or vaccine withdrawal. 
If solicited or unsolicited adverse events have been reported and the subject indicated that 
the symptoms required medical attendance or were of concern, the subject must be 
contacted for further information. 
When the subject is contacted for any of these reasons, the contact must be documented in 
the subject’s source documentation. 
All AEs, regardless of severity, will be monitored until resolution or until the investigator 
assesses them as chronic or stable. All subjects experiencing AEs - whether considered 
associated with the use of the study vaccine or not - must be monitored until symptoms 
subside and any abnormal laboratory values have returned to baseline, or until there is a 
satisfactory explanation for the changes observed, or until death, in which case a full 
pathologist’s report should be supplied, if possible. The investigator’s assessment of 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 62 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
ongoing Adverse Events at the time of each subject’s last visit should be documented in 
the subject’s medical chart. 
7.1.4 Serious Adverse Events 
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any 
dose results in one or more of the following: 
 Death. 
 Is life-threatening (i.e., the subject was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred); it does not refer to an event 
which hypothetically might have caused death if it were more severe. 
 Required or prolonged hospitalization. 
 Persistent or significant disability/incapacity (i.e., the event causes a substantial 
disruption of a person’s ability to conduct normal life functions). 
 Congenital anomaly/or birth defect. 
 An important and significant medical event that may not be immediately life 
threatening or resulting in death or hospitalization but, based upon appropriate 
medical judgment, may jeopardize the subject or may require intervention to prevent 
one of the other outcomes listed above. 
Adverse events which do not fall into these categories are defined as non-serious. 
It should be noted that a severe adverse event need not be serious in nature and that a 
serious adverse event need not, by definition, be severe. 
Serious adverse events will be captured both on the Vaccines Serious Adverse Event 
(VSAE) form as well as on the AE CRF. All SAEs will be evaluated by the investigator 
for relationship of the event to study vaccine. SAEs that are judged to be possibly or 
probably related to the study vaccine should be reported to the Sponsor as 
related/suspected events. 
The relationship of the study treatment to an SAE will be determined by the investigator 
based on the following definitions: 
1. Related/suspected 
The SAE is judged by the investigator to be possibly or probably related to the study 
vaccine on the AE CRF page (see section 7.1.3, Evaluation of Adverse Events). 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 63 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2. Not Related 
The SAE is not related if exposure to the study vaccine has not occurred, or the 
occurrence of the SAE is not reasonably related in time, or the SAE is considered 
unlikely to be related to use of the study vaccine, i.e., there are no facts (evidence) or 
arguments to suggest a causal relationship. 
The relationship of the study vaccine to an SAE will be determined by the investigator. 
In addition, SAEs will be evaluated by the Sponsor or designee for “expectedness.” An 
unexpected AE is one that is not listed in the current Summary of Product Characteristics 
or the Investigator’s Brochure or an event that is by nature more specific or more severe 
than a listed event. 
In addition, a pre-existing event or condition that results in hospitalization should be 
recorded on the Medical History CRF. If the onset of an event occurred before the subject 
entered the study (e.g., any pre-planned hospitalization for conditions like cosmetic 
treatments or for non-emergency routine visits for a pre-existing condition), the 
hospitalization would not lead to an AE being classified as serious unless, in the view of 
the investigator, hospitalization was prolonged as a result of participation in the clinical 
study or was necessary due to a worsening of the pre-existing condition. 
7.1.4.1 
Adverse Events of Special Interest 
Adverse events of special interest (AESIs) are predefined adverse events that will be 
specifically highlighted to the investigator and will be summarized separately at the end 
of the study. All AESIs occurring during the study will be categorized and reported as a 
SAE. 
Reactive arthritis (ReA) will be collected and analyzed as an AESI for this study.  
Reactive arthritis is defined as non-purulent joint inflammation that develops in response 
to an infection in another part of the body. Since the inflammation is triggered by a 
previous condition, it is termed “reactive”. Intestinal pathogens that have been associated 
with reactive arthritis include Campylobacter, Salmonella, Yersinia, Clostridium difficile, 
and Shigella. If reactive arthritis is caused by an auto immune response, there is at least a 
possibility that it could be initiated by vaccination of susceptible people with the 
1790GAHB vaccine. 
For diagnosis of ReA, imaging and aspiration are not required (unless clinically 
indicated). 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 64 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.1.5 Methods for Recording Adverse Events and Serious Adverse Events 
Findings regarding Adverse Events must be reported on an Adverse Events CRF, as 
specified in section 7.1.1, Solicited Adverse Events, and on the VSAE form, if applicable, 
which is part of the Investigator Site File. All findings in subjects experiencing AEs must 
be reported also in the subject's source document. 
All SAEs which occur during the course of the study, whether considered to be associated 
with the study vaccination or not, must be reported within 24 hours of the site becoming 
aware of the event to SBVGH or its designee. Specific instructions and contact details 
for collecting and reporting SAEs to SBVGH will be provided to the investigator. 
All SAEs are also to be documented on the Adverse Events CRF. Any medication or 
other therapeutic measures used to treat the AE will be recorded on the appropriate 
CRF(s) in addition to the outcome of the AE. 
After receipt of the initial report, representatives of SBVGH or its designee will contact 
the investigator if it is necessary to obtain further information for assessment of the event. 
All SAEs must be reported by the investigator to his/her IRB or applicable regulatory 
authorities in accordance with institutional policy/regulatory requirements and adequate 
documentation of this notification must be provided to the Sponsor. 
SBVGH or its designee must also comply with the applicable regulatory requirement(s) 
related to the reporting of suspected unexpected serious adverse vaccine reactions (also 
known as SUSARs) to the regulatory authority(ies) and the IRB/EC. If a SUSAR or other 
safety signal relating to use of one of the study vaccines is reported to SBVGH or its 
designee, the Sponsor will communicate the information to the investigator and the 
investigator will be responsible for submitting this information to the IRB and other 
relevant authorities. 
7.1.5.1 
Post-Study Events 
Any SAE that occurs outside of the protocol-specified follow-up period and considered to 
be caused by the study vaccine must be reported to SBVGH or its designee. These SAEs 
will be processed by SBVGH or its designee as during the course of the study, until 6 
months after last subject last visit. Instructions and contact details for collecting and 
reporting these suspected SAEs will be provided to the investigator. 
7.1.6 Pregnancies 
To ensure subjects’ safety, each pregnancy in a subject after study vaccination must be 
reported to SBVGH or delegate within 72 hours of the site learning of its occurrence. If 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 65 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
the subject agrees to submit this information, the pregnancy must be followed to 
determine outcome, including spontaneous or voluntary termination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. This follow-up should occur even if intended duration of 
safety follow-up for the study has ended. 
Pregnancy data must be recorded on a Pregnancy Report CRF (initial report) and 
Pregnancy Follow-Up CRF (outcome report) and reported to SBVGH or delegate. 
Instructions and contact details for submitting the Pregnancy CRFs will be provided to the 
investigator. 
Any pregnancy outcome meeting the definition of a SAE (see section 7.1.4, Serious 
Adverse Events) must also be reported on the VSAE Report Form. 
7.1.7 Safety Laboratory Measurements 
For list of safety laboratory measurement, refer to synopsis Table 3, Hematological, 
Haematochemical Blood Tests and Urinalysis Table. 
Safety laboratory measurement will be performed as described in Section 3.5, Collection 
of Clinical Specimens.  
Significant alterations in hematology, blood chemistry and urinalysis will be clinically 
assessed by the investigator’s medical judgment based on interpretation of deviations 
from institution’s normal values.  
Any abnormality in laboratory measurements classified as clinically significant must be 
reported in the Adverse Event CRF form. 
If a subject is to have blood drawn and/or urine testing for safety laboratory for repeat 
safety assessment (e.g., in case of markedly abnormal safety laboratory parameter), 
investigator’s medical judgment will be applied concerning values that would trigger 
reanalysis and frequency of repeats.  
Safety laboratory assessments will be performed at the site laboratory, and results of these 
tests will be recorded in the source documents and in the CRF.  
7.2 
Efficacy Assessment 
This study has no efficacy measurements. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 66 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.3 
Immunogenicity Assessment 
The measure of immunogenicity used in this study i.e. IgG enzyme-linked 
immunosorbent assay (ELISA) in sera is standard, widely used and generally recognized 
as reliable, accurate, and relevant (able to describe the quality and extent of the immune 
response). The ELISA methodology used in this study has been adopted based on 
scientific consensus and has been deemed appropriate to describe the immune response 
against Shigella sonnei GMMA in this study. 
Testing will be conducted by a SBVGH or designated laboratory in a blinded manner 
towards the treatment arm and the visit. 
The measure of immunogenicity used in this study is IgG ELISA against Shigella sonnei 
OAg. The serologic assays will be conducted on serum samples and will be performed by 
a SBVGH or designated laboratory in a blinded manner towards the treatment arm and 
the visit. 
For reference of visits the measurements are taken, refer to section 3.5 and to the Clinical 
Specimen Laboratory Manual.

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 67 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8. 
STATISTICAL CONSIDERATIONS 
8.1 
Endpoints 
8.1.1 Primary Endpoint(s) 
8.1.1.1 
Primary Safety Endpoint(s) 
The safety profile of the two vaccine doses and control(s) will be assessed through 
measurement of the following:  
a. Number and percentage of subjects with solicited local and systemic adverse 
reactions during 7 days following each vaccination. 
b. Numbers and percentage of subjects with deviations from normal ranges of safety 
laboratory data after each vaccination.  
c. Number and percentage of subjects with reported unsolicited adverse events during 
28 days following each vaccination.  
d. Number and percentage of subjects with reported SAEs throughout the study 
duration. 
e. Number and percentage of subjects with reported reactive arthritis (AESIs). 
8.1.1.2 
Primary Efficacy Endpoint(s) 
The study does not have primary efficacy endpoint(s). 
8.1.1.3 
Primary Immunogenicity Endpoint(s) 
The study does not have primary immunogenicity endpoint(s). 
8.1.2 Secondary Endpoint(s) 
8.1.2.1 
Secondary Safety Endpoint(s) 
The study does not have secondary safety endpoint(s). 
8.1.2.2 
Secondary Efficacy Endpoint(s) 
The study does not have secondary efficacy endpoint(s), 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 68 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.1.2.3 
Secondary Immunogenicity Endpoint(s) 
The measures of the immunogenicity outcome, (i.e., the anti-LPS S. sonnei serum IgG), 
will include: 
a. IgG Geometric mean concentrations (GMCs) pre-vaccination (Day 1), 28 days after 1st 
vaccination and 28 days after 2nd vaccination, as determined by Enzyme-linked 
Immunosorbent Assay (ELISA), and applicable geometric mean ratios between post- and 
pre-vaccination samples. 
b. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination 
Seroresponse is aimed to define a significant increase in post vaccination samples based 
on the biological performance of this specific serology assay and it is defined as:  
- 
If the baseline value is greater than 50 ELISA Units (EU) then an increase of at 
least 50% in the post-vaccination sample as compared to baseline [i.e. ((Post-vac 
minus baseline)/baseline)100% ≥ 50%] 
- 
If the baseline value is less or equal to 50 EU then an increase of at least 25 EU in 
the post-vaccination sample as compared to baseline [i.e. (post-vac minus 
baseline) ≥ 25 EU] 
c. Number and percentage of subjects with titers post vaccination concentration ≥ 121 
for anti-LPS S. sonnei at 28 days after 1st vaccination and 28 days after 2nd vaccination 
d. IgG Geometric mean concentrations (GMCs) pre-vaccination (Day 1), 28 days after 1st 
vaccination and 28 days after 2nd vaccination by antibody titer at baseline (i.e., above vs. 
below the assay detection limit), as determined by Enzyme-linked Immunosorbent Assay 
(ELISA), and applicable geometric mean ratios between post- and pre-vaccination 
samples. 
e. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination by antibody titer at baseline 
(i.e., above vs. below the assay detection limit).  
A post vaccination concentration ≥ 121 anti-LPS serum IgG units in the SBVGH ELISA 
corresponds to a titer of 1:800 in the ELISA method used by Cohen et al. (Cohen et al., 
1989). This antibody level is the median antibody concentration of a set of 87 
convalescent subjects previously infected by S. sonnei. The value of 121 anti-LPS serum 
IgG units in the Novartis SBVGH ELISA was determined by calibration against the 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 69 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Cohen ELISA (i.e., the SBVGH standard serum was tested in Cohen’s lab using the 
Cohen’s methodology) 
8.1.3 Exploratory Endpoint(s) 
8.1.3.1 
Exploratory Safety Endpoint(s) 
The study does not have exploratory safety endpoint(s). 
8.1.3.2 
Exploratory Efficacy Endpoint(s) 
The study does not have exploratory efficacy endpoint(s). 
8.1.3.3 
Exploratory Immunogenicity Endpoint(s) 
Other assays (including serum secretory IgA) might be done to further characterize the 
immune response to the study vaccine. 
8.2 
Success Criteria 
This is a Phase 2a trial and there is no pre-defined success criterion. 
8.2.1 Success Criteria for Primary Objective(s) 
Not applicable. 
8.2.1.1 
Success Criteria for Primary Safety Objective(s) 
Not applicable. 
8.2.1.2 
Success Criteria for Primary Efficacy Objective(s) 
Not applicable. 
8.2.1.3 
Success Criteria for Primary Immunogenicity Objective(s) 
Not applicable. The study does not have primary immunogenicity endpoint(s). 
8.2.2 Success Criteria for Secondary Objective(s) 
Not applicable. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 70 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.2.2.1 
Success Criteria for Secondary Safety Objective(s) 
Not applicable. The study doesn’t have secondary safety objectives. 
8.2.2.2 
Success Criteria for Secondary Efficacy Objective(s) 
Not applicable. The study doesn’t have secondary efficacy objectives. 
8.2.2.3 
Success Criteria for Secondary Immunogenicity Objective(s) 
This is a Phase 2a trial and there are no pre-defined success criteria for secondary 
immunogenicity objectives. 
8.3 
Analysis Sets 
8.3.1 All Enrolled Set 
All screened subjects who provide informed consent and provide demographic and/or 
baseline screening assessments, regardless of the subject’s randomization and treatment 
status in the study and received a Subject ID (where the first two digits identify the site 
number) 
8.3.2 All Exposed Set 
All subjects in the enrolled set who receive a study vaccination. 
8.3.3 Safety Set 
Solicited Safety Set (solicited local and systemic adverse events and other solicited 
adverse events) 
All subjects in the Exposed Set with any solicited adverse event data and/or indicators of 
solicited adverse events (e.g., use of analgesics/antipyretics). 
Unsolicited Safety Set (unsolicited adverse events) 
All subjects in the Exposed Set with unsolicited adverse event data. 
Overall Safety Set 
All subjects who are in the Solicited Safety Set and/or Unsolicited Safety Set. 
Subjects will be analyzed as “treated” (i.e., according to the vaccine a subject received, 
rather than the vaccine to which the subject may have been randomized). 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 71 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.3.4 Full Analysis Set (FAS) Immunogenicity Set 
Full Analysis Set Immunogenicity 
All subjects in the All Enrolled Set who are randomized, receive at least one study 
vaccination and provide immunogenicity data at data at relevant time points. 
‐ 
Received at least one study vaccination and provide immunogenicity data 28 days 
after 1st vaccination. (FAS 1 - day 28 after 1st vaccination) 
‐ 
Received at least one study vaccination and provide immunogenicity data 28 days 
after 2nd vaccination. (FAS 2 - day 28 after 2nd vaccination) 
In case of vaccination error, subjects in the FAS sets will be analyzed “as randomized” 
(i.e., according to the vaccine a subject was designated to receive, which may be different 
from the vaccine the subject actually received). 
8.3.5 Per Protocol (PP) Set Immunogenicity Set 
All subjects in the FAS Immunogenicity who: 
 Correctly receive the vaccine (i.e., receive the vaccine to which the subjects is 
randomized and at the scheduled time points). 
 Have no protocol deviations leading to exclusion (see section 8.3.8, Protocol 
Deviations) as defined prior to unblinding. 
 Are not excluded due to other reasons defined prior to unblinding or analysis (see 
section 8.3.8, Protocol Deviations) 
PPS are subsets of FAS and should be always defined even if the objectives do not 
require it. 
Examples for subjects excluded due to other reasons than protocol deviations are: 
- 
Subjects who withdrew informed consent. 
8.3.6 Other Analysis Sets 
Modified FAS 
The differences between FAS and Modified FAS are:  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 72 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
‐ 
Subjects who received the same wrong vaccine at the two vaccinations will be 
analyzed in the vaccine the subject actually received (in the FAS they will be 
analyzed according to the vaccine the subject was designed to receive) 
‐ 
If a subject didn’t receive the vaccination but a blood sample after the vaccination 
visit (where subject didn’t receive the vaccination) was collected then subject will be 
excluded from the immunogenicity analysis for all visits after the vaccination visit. 
8.3.7 Subgroups 
Not applicable. 
8.3.8 Protocol Deviations 
A protocol deviation is any change, divergence, or departure from the study design or 
procedures of a study protocol. A protocol deviation may be a reason to remove data from 
an analysis set at the time of analysis. CSR-reportable protocol deviations will be defined 
as exclusionary from the analysis according to protocol objectives and endpoints, which 
will be specified in the statistical analysis plan. In some cases exclusion of data may be 
due to a reason other than a protocol deviation, e.g. early termination. 
8.4 
Statistical Analysis Plan 
8.4.1 Analysis of Demographic and Baseline Characteristics 
Descriptive statistics (mean, standard deviation, median, minimum and maximum) for, 
age, height and weight and BMI at enrolment will be calculated overall and by vaccine 
group. 
Distributions of subjects by sex and ethnic origin will be summarized overall and by 
vaccine group. 
8.4.2 Analysis of Primary Objective(s) 
8.4.2.1 
Analysis of Primary Safety Objective(s) 
The analysis of safety assessments in this study will include summaries of the following 
categories of safety data collected for each subject: 
 Vaccine exposure. 
 Solicited local and systemic adverse events. 
 Unsolicited adverse events. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 73 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
 Clinical Laboratory Investigations.  
8.4.2.1.1 Analysis of Extent of Exposure 
The frequencies and percentages of subjects with vaccinations will be summarized overall 
and by vaccine group. Data will be tabulated for the All Enrolled Set.  
8.4.2.1.2 Analysis of Solicited Local, Systemic and Other Adverse Events 
All solicited adverse events will be summarized according to defined severity grading 
scales.  
Frequencies and percentages of subjects experiencing each adverse event will be 
presented for each symptom severity. Summary tables showing the occurrence of any 
local or systemic adverse event overall and at each time point will also be presented. 
Post-vaccination solicited adverse events reported from day 1 to day 7 will be 
summarized for the intervals day 1-3, day 4-7, day 1-7 by maximal severity and by 
vaccine group. The severity of solicited local adverse events, including injection-site 
erythema and induration will be summarized according to categories based on linear 
measurement:  25 to 50 mm, 51 to 100 mm, >100mm. 
Injection site pain and systemic adverse events (except fever) occurring up to 7 days after 
each vaccination will be summarized according to “mild”, “moderate” or “severe”. 
Each solicited local and systemic adverse event will also be further summarized as “none” 
versus “any”. 
Implausible measurements (for further definition see statistical analysis plan) will be left 
out of the analysis. 
Use of antipyretics and analgesics will be summarized by frequency by type of use 
(prophylactic versus treatment) and percentage of subjects reporting use.  
Body temperature will be summarized by 0.5 °C increments from 36.0 °C up to ≥40 °C 
and will be broken down according by route of measurement. 
8.4.2.1.3 Analysis of Unsolicited Adverse Events 
This analysis applies to all adverse events occurring during the study, judged either as 
probably related, possibly related, or not related to vaccination by the investigator, 
recorded in AE CRF, with a start date on or after the date of first vaccination. AE starting 
prior to the first vaccination will only be listed. The original verbatim terms used by 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 74 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
investigators to identify adverse events in the CRFs will be mapped to preferred terms 
using the MedDRA dictionary. The adverse events will then be grouped by MedDRA 
preferred terms into frequency tables according to system organ class (SOC). 
All reported adverse events, as well as adverse events judged by the investigator as at 
least possibly related to study vaccine, will be summarized according to SOC and 
preferred term within SOC. These summaries will be presented by vaccination group. 
When an adverse event occurs more than once for a subject, the maximal severity and 
strongest relationship to the vaccine group will be counted. 
Separate summaries will be produced for the following categories: 
 Serious adverse events and adverse events of special interest. 
 Adverse events that are possibly or probably related to vaccine. 
 Adverse event leading to withdrawal. 
Data listings of all adverse events will be provided by subject. In addition, adverse events 
in the categories above will be provided as listed data. 
8.4.2.1.4 Analysis of Safety Laboratory Values 
The investigator must assess all safety laboratory results (see section 7.1.7). Clinically 
significant modifications in blood chemistry, hematology, and urinalysis test values will 
be assessed by medical judgment based on interpretation of deviations from the 
institution’s normal values. 
All laboratory safety data will be analyzed descriptively by vaccine group. Safety 
laboratory data will be shown in a 3 x 3 table by visit using categorization of laboratory 
values of hematological and haematochemical blood tests and urinalysis according to 
institutional normal reference range (below, within, above). 
8.4.2.2 
Analysis of Primary Efficacy Objective(s) 
This study does not include primary efficacy objectives. 
8.4.2.2.1 Statistical Hypotheses 
Not applicable.  
8.4.2.2.2 Analysis Sets 
Not applicable. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 75 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.4.2.2.3 Statistical Methods 
Not applicable. 
8.4.2.3 
Analysis of Primary Immunogenicity Objective(s) 
This study does not have primary immunogenicity objectives. 
8.4.2.3.1 Statistical Hypotheses 
Not applicable. 
8.4.2.3.2 Analysis Sets 
Not applicable. 
8.4.2.3.3 Statistical Methods 
Not applicable. 
8.4.3 Analysis of Secondary Objective(s) 
8.4.3.1 
Analysis of Secondary Safety Objective(s) 
This study does not have secondary safety objectives. 
8.4.3.1.1 Analysis of Extent of Exposure 
Not applicable. 
8.4.3.1.2 Analysis of Solicited Local, Systemic and Other Adverse Events 
Not applicable. 
8.4.3.1.3 Analysis of Unsolicited Adverse Events 
Not applicable. 
8.4.3.1.4 Statistical Hypotheses 
Not applicable. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 76 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.4.3.1.5 Analysis Sets 
Not applicable. 
8.4.3.1.6 Statistical Methods 
Not applicable. 
8.4.3.2 
Analysis of Secondary Efficacy Objective(s) 
This study does not have secondary efficacy objectives. 
8.4.3.2.1 Statistical Hypotheses 
Not applicable. 
8.4.3.2.2 Analysis Sets 
Not applicable. 
8.4.3.2.3 Statistical Methods 
Not applicable. 
8.4.3.3 
Analysis of Secondary Immunogenicity Objective(s) 
8.4.3.3.1 Statistical Hypotheses 
This Phase 2a safety and immunogenicity study is aimed to descriptively evaluate the 
safety and immunogenicity profiles of the study vaccines. No specific hypotheses are 
tested in this study.  
8.4.3.3.2 Analysis Sets 
The modified FAS will be the primary analysis set for the immunogenicity objective. 
8.4.3.3.3 Statistical Methods 
Analysis of continuous variables 
The ELISA concentrations will be logarithmically transformed (base10) (to fulfil the 
normal distribution assumption). GMC will be calculated, with their associated two-sided 
95% CIs, by exponentiating the corresponding log-transformed means and their 95% CI. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 77 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Additionally, within-subject GMRs will be computed for GMTs/GMCs at one month 
after first and second vaccination versus baseline (day 1). The GMRs and 95% CIs will be 
constructed by exponentiating the mean within-subject differences in log-transformed 
titers and the corresponding 95% CIs. 
Analysis of binary variables 
The number and percentages of subjects with seroresponse from baseline and with high 
antibody level after vaccination (i.e. post vaccination antibody level ≥ 121 IgG units in 
the SBVGH ELISA), will be summarized. Two-sided 95% Clopper-Pearson CIs for the 
percentages will be computed. 
Titers below the limit of detection will be set to half that limit for the purposes of 
analysis. Missing values of immunogenicity will be excluded from analyses (i.e. 
complete-case analysis) since they are considered missing completely at random, i.e. not 
informative and with no impact on inferences.  
8.4.4 Analysis of Exploratory Objectives 
 Other assays, including serum secretory IgA, might be done to further characterize the 
immune response to the study vaccine. The analysis will be described in the statistical 
analysis plan. 
8.4.4.1 
Analysis of Exploratory Safety Objective(s) 
Not applicable. 
8.4.4.2 
Analysis of Exploratory Efficacy Objective(s) 
Not applicable. 
8.4.4.3 
Analysis of Exploratory Immunogenicity Objective(s) 
Not applicable. 
8.5 
Sample Size and Power Considerations of Primary Objectives 
No formal statistical sample size and power computations are performed since the 
objectives of the study are to descriptively assess the immunogenicity and safety of the 
investigational vaccine. 
8.6 
Interim Analysis 
No interim analysis of data from this study is planned. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 78 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
9. 
SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING 
Study monitoring and auditing will be standardized and performed in accordance with the 
Sponsor’s or delegated contract research organization’s (CRO) standard operating 
procedures and applicable regulatory requirements (e.g., FDA, EMA, and ICH 
guidelines). 
Prior to enrolment of the first study subject, SBVGH or delegate will train investigators 
and/or their study staff on the study protocol, all applicable study procedures, 
documentation practices and all electronic systems. CRFs supplied by the Sponsor must 
be completed for each enrolled subject (see section 8.3.1, All Enrolled Set for definition 
of enrolled subject). Documentation of screened but not enrolled subjects must be 
maintained at the site and made available for review by the site monitor. Data and 
documents will be checked by the Sponsor and/or monitor. 
9.1 
Source Documentation 
Prior to the start of the study, the site staff participating in the study conduct will be 
instructed on what documents will be required for review as source documents. The kinds 
of documents that will serve as source documents will be agreed between Sponsor or 
delegate and investigator and designees and specified in the SDA prior to subject 
enrolment. 
In addition, source documentation must include all of the following: subject identification 
(on each page), eligibility and participation, proper informed consent procedures, dates of 
visits, adherence to protocol procedures, adequate reporting and follow-up of adverse 
events, documentation of prior/concomitant medication/vaccines, study vaccine 
receipt/dispensing/return records, study vaccine administration information, any data 
collected by a conversation with the subject and date of completion and reason. 
The subject must also allow access to the subject’s medical records. Each must be 
informed of this prior to the start of the study and consent for access to medical records 
may be required in accordance with local regulations. 
All safety data reported by subjects must be written down in source documents prior to 
entry of the data into CRFs. If there are multiple sources of information (e.g., verbal 
report of the subject, telephone contact details, medical chart) supporting the diagnosis of 
an adverse event, these sources must be identified in the source documents, discrepancies 
between sources clarified, the ultimate diagnosis must be justified and written in the 
source documents, and this diagnosis must be captured in the Adverse Event CRF (AE 
CRF). The AE CRF must also capture which source(s) of information were used to 
determine the adverse event (e.g., subject recall, medical chart). 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 79 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
9.2 
Study Monitoring, Auditing and Source Data Verification 
Prior to enrolment of the first study subject, SBVGH or its designee (e.g., a CRO) will 
develop a Clinical Monitoring Plan (or comparable documentation) to specify how 
centralized and/or on-site monitoring, including clinical specimens reconciliation, will be 
performed for the study. Study progress will be monitored by SBVGH or its designee as 
frequently as necessary to ensure: 
 that the rights and well-being of human subjects are protected, 
 the reported study data are accurate, complete, and verifiable from the source 
documents and 
 the conduct of the study is in compliance with the current approved 
protocol/amendment(s), GCP and applicable regulatory requirements. 
Contact details for the SBVGH team or its designee involved in study monitoring will be 
provided to the investigator. Study data recorded on CRFs will be verified by checking 
the CRF entries against source documents in order to ensure data completeness and 
accuracy as required by study protocol except for those parameters which are specifically 
described in section 7, Assessment being entered directly into the EDC system. 
Data verification may also be performed through a centralized review of data (e.g., 
checking for outliers or other anomalies). Additional documents such as the investigator 
site file, pharmacy records, and informed consent documentation must also be available 
for review if requested. Arrangements for monitoring visits will be made in advance in 
accordance with the monitoring plan, except in case of emergency. 
The investigator and/or site staff must make source documents of subjects enrolled in this 
study available for inspection by SBVGH or its representative at the time of each 
monitoring visit and Sponsor audits, when applicable. These documents must also be 
available for inspection, verification and copying, as required by regulations, by officials 
of the regulatory health authorities (e.g., FDA, EMA and others) and/or ECs/IRBs. The 
investigator and study site staff must comply with applicable privacy, data protection and 
medical confidentiality laws for use and disclosure of information related to the study and 
enrolled subjects. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 80 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
10. 
DATA MANAGEMENT 
10.1 
Data Entry and Management 
In this study, all clinical data (including, but not limited to, AE/SAEs, concomitant 
medications, medical history, and physical assessments), safety data, and immunogenicity 
data will be entered onto case report forms (CRFs) in a timely fashion by the investigator 
and/or the investigator’s dedicated site staff. Data entered onto CRFs are stored on a 
secure website. The data collected on this secure website are assimilated into an 
electronic data capture (EDC) system, which is compliant with Title 21 Part 11 policies of 
the Code of Federal Regulations (FDA 1997). The data system includes password 
protection and internal quality checks. The EDC system will be designed and validated by 
the Sponsor prior to activation for data entry by sites. The investigator or designated 
delegate must review data entered and electronically sign the CRFs to verify their 
accuracy. 
Access to the EDC system for data entry or review will require training and distinct 
individual access code assignments to those site staff members who will be entering study 
data and those involved in study oversight who may review study data. Data are collected 
within the EDC system, to which the Sponsor and site monitors have exclusively “read 
only” access. 
10.2 
Data Clarification 
As part of the conduct of the trial, the Sponsor may have questions about the data entered 
by the site, referred to as queries. The monitors and the Sponsor are the only parties that 
can generate a query. All corrections and clarifications will be entered into the EDC 
system and will be identified by the person entering the information, the reason for the 
change, as well as the time of the changes made. If changes are made to a previously and 
electronically signed CRF, the investigator must confirm and endorse the changes. 
10.3 
Data Protection 
SBVGH respects the subjects’ rights to privacy and will ensure the confidentiality of their 
medical information in accordance with all applicable laws and regulations. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 81 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
11. 
RECORD RETENTION 
Investigators must retain all study records required by SBVGH and by the applicable 
regulations in a secure and safe facility. The investigator must consult a SBVGH 
representative before disposal of any study records, and must notify the Sponsor of any 
change in the location, disposition, or custody of the study files. Essential documents 
must be retained for 15 years. “Essential documents” are defined as documents that 
individually and collectively permit evaluation of the conduct of a study and the quality 
of the data produced. These documents should be retained for a longer period, however, if 
required by the applicable national regulatory or institutional requirements.  
These principles of record retention will also be applied to the storage of laboratory 
samples, provided that the integrity of the stored sample permits testing. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 82 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
12. 
USE OF INFORMATION AND PUBLICATION 
SBVGH assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov, and in compliance with current regulations. 
SBVGH also assures that key results of this clinical study will be posted in a publicly 
accessible database within the required time-frame from the end of study as defined in 
section 3.9, End of Study. 
In accordance with standard editorial, ethical practices and current guidelines of Good 
Publication Practice (Graf 2009), SBVGH will generally support publication of 
multicenter studies only in their entirety and not as individual center data. In this case, a 
coordinating investigator will be designated by mutual agreement prior to the start of the 
study. The coordinating investigator will also sign the clinical study report on behalf of 
the principal investigators (CPMP/EWP/2747/00). Authorship will be determined by 
mutual agreement and in line with International Committee of Medical Journal Editors 
authorship requirements. Any formal publication of the study in which contribution of 
SBVGH personnel exceeded that of conventional monitoring will be considered as a joint 
publication by the investigator and the appropriate SBVGH personnel. 
SBVGH must be notified of any intent to publish data collected from the study and prior 
approval from SBVGH must be obtained prior to submission for publication. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 83 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
13. 
ETHICAL CONSIDERATIONS 
13.1 
Regulatory and Ethical Compliance 
The study will be conducted in compliance with the protocol, GCP and applicable 
regulatory requirement(s). 
This clinical study was designed and shall be implemented and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations and with the ethical principles laid down in the Declaration of 
Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997). 
13.2 
Informed Consent Procedures 
Eligible subjects may only be included in the study after providing written informed 
consent, as described in section 5.1.1, Informed Consent/Assent. Before the start of the 
study, the investigator will have the informed consent and any other materials that will be 
provided to the subjects reviewed and approved by the IRB/EC. This review and approval 
will be documented and stored with other study documents. The investigator or designee 
must fully inform the subject or legal guardian of all pertinent aspects of the study. A 
copy of the written informed consent will be given to the subject or the designee. The 
subject/designee must be allowed ample time to ask about the details of the study and to 
make a decision as to whether or not to participate in the study. The subject must sign the 
consent form indicating their agreement to participate in the study before any study-
related procedures are conducted. If the subject is unable to read and write, a witness must 
be present during the informed consent discussion and at the time of informed consent 
signature. 
Prior to the start of the study, SBVGH will provide to investigators a proposed informed 
consent form that complies with the ICH GCP guideline and regulatory requirements and 
is considered appropriate for this study. Any changes to the proposed consent form 
suggested by the investigator must be agreed to by SBVGH before submission to the 
IRB/EC and a copy of the approved version must be provided to the SBVGH monitor 
after IRB/EC approval. 
Women of childbearing potential should be informed that taking the study medication 
may involve unknown risks to the fetus if pregnancy were to occur during the study and 
agree that in order to participate in the study they must adhere to the contraception 
requirements indicated in the protocol for the duration of the study. If case of doubts on 
the ability of a subject to adhere to these requirements, that subject should not be allowed 
in the study.  

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 84 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
13.3 
Responsibilities of the Investigator and IRB/EC 
The protocol and the proposed informed consent form must be reviewed and approved by 
a properly constituted IRB/EC before study start. Properly constituted IRB/EC is defined 
in ICH Guideline for Good Clinical Practice E6 (R1), Section 3 (ICH 1997). A signed and 
dated statement that the protocol and informed consent have been approved by the 
IRB/EC must be given to SBVGH before study initiation. Prior to study start and at any 
time the protocol is amended during study conduct, the investigator is required to sign a 
protocol signature page confirming his/her agreement to conduct the study in accordance 
with these documents and all of the instructions and procedures found in this protocol and 
to give access to all relevant data and records to SBVGH monitors, auditors, SBVGH 
Clinical Quality Assurance representatives, designated agents of SBVGH, IRBs/ECs, and 
regulatory authorities as required. If an inspection of the clinical site is requested by a 
regulatory authority, the investigator must inform SBVGH immediately that this request 
has been made. 
The investigator also responsible for the following: 
 Maintaining a list of appropriately qualified persons to whom the investigator has 
delegated significant study-related duties. 
 Demonstrating the capability of recruiting the required number of suitable subjects 
within the recruitment period. 
 Demonstrating sufficient time and staffing to properly conduct and complete the study 
within the agreed study period. 
 Ensuring that all persons assisting with the study are adequately informed about the 
protocol, the investigational product(s), and their study-related duties and functions 
 Ensuring that appropriately trained health care professionals are responsible for all 
study-related medical decisions and for ensuring appropriate medical care of subjects 
experiencing any adverse event related to the study. 
The investigator should not implement any deviation from, or changes of the protocol 
without agreement by the Sponsor and prior review and documented approval/favourable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an 
immediate hazard(s) to study subjects, or when the change(s) involves only logistical or 
administrative aspects of the study (e.g., change in monitor(s), change of telephone 
number(s)). In addition, the investigator, or person designated by the investigator, should 
document and explain any deviation from the approved protocol. 
The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior IRB/IEC 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 85 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
approval/favourable opinion. As soon as possible, the implemented deviation or change, 
the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be 
submitted: 
(a) to the IRB/IEC for review and approval/favourable opinion, 
(b) to the Sponsor for agreement and, if required, 
(c) to the regulatory authority(ies). 
13.4 
Protocol Amendments 
An amendment is a written description of change(s) to or formal clarification of a study 
protocol which may impact on the conduct of the clinical study, potential benefit of the 
clinical study, or may affect subject safety, including changes of study objectives, study 
design, subject population, sample sizes, study procedures, or significant administrative 
aspects. An administrative change of a study protocol is a minor correction or 
clarification that has no significant impact on the way the clinical study is to be conducted 
and no effect on subject safety (e.g., change of telephone number(s), logistical changes). 
Protocol amendments must be approved by SBVGH, health authorities where required, 
and the IRB/EC. In cases when the amendment is required in order to protect the subject 
safety, the amendment can be implemented prior to IRB/EC approval. Notwithstanding, 
the need for formal approval of a protocol amendment, the investigator is expected to take 
any immediate action required for the safety of any subject included in this study, even if 
this action represents a deviation from the protocol. In such cases, SBVGH should be 
notified of this action, the IRB/EC at the study site, and, if required by local regulations, 
the relevant health authority) should be informed within 10 working days. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 86 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
14. 
REFERENCE LIST 
Badenhorst, C. J., Fourie, J., Steyn, K., Jooste, P. L., Lombard, C. J., Bourne, L. & 
Slazus, W. 1995. The Haematological Profile Of Urban Black Africans Aged 15-64 Years 
In The Cape Peninsula. East Afr Med J, 72, 19-24. 
Bardhan, P., Faruque, A. S., Naheed, A. & Sack, D. A. 2010. Decrease In Shigellosis-
Related Deaths Without Shigella Spp.-Specific Interventions, Asia. Emerg Infect Dis, 16, 
1718-23. 
Berlanda Scorza, F., Colucci, A. M., Maggiore, L., Sanzone, S., Rossi, O., Ferlenghi, I., 
Pesce, I., Caboni, M., Norais, N., Di Cioccio, V., Saul, A. & Gerke, C. 2012. High Yield 
Production Process For Shigella Outer Membrane Particles. Plos One, 7, E35616. 
Beveridge, T. J. 1999. Structures Of Gram-Negative Cell Walls And Their Derived 
Membrane Vesicles. J Bacteriol, 181, 4725-33. 
Cohen, D., Ashkenazi, S., Green, M. S., Gdalevich, M., Robin, G., Slepon, R., Yavzori, 
M., Orr, N., Block, C., Ashkenazi, I., Shemer, J., Taylor, D. N., Hale, T. L., Sadoff, J. C., 
Pavliakova, D., Schneerson, R. & Robbins, J. B. 1997. Double-Blind Vaccine-Controlled 
Randomised Efficacy Trial Of An Investigational Shigella Sonnei Conjugate Vaccine In 
Young Adults. Lancet, 349, 155-9. 
Cohen, D., Block, C., Green, M. S., Lowell, G. & Ofek, I. 1989. Immunoglobulin M, A, 
And G Antibody Response To Lipopolysaccharide O Antigen In Symptomatic And 
Asymptomatic Shigella Infections. J Clin Microbiol, 27, 162-7. 
Ezeilo, G. C. 1972. Non-Genetic Neutropenia In Africans. Lancet, 2, 1003-4. 
Karita, E., Ketter, N., Price, M. A., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, 
O., Jaoko, W., Mutua, G., Ruzagira, E., Mulenga, J., Sanders, E. J., Mwangome, M., 
Allen, S., Bwanika, A., Bahemuka, U., Awuondo, K., Omosa, G., Farah, B., Amornkul, 
P., Birungi, J., Yates, S., Stoll-Johnson, L., Gilmour, J., Stevens, G., Shutes, E., Manigart, 
O., Hughes, P., Dally, L., Scott, J., Stevens, W., Fast, P. & Kamali, A. 2009. Clsi-Derived 
Hematology And Biochemistry Reference Intervals For Healthy Adults In Eastern And 
Southern Africa. Plos One, 4, E4401. 
Kotloff, K. L., Winickoff, J. P., Ivanoff, B., Clemens, J. D., Swerdlow, D. L., Sansonetti, 
P. J., Adak, G. K. & Levine, M. M. 1999. Global Burden Of Shigella Infections: 
Implications For Vaccine Development And Implementation Of Control Strategies. Bull 
World Health Organ, 77, 651-66. 

Sclavo Behring Vaccines Institute for Global Health  
Protocol H03_04TP 
28 JUL 15 Version 1.0 
Confidential 
Page 87 of 87 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Levine, M. M., Kotloff, K. L., Barry, E. M., Pasetti, M. F. & Sztein, M. B. 2007. Clinical 
Trials Of Shigella Vaccines: Two Steps Forward And One Step Back On A Long, Hard 
Road. Nat Rev Microbiol, 5, 540-53. 
Livio, S., Strockbine, N. A., Panchalingam, S., Tennant, S. M., Barry, E. M., Marohn, M. 
E., Antonio, M., Hossain, A., Mandomando, I., Ochieng, J. B., Oundo, J. O., Qureshi, S., 
Ramamurthy, T., Tamboura, B., Adegbola, R. A., Hossain, M. J., Saha, D., Sen, S., 
Faruque, A. S., Alonso, P. L., Breiman, R. F., Zaidi, A. K., Sur, D., Sow, S. O., Berkeley, 
L. Y., O'reilly, C. E., Mintz, E. D., Biswas, K., Cohen, D., Farag, T. H., Nasrin, D., Wu, 
Y., Blackwelder, W. C., Kotloff, K. L., Nataro, J. P. & Levine, M. M. 2014. Shigella 
Isolates From The Global Enteric Multicenter Study Inform Vaccine Development. Clin 
Infect Dis, 59, 933-41. 
Lugada, E. S., Mermin, J., Kaharuza, F., Ulvestad, E., Were, W., Langeland, N., Asjo, B., 
Malamba, S. & Downing, R. 2004. Population-Based Hematologic And Immunologic 
Reference Values For A Healthy Ugandan Population. Clin Diagn Lab Immunol, 11, 29-
34. 
Passwell, J. H., Ashkenazi, S., Harlev, E., Miron, D., Ramon, R., Farzam, N., Lerner-
Geva, L., Levi, Y., Chu, C., Shiloach, J., Robbins, J. B., Schneerson, R. & Israel Shigella 
Study, G. 2003. Safety And Immunogenicity Of Shigella Sonnei-Crm9 And Shigella 
Flexneri Type 2a-Repasucc Conjugate Vaccines In One- To Four-Year-Old Children. 
Pediatr Infect Dis J, 22, 701-6. 
Passwell, J. H., Ashkenzi, S., Banet-Levi, Y., Ramon-Saraf, R., Farzam, N., Lerner-Geva, 
L., Even-Nir, H., Yerushalmi, B., Chu, C., Shiloach, J., Robbins, J. B. & Schneerson, R. 
2010. Age-Related Efficacy Of Shigella O-Specific Polysaccharide Conjugates In 1-4-
Year-Old Israeli Children. Vaccine, 28, 2231-5. 
Zhang, W., Luo, Y., Li, J., Lin, L., Ma, Y., Hu, C., Jin, S., Ran, L. & Cui, S. 2011. Wide 
Dissemination Of Multidrug-Resistant Shigella Isolates In China. J Antimicrob 
Chemother, 66, 2527-35. 
 

P P D
P P D
P P D

P P D
P P D
P P D
P P D

P P D
P P D
P P D
P P D

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 1 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
 
 
 
CLINICAL STUDY PROTOCOL H03_04TP 
Amendment 1 of 03 November 2015 
Version 2.0 of 04 November 2015 
 
Amendment 2 of 25 May 2016 
Version 3.0 of 27 May 2016 
 
Amendment 3 of 02 Nov 2016 
Version 4.0 of 03 Nov 2016 
 
 
 
  
A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate 
The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB 
Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From 
A Country Endemic For Shigellosis 
 
 
Property of GSK Vaccines Institute for Global Health (hereafter referred to as 
GVGH) 
Confidential 
May not be used, divulged, published or otherwise disclosed without written 
 consent of GSK Vaccines Institute for Global Health.

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 2 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
TABLE OF CONTENTS 
TABLE OF CONTENTS ..................................................................................................... 2 
PROTOCOL SYNOPSIS H03_04TP .................................................................................. 8 
LIST OF ABBREVIATIONS ............................................................................................ 23 
1. 
BACKGROUND AND RATIONALE .................................................................... 25 
1.1 
Background .......................................................................................................... 26 
1.2 
Rationale .............................................................................................................. 27 
2. 
OBJECTIVES ........................................................................................................... 28 
2.1 
Primary Objective(s) ............................................................................................ 28 
2.2 
Secondary Objective(s) ........................................................................................ 28 
2.3 
Exploratory Objective(s) ..................................................................................... 28 
3. 
STUDY DESIGN ..................................................................................................... 29 
3.1 
Overview of Study Design ................................................................................... 29 
3.2 
Study Period ......................................................................................................... 30 
3.3 
Blinding Procedures ............................................................................................. 30 
3.4 
Data Collection .................................................................................................... 31 
3.4.1 Data Collected from Subjects ....................................................................... 31 
3.4.2 Tools Used for Data Collection .................................................................... 31 
3.5 
Collection of Clinical Specimens ........................................................................ 32 
3.6 
Stopping/Pausing Guidelines ............................................................................... 34 
3.7 
Procedures related to neutropenia ........................................................................ 34 
3.8 
Data Monitoring Committee ................................................................................ 36 
3.9 
Premature Withdrawal from Study ...................................................................... 36 
3.10 End of Study ........................................................................................................ 39 
4. 
SELECTION OF STUDY POPULATION .............................................................. 40 
4.1 
Inclusion Criteria ................................................................................................. 40 
4.2 
Exclusion Criteria ................................................................................................ 40 
4.3 
Criteria for Delay of Vaccination ........................................................................ 42 
5. 
STUDY PROCEDURES .......................................................................................... 44 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 3 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
5.1 
Pre-vaccination Clinic Visit(s) ............................................................................ 44 
5.1.1 Informed Consent/Assent ............................................................................. 44 
5.1.2 Screening ...................................................................................................... 45 
5.1.3 Enrolment ..................................................................................................... 46 
5.1.4 Randomization .............................................................................................. 47 
5.2 
Vaccination Clinic Visit(s) .................................................................................. 47 
5.2.1 Post-vaccination Procedures ......................................................................... 48 
5.2.2 Post-vaccination Reminders ......................................................................... 48 
5.3 
Post-vaccination Visit(s) ...................................................................................... 48 
5.3.1 Follow-up Home Visit(s) .............................................................................. 48 
5.3.2 Follow-up Clinic Visit(s) .............................................................................. 49 
5.3.3 Safety Follow-up Calls ................................................................................. 50 
5.4 
Unscheduled Visits .............................................................................................. 50 
5.5 
Study Termination Visit ...................................................................................... 50 
5.5.1 Early Termination Visit ................................................................................ 51 
6. 
TREATMENT OF SUBJECTS ................................................................................ 53 
6.1 
Study Vaccine(s) .................................................................................................. 53 
6.2 
Non-Study Vaccines ............................................................................................ 54 
6.3 
Vaccine Preparation and Administration ............................................................. 54 
6.4 
Vaccine Administration Error or Overdose of Vaccine ...................................... 55 
6.5 
Prior and Concomitant Medications and Vaccines .............................................. 55 
6.6 
Vaccine Supply, Labeling, Storage and Tracking ............................................... 56 
7. 
ASSESSMENTS ...................................................................................................... 58 
7.1 
Safety Assessment ............................................................................................... 58 
7.1.1 Solicited Adverse Events .............................................................................. 58 
7.1.2 Unsolicited Adverse Events .......................................................................... 61 
7.1.3 Evaluation of Adverse Events ...................................................................... 61 
7.1.4 Serious Adverse Events ................................................................................ 63 
7.1.4.1 Adverse Events of Special Interest ........................................................ 64 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 4 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.1.5 Methods for Recording Adverse Events and Serious Adverse Events ......... 65 
7.1.5.1 Post-Study Events .................................................................................. 65 
7.1.6 Pregnancies ................................................................................................... 66 
7.1.7 Safety Laboratory Measurements ................................................................. 66 
7.2 
Efficacy Assessment ............................................................................................ 67 
7.3 
Immunogenicity Assessment ............................................................................... 67 
8. 
STATISTICAL CONSIDERATIONS ..................................................................... 68 
8.1 
Endpoints ............................................................................................................. 68 
8.1.1 Primary Endpoint(s)...................................................................................... 68 
8.1.1.1 Primary Safety Endpoint(s) ................................................................... 68 
8.1.1.2 Primary Efficacy Endpoint(s) ................................................................ 68 
8.1.1.3 Primary Immunogenicity Endpoint(s) ................................................... 68 
8.1.2 Secondary Endpoint(s).................................................................................. 68 
8.1.2.1 Secondary Safety Endpoint(s) ............................................................... 68 
8.1.2.2 Secondary Efficacy Endpoint(s) ............................................................ 68 
8.1.2.3 Secondary Immunogenicity Endpoint(s) ............................................... 69 
8.1.3 Exploratory Endpoint(s) ............................................................................... 70 
8.1.3.1 Exploratory Safety Endpoint(s) ............................................................. 70 
8.1.3.2 Exploratory Efficacy Endpoint(s) .......................................................... 70 
8.1.3.3 Exploratory Immunogenicity Endpoint(s) ............................................. 70 
8.2 
Success Criteria ................................................................................................... 70 
8.2.1 Success Criteria for Primary Objective(s) .................................................... 70 
8.2.1.1 Success Criteria for Primary Safety Objective(s) .................................. 70 
8.2.1.2 Success Criteria for Primary Efficacy Objective(s) .............................. 70 
8.2.1.3 Success Criteria for Primary Immunogenicity Objective(s) .................. 70 
8.2.2 Success Criteria for Secondary Objective(s) ................................................ 70 
8.2.2.1 Success Criteria for Secondary Safety Objective(s) .............................. 71 
8.2.2.2 Success Criteria for Secondary Efficacy Objective(s) .......................... 71 
8.2.2.3 Success Criteria for Secondary Immunogenicity Objective(s) .............. 71 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 5 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.3 
Analysis Sets ........................................................................................................ 71 
8.3.1 All Enrolled Set ............................................................................................ 71 
8.3.2 All Exposed Set ............................................................................................ 71 
8.3.3 Safety Set ...................................................................................................... 71 
8.3.4 Full Analysis Set (FAS) Immunogenicity Set .............................................. 72 
8.3.5 Per Protocol (PP) Set Immunogenicity Set ................................................... 72 
8.3.6 Other Analysis Sets....................................................................................... 72 
8.3.7 Subgroups ..................................................................................................... 73 
8.3.8 Protocol Deviations ...................................................................................... 73 
8.4 
Statistical Analysis Plan ...................................................................................... 73 
8.4.1 Analysis of Demographic and Baseline Characteristics ............................... 73 
8.4.2 Analysis of Primary Objective(s) ................................................................. 73 
8.4.2.1 Analysis of Primary Safety Objective(s) ............................................... 73 
8.4.2.1.1 
Analysis of Extent of Exposure ...................................................... 74 
8.4.2.1.2 
Analysis of Solicited Local, Systemic and Other Adverse Events . 74 
8.4.2.1.3 
Analysis of Unsolicited Adverse Events ........................................ 74 
8.4.2.1.4 
Analysis of Safety Laboratory Values ............................................ 75 
8.4.2.2 Analysis of Primary Efficacy Objective(s) ............................................ 75 
8.4.2.2.1 
Statistical Hypotheses ..................................................................... 75 
8.4.2.2.2 
Analysis Sets .................................................................................. 75 
8.4.2.2.3 
Statistical Methods ......................................................................... 76 
8.4.2.3 Analysis of Primary Immunogenicity Objective(s) ............................... 76 
8.4.2.3.1 
Statistical Hypotheses ..................................................................... 76 
8.4.2.3.2 
Analysis Sets .................................................................................. 76 
8.4.2.3.3 
Statistical Methods ......................................................................... 76 
8.4.3 Analysis of Secondary Objective(s) ............................................................. 76 
8.4.3.1 Analysis of Secondary Safety Objective(s) ........................................... 76 
8.4.3.1.1 
Analysis of Extent of Exposure ...................................................... 76 
8.4.3.1.2 
Analysis of Solicited Local, Systemic and Other Adverse Events . 76 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 6 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.4.3.1.3 
Analysis of Unsolicited Adverse Events ........................................ 76 
8.4.3.1.4 
Statistical Hypotheses ..................................................................... 76 
8.4.3.1.5 
Analysis Sets .................................................................................. 77 
8.4.3.1.6 
Statistical Methods ......................................................................... 77 
8.4.3.2 Analysis of Secondary Efficacy Objective(s) ........................................ 77 
8.4.3.2.1 
Statistical Hypotheses ..................................................................... 77 
8.4.3.2.2 
Analysis Sets .................................................................................. 77 
8.4.3.2.3 
Statistical Methods ......................................................................... 77 
8.4.3.3 Analysis of Secondary Immunogenicity Objective(s) ........................... 77 
8.4.3.3.1 
Statistical Hypotheses ..................................................................... 77 
8.4.3.3.2 
Analysis Sets .................................................................................. 77 
8.4.3.3.3 
Statistical Methods ......................................................................... 77 
8.4.4 Analysis of Exploratory Objectives .............................................................. 78 
8.4.4.1 Analysis of Exploratory Safety Objective(s) ......................................... 78 
8.4.4.2 Analysis of Exploratory Efficacy Objective(s) ..................................... 78 
8.4.4.3 Analysis of Exploratory Immunogenicity Objective(s) ......................... 78 
8.5 
Sample Size and Power Considerations of Primary Objectives .......................... 78 
8.6 
Interim Analysis ................................................................................................... 79 
9. 
SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING ...... 80 
9.1 
Source Documentation ......................................................................................... 80 
9.2 
Study Monitoring, Auditing and Source Data Verification ................................. 81 
10. 
DATA MANAGEMENT ......................................................................................... 82 
10.1 Data Entry and Management ............................................................................... 82 
10.2 Data Clarification ................................................................................................. 82 
10.3 Data Protection .................................................................................................... 82 
11. 
RECORD RETENTION .......................................................................................... 83 
12. 
USE OF INFORMATION AND PUBLICATION .................................................. 84 
13. 
ETHICAL CONSIDERATIONS ............................................................................. 85 
13.1 Regulatory and Ethical Compliance .................................................................... 85 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 7 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
13.2 Informed Consent Procedures .............................................................................. 85 
13.3 Responsibilities of the Investigator and IRB/EC ................................................. 86 
13.4 Protocol Amendments ......................................................................................... 87 
14. 
REFERENCE LIST .................................................................................................. 88 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 8 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
PROTOCOL SYNOPSIS H03_04TP 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
Title of Study:  
A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate 
The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 
1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult 
Subjects From A Country Endemic For Shigellosis. 
Study Period:  
Each subject will be followed up for 
approximately 1 month after last 
vaccination.  Following the screening 
period, the total study duration will be 
approximately 2 months for each subject. 
Clinical Phase:  
Phase 2a 
Background and Rationale:  
Shigellosis remains a major health problem in developing countries with approximately 
100 million cases per year mostly in children ≤5 years. Antibiotic resistance of Shigella 
is increasing and no vaccine is currently available against shigellosis. Among the 
Shigella serotypes that are epidemiologically more relevant, the investigators of the 
recently published GEMS study, aimed to identify the main causes of moderate to 
severe diarrhea (MSD) in Africa and Asia (Livio et al., 2014) have concluded that a 
quadrivalent vaccine containing S. sonnei and 3 serotype/subserotypes of S. flexneri (S. 
flexneri 2a, S. flexneri 3a, and S. flexneri 6) can provide broad coverage against Shigella 
serotypes (up to 65%), which cause shigellosis in the developing world, and can also 
provide broad coverage for travelers.  
The GVGH candidate vaccine against shigellosis caused by Shigella sonnei 
(1790GAHB) has been developed with a novel technology based on high yield 
production of Generalized Modules for Membrane Antigens (GMMA) from S. sonnei. 
GMMA are outer membrane particles naturally released from the S. sonnei during 
growth.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 9 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
The candidate S. sonnei 1790GAHB vaccine was chosen as a prototype Shigella vaccine 
based on the GMMA technology since S. sonnei is among the most common serotypes 
causing dysentery in humans.  
This GVGH S. sonnei 1790GAHB vaccine has been tested in two parallel Phase 1 trials 
in European adult population: H03_01TP looking at the intramuscular (IM) 
administration and H03_02TP looking at the intradermal (ID), intranasal (IN) and IM 
administration. Based on the preliminary results from these phase 1 studies, it has been 
decided to proceed with further development using only the IM route of immunization 
and to test in the proposed H03_04TP study two doses selected based on the results 
from H03_01TP study.  
The two doses have been selected as follows: 25 µg is the lowest dose that in phase 1 
consistently induced antibody titers comparable to antibodies in a population of 
convalescent subjects after natural infection while 100 µg is tested for two reasons i.e.1) 
a higher dosage may be needed to induce high antibody titers in endemic population and 
2) there is a need to test in African populations the tolerability of  a higher dose of 
GMMA that will be ultimately needed  in the multivalent vaccine against Shigellosis. 
The purpose of H03_04TP study is to evaluate the safety and the immunogenicity of 
two different doses (25 µg and 100 µg) of the GVGH S. sonnei 1790GAHB vaccine in 
healthy adults and represents the first step towards testing of the GMMA vaccine in the 
vaccine target population of children from developing countries where shigellosis is 
endemic. 
Study Objectives:  
Primary Objective:  
To evaluate the safety profile of two injections of S. sonnei 1790GAHB vaccine in 
healthy adults in a Shigella endemic country 
Secondary Objective:  
To evaluate the immunogenicity profile of two injections of S. sonnei 1790GAHB 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 10 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
vaccine in healthy adults by measuring the anti-LPS S. sonnei serum IgG. 
Study Design:  
This is a phase 2a, randomized, controlled, single center, observer blind trial that will 
enroll approximately 72 healthy adult subjects, 18-45 years of age inclusive. 
As currently there is no vaccine available against shigellosis, the safety of the 
1790GAHB vaccine will be evaluated against two licensed control vaccines: one dose 
of Menveo as 1st injection and one dose of Boostrix as 2nd injection.  
Subjects will be randomized to one of the three parallel treatment arms in a 1:1:1 ratio 
to receive either the study vaccine dose A (25 µg), the study vaccine dose B (100 µg) or 
the control vaccines as follows: 
Table 1 Overview of the Study Groups 
 
No. Subjects 
Group A (25 µg) 
24 
Group B (100 µg) 
24 
Group C (Control) 
24 
Total 
72 
Two injections of the study vaccine or the two control vaccines will be administered 28 
days apart.  
The study includes a screening visit (performed at study Days -28/-1), five Clinical 
Visits (performed at study Day 1, 7, and 28 days after 1st injection and 7 and 28 days 
after 2nd injection) and daily home visits performed for 6 days after the 1st and 2nd 
injection. 
During the screening period before 1st vaccination, subjects providing informed consent 
will be screened for general health status.  
Blood (approximately 10 mL) will be drawn from all subjects before the first injection 
(visit 1), 28 days after the first injection (visit 3), and 28 days after the second injection 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 11 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
(visit 5) for immunogenicity evaluation. 
Appropriately trained study staff will be instructed to complete the subject’s diary card 
during daily home visits following discussion with the subject to (i) describe solicited 
local (i.e. injection site erythema, induration and pain) and systemic (i.e. fever 
[temperature ≥ 38.0°C measured axillary], fatigue, malaise, myalgia, chills, arthralgia 
and headache) adverse events (AEs) occurring during the day of each injection visit 
(visit 1 and 3) and for the following 6 days; (ii) indicate if any analgesic/antipyretic to 
prevent or treat pain/fever was taken after injection.  
In addition to the solicited adverse events data, from study visit 1 through visit 5 (i.e. 
study termination visit) any unsolicited AE, all serious adverse events (SAEs), all AEs 
leading to vaccine/study withdrawal, all Adverse Events of Special Interest (AESI, see 
below) and all concomitant medications associated with those events, will be collected 
and recorded in the subject's source document and on an Adverse Events CRF(s). In 
case of such events, subjects will be instructed to contact the site as soon as possible to 
report the event(s).  
Reactive arthritis or neutropenia will be collected and analyzed as AESIs for this study.  
Number of Subjects planned:  
A total of 24 subjects per group will be enrolled in each of the three study groups in 
order to have 20 evaluable subjects in each group. This allows for a drop-out rate of 
15% during the course of the trial. Thus a total of approximately 72 subjects will be 
enrolled in the trial.  
Study Population and Subject Characteristics:  
Subjects, who meet all inclusion criteria and none of the exclusion criteria (refer to 
section 4. Selection Of Study Population), will be eligible for enrollment. 
Study Procedures: 
Before any study procedure is performed, informed consent will be obtained and 
subjects will be enrolled only after their eligibility for participation is confirmed by the 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 12 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
investigator.  
Study will be explained in either Swahili or in English where prospective participants 
express a preference.  For subjects who are illiterate the whole informed consent 
document will be explained in the presence of an impartial witness.   
For all women of childbearing potential the screening will include the evaluation of 
human chorionic gonadotropin (hCG) in blood to exclude pregnancy and women 
refusing to perform the test or with positive test will be immediately excluded from the 
study. Informed consent process will include counseling about pregnancy and family 
planning. hCG in urine will then be evaluated (using a dipstick) at visit 1 before 
randomization; it will be repeated on visit 3 before 2nd vaccination and on the day of the 
last study visit (visit 5). The pregnancy test should be negative prior to each injection. 
All pregnancies that occur during the study will be recorded into the Pregnancy CRF 
appropriate pages and followed until delivery or abortion, as applicable. 
Female subjects of child-bearing potential must use acceptable birth control measures 
(defined as oral, injected or implantable contraceptives) for the two months preceding 
1st vaccination and during entire study participation.  
Vaccination Procedure: Subjects will receive the study vaccines at study Day 1 (visit 1) 
and at study Day 29 (visit 3) in accordance with group assignment in a blinded fashion. 
Vaccines should be administered by unblinded study personnel by deep IM injection 
into the deltoid area of the non-dominant arm unless there is a reason to vaccinate 
elsewhere which should be documented. After receiving the vaccination, subjects will 
be observed for at least 1 hour for any immediate reactions.  
Procedure for collection of solicited AE: appropriately trained study staff will record 
solicited local and systemic adverse events and medications/vaccinations taken/received 
by the subject into a Diary Card and following discussion with the subject. Beginning in 
the evening  following study vaccine administration (approximately 6 hours), and daily 
thereafter through the following 6 days, solicited local and systemic adverse events 
including other reactions (i.e. body temperature measurements and use of 
analgesics/antipyretics) will be reported daily by field workers on a Diary Card. For this 
purpose daily home visits will be performed for 6 days after each injection and a 
consultation at the vaccination clinic will be performed at 7 days after each injection 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 13 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
(clinic Visits 2 and 4). 
Any unsolicited AE occurring during the day of injection with study vaccines and for 
the following 28 days, solicited local and systemic AE that continue beyond 7 days after 
study vaccination, all SAEs, AEs leading to vaccine/ study withdrawal, AESI and 
concomitant medications associated with those events will be collected and recorded 
from Visit 1 to Visit 5 in the subject's records and on the Adverse Events CRF. The 
information obtained by study personnel will be recorded on the appropriate web based 
system, referred to as Electronic Data Capture (EDC). 
Safety procedures: All subjects providing informed consent will undergo a general 
physical examination at the screening visit (study Day -28/-1) and at visit 1 (Day 1) for 
evaluation of the general health status by clinical assessment, verification of inclusion 
and exclusion criteria and review of medical history. On visit 3, prior to 2nd injection 
with the investigational vaccine or control, subjects will be assessed for continued 
eligibility with regard to the inclusion and exclusion criteria and physical examination. 
A brief symptom-directed physical examination (if necessary according to symptoms 
the subject has reported) will be performed at Clinic visits 2, 4 and 5.  
Blood Draw Procedure: Approximately 10 mL of blood will be obtained as part of the 
initial screening for hematology, renal, and liver function tests, and serological tests for 
hepatitis B and HIV. In addition, an analysis of the urine will be performed. Each 
randomized subject will have 10 mL of blood drawn before the 1st and 2nd vaccination, 
and 28 days after the 2nd vaccination for immunological studies. Additional blood draws 
of 10 mL for hematology, renal and liver panels will be obtained 7 and 28 days after 1st 
and 2nd vaccination, urinalysis will be conducted at the same time points. 
All subjects will undergo study termination procedures on visit 5 (28 days after 2nd 
injection visit). 
Study Vaccines:  
GVGH S. sonnei (1790GAHB) vaccine 
The investigational agent is the GVGH S. sonnei vaccine. The vaccine consists of S. 
sonnei 1790-GMMA (approximately 200 µg/mL, measured by protein content) 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 14 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
adsorbed to Alhydrogel (0.7 mg Al3+/mL) in Tris-buffered saline. The vaccine does not 
contain any preservative and is available as a liquid formulation in single dose vials 
with 0.7 mL of injectable solution containing approximately 140 µg of GMMA (as 
protein content), adsorbed onto 0.49 mg Al3+.  
The vaccine will be used at two different antigen doses obtained by bed-side mixing. 
Following dilution with Alhdyrogel (0.7 mg Al3+/mL) in Tris–buffered saline, the 
volume administered will be 0.5 mL for both doses: 
Group A: Each 0.5 mL dose of 1790GAHB will contain approximately 25 μg of 
GMMA total protein and 0.35 mg of Al3+.  
Group B: Each 0.5 mL dose of 1790GAHB will contain approximately 100 μg of 
GMMA total protein and 0.35 mg of Al3+.  
Bedside mixing, possibly necessary additional labelling of clinical study materials at the 
study site and vaccine administration will be performed according to GVGH 
instructions and by trained site staff. The site staff responsible for these activities will be 
personnel who are respectively qualified according to applicable laws and regulations. 
GVGH will provide specific procedures and training for these activities. 
Control vaccines 
Menveo: vaccine indicated for active immunization to prevent invasive meningococcal 
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. The vaccine 
contains no preservative or adjuvant. Each 0.5 mL dose of vaccine contains 10 μg 
MenA oligosaccharide, 5 μg of each of MenC, MenY and MenW-135 oligosaccharides 
conjugated to 32.7 to 64.1 μg of CRM197 protein. 
Boostrix: Vaccine indicated for active booster immunization against tetanus, diphtheria, 
and pertussis. It contains tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis antigens (inactivated pertussis toxin [PT], formaldehyde-treated filamentous 
hemagglutinin [FHA] and pertactin). Each antigen is individually adsorbed onto 
aluminum hydroxide.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 15 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
No other concomitant vaccines or treatments will be used as part of study procedures. 
Primary Endpoint(s):  
The safety profile of the two injections of the investigational vaccine and control(s) will 
be assessed through measurement of the following:  
a. Number and percentage of subjects with solicited local and systemic adverse 
reactions during 7 days following each vaccination. 
b. Numbers and percentage of subjects with deviations from normal ranges of safety 
laboratory data after each vaccination.  
c. Number and percentage of subjects with reported unsolicited adverse events during 
28 days following each vaccination.  
d. Number and percentage of subjects with reported SAEs throughout the study 
duration. 
e. Number and percentage of subjects with reported reactive arthritis or neutropenia 
(defined AESIs). 
Secondary Endpoint(s):  
The measures of the immunogenicity outcome, (i.e., the anti-LPS S. sonnei serum IgG), 
will include: 
a. IgG geometric mean concentrations (GMCs) pre-vaccination (Day 1), 28 days after 
1st vaccination and 28 days after 2nd vaccination, as determined by Enzyme-linked 
Immunosorbent Assay (ELISA), and applicable geometric mean ratios between post- 
and pre-vaccination samples. 
b. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination 
Seroresponse is aimed to define a significant increase in post vaccination samples based 
on the biological performance of this specific serology assay and it is defined as:  
- 
If the baseline value is greater than 50 ELISA Units (EU) then an increase of at 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 16 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
least 50% in the post-vaccination sample as compared to baseline [i.e. ((Post-vac 
minus baseline)/baseline)100% ≥ 50%] 
- 
If the baseline value is less or equal to 50 EU then an increase of at least 25 EU in 
the post-vaccination sample as compared to baseline [i.e. (post-vac minus baseline) 
≥ 25 EU] 
c. Number and percentage of subjects with titers post vaccination concentration ≥ 121 
for anti-LPS S. sonnei at 28 days after 1st vaccination and 28 days after 2nd vaccination 
d. IgG GMCs pre-vaccination (Day 1), 28 days after 1st vaccination and 28 days after 
2nd vaccination by antibody titer at baseline (i.e., above vs. below the assay detection 
limit), as determined by ELISA, and applicable geometric mean ratios between post- 
and pre-vaccination samples. 
e. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination by antibody titer at baseline 
(i.e., above vs. below the assay detection limit).  
A post vaccination concentration ≥ 121 anti-LPS serum IgG units in the GVGH ELISA 
corresponds to a titer of 1:800 in the ELISA method used by Cohen et al. (1989 J. Clin. 
Microbiol. 27:162). This antibody level is the median antibody concentration of a set of 
87 convalescent subjects previously infected by S. sonnei. The value of 121 anti-LPS 
serum IgG units in the GVGH ELISA was determined by calibration against the Cohen 
ELISA (i.e., the GVGH standard serum was tested in Cohen’s lab using the Cohen’s 
methodology). 
Exploratory endpoints 
Other assays, including serum secretory IgA, might be done to further characterize the 
immune response to the study vaccine. 
Statistical Analyses:  
This Phase 2a safety and immunogenicity study is aimed to descriptively evaluate the 
safety and immunogenicity profiles of the study vaccines. No specific hypotheses are 
tested in this trial. A total of 72 subjects will be enrolled in this study: 24 subjects per 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 17 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Name of Sponsor: 
GSK Vaccines 
Institute for Global 
Health (GVGH) 
Protocol number: 
H03_04TP 
Generic name of study vaccine(s): 
S. sonnei 1790GAHB Vaccine 
 
group will be enrolled in order to have 20 evaluable subjects in each group (15% drop-
out rate). With 20 evaluable subjects in each vaccine group, the probability of observing 
at least one adverse event per group is 87%, if the actual rate of the event is 10%.  
Interim Analysis:  
For up to 45 subjects, once they have completed the study, a group unblinded 
preliminary immunogenicity analysis and a blinded interim safety analysis will be 
performed. Individual subject results from preliminary analyses will not be made 
available to site and sponsor personnel until the end of the study. The results of these 
immunogenicity and safety analyses will not impact the conduct of the study, but will 
inform the planning of future studies with the same vaccine (see also section 8.6 of the 
protocol).  
Data Monitoring Committee:  
An independent data safety monitoring board (DSMB) will receive a summary of all 
safety data (solicited local and systemic AE, unsolicited AE and SAEs) and listings of 
clinically significant modifications in hematology, blood chemistry and urine 
dipstick/urinalysis test values obtained during one week follow-up post-first vaccination 
of the initial 18 subjects. Further recruitment will be put on hold until the DSMB 
opinion is received.  
Throughout the entire study the DSMB will be consulted for any safety issue that might 
be reported during the trial. 
See section 3.8 of the protocol for more details. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 18 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Table 2 
Time and Events Table 
Study Periods 
Screening 
Treatment 
Visit Type 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Visit Number 
n/a 
1 
Daily for 6 
days 
2 
3 
Daily for 6 days 
4 
5 
Study Day* 
n/a 
1 
 
V1+7 
V1+28 
 
V3+7 
V3+28 
Time Window (days) (min/max) 
-28/-1 
0 
0 
0/+1 
0/+7 
0 
0/+1 
0/+7 
Study Event 
References 
 
Study Treatment 
Vaccination  
Section 5.2 
 
X 
 
 
X 
 
 
 
Screening and Safety 
Informed Consent[a] 
Section 5.1.1 
X 
 
 
 
 
 
 
 
Medical History 
Section 5.1.2 
X 
 
 
 
 
 
 
 
Physical Examination[b] 
Sections 5.1.2 and 5.3.1 
X 
X 
 
X 
X 
 
X 
X 
Pregnancy Test  
Sections 5.5.2 and 5.1.2 
X 
(blood) 
X 
(urine) 
 
 
X 
(urine) 
 
 
X 
(urine) 
Inclusion/Exclusion Criteria[c] 
Section 4.0 
X 
X 
 
 
X 
 
 
 
Randomization 
Section 5.1.4 
 
X 
 
 
 
 
 
 
Blood draw for Serology for HIV, 
HBV 
Section 5.1.2 
X 
 
 
 
 
 
 
 
Safety blood draw[d] 
Sections 3.5 and 5.1.2 
X 
 
 
X 
X 
 
X 
X 
Urine dipstick (urinalysis as 
required) 
Sections 3.5 and 5.1.2 
X 
 
 
X 
X 
 
X 
X 
Post Injection Assessment[e] 
Sections 5.1.2 
 
X 
 
 
X 
 
 
 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 19 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Study Periods 
Screening 
Treatment 
Visit Type 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Home visits 
Clinic 
Clinic 
Visit Number 
n/a 
1 
Daily for 6 
days 
2 
3 
Daily for 6 days 
4 
5 
Study Day* 
n/a 
1 
 
V1+7 
V1+28 
 
V3+7 
V3+28 
Time Window (days) (min/max) 
-28/-1 
0 
0 
0/+1 
0/+7 
0 
0/+1 
0/+7 
Study Event 
References 
 
Post Injection Assessment[f] 
Sections 5.2.1 and 5.3.1 
and 5.3.2 
 
X 
X 
X 
X 
X 
X 
 
Assess all AEs[g] 
Section 7.1 
 
X 
X 
X 
X 
X 
X 
X 
Assess/ Inquire about AE leading 
to withdrawal, all SAE and AESI[h] 
Sections 7.1.4.1 and 
7.1.3 
 
X 
X 
X 
X 
X 
X 
X 
Assess Medications and 
Vaccinations 
Sections 5.1.2 and 6.5 
X 
X 
X 
X 
X 
X 
X 
X 
Study Termination 
Section 5.5 
 
 
 
 
 
 
 
X 
Immunogenicity 
Serology blood draw 
Sections 3.5 and 7.3 
 
X 
 
 
X 
 
 
X 
* Study days should be calculated based on the actual date of the previous visit (as to comply with requested Study Visit Time Window) 
a. 
Informed Consent to be obtained before any study procedure 
b. Physical examination must be performed by a qualified health professional in accordance with local regulations and licensing requirements designated 
within the Site Responsibility Delegation Log.  
c. 
Compliance with Exclusion/Inclusion criteria should be verified.  
d. In case of neutropenia, Complete Blood Count to be repeated on a weekly basis until resolution. If neutropenia occurs at the last study visit, Complete 
Blood Count to be repeated on a regular basis until resolution.  
e. 
A post-injection local and system adverse event and body temperature measurement will be performed approximately 30 and 60 minutes after each 
vaccination during the clinic visit.   

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 20 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
f. 
Beginning in the evening  following study vaccine administration (approximately 6 hours), and daily thereafter through the following 6 days, solicited 
local and systemic adverse events including body temperature measurements and use of analgesics/antipyretics will be reported by field workers in a 
diary card based on subject’s observation and interview.  
g. All unsolicited adverse events will be captured through 28 days following each vaccination.  
h. SAEs, AESI and AEs leading to study or vaccine withdrawal will be collected through entire study duration. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 21 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Table 3  
Safety Tests Table  
HEMATOLOGY 
White Blood Cells (WBC) 
Red Blood Cells (RBC) 
Haemoglobin 
Haematocrit 
Platelets 
Eosinophils 
Basophils 
Neutrophils 
Monocytes 
Lymphocytes 
Prothrombin time* 
CLINICAL CHEMISTRY 
Total bilirubin 
Aspartic Aminotransferase (ASAT/GOT) 
Alanine Aminotransferase (ALAT/GPT) 
γ-Glutamyl Transferase (γ-GT) 
Lactic Dehydrogenase (LDH) 
Alkaline Phosphatase (AP) 
Total Proteins* 
Glucose (random glucose) 
Blood Urea Nitrogen (BUN) 
Creatinine 
Sodium 
Potassium 
SEROLOGY for VIROLOGY 
HbsAg* 
HIV antibodies* 
PREGNANCY TEST 
Human chorionic gonadotropin (hCG) in blood * 
Human chorionic gonadotropin (hCG) in urine 
* Performed at screening only 
 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 22 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
URINE DIPSTICK 
Glucose 
Proteins 
pH 
Ketones 
Nitrites 
Blood 
URINALYSIS: Microscopic test on urine 
(performed if urine dipstick shows deviations from normal values) 
Leucocytes (WBC) 
Erythrocytes (RBC) 
Epithelial Cells 
Casts 
Bacteria 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 23 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
LIST OF ABBREVIATIONS 
AE 
 
Adverse Event 
AESI 
 
Adverse Events of Special Interest 
AP 
 
(Statistical) Analysis Plan 
ANC 
 
Absolute Neutrophil Count 
BMI 
 
Body mass index 
BUN 
 
Blood Urea Nitrogen 
CBC 
 
Complete Blood Count 
CI 
 
Confidence Interval 
CRF 
 
Case Report Form 
CRO 
 
Contract Research Organization 
DSMB 
 
Data Safety Monitoring Board 
EC 
 
Ethics Committee 
eCRF 
 
Electronic Case Report Form 
EDC 
 
Electronic Data Capture 
EDT 
 
Electronic Data Transfer 
ELISA 
 
Enzyme-linked Immunosorbent Assay 
EMA 
 
European Medicines Agency 
FAS 
 
Full Analysis Set 
FDA 
 
Food and Drug Administration 
GCP 
 
Good Clinical Practices 
GMC 
 
Geometric Mean Concentration 
GMMA 
 
Generalized Modules for Membrane Antigens 
GMR 
 
Geometric Mean Ratio 
GMT 
 
Geometric Mean Titer 
HIV 
 
Human Immunodeficiency Virus 
IB 
 
Investigator’s Brochure 
ICF 
 
Informed Consent Form 
ICH 
 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
ID 
 
Intradermal 
IM 
 
Intramuscular 
IN 
 
Intranasal 
IV 
 
Intravenous 
IRB 
 
Institutional Review Board 
ITT 
 
Intention-To-Treat 
MITT 
 
Modified Intention-To-Treat 
MSD 
 
Moderate to Severe Diarrhea 
LPS 
 
Lipopolysaccharide 
LSLV 
 
Last Subject Last Visit 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 24 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
MedDRA 
 
Medical Dictionary for Regulatory Activities 
NOCD 
 
New onsets of chronic diseases 
OAg 
 
O antigen (of Shigella sonnei) 
OMV 
 
Outer Membrane Vesicles 
PO 
 
Per Os (orally) 
PP 
 
Per Protocol 
PSB 
 
Product Stewardship Board 
ReA 
 
Reactive arthritis 
SAE 
 
Serious Adverse Event 
GVGH 
 
GSK Vaccines Institute for Global Health 
SDA 
 
Source Data Agreement 
SOC 
 
System Organ Class 
SOP 
 
Standard Operating Procedure 
SPC 
 
Summary of Product Characteristics 
WHO 
 
World Health Organization 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 25 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
1. 
BACKGROUND AND RATIONALE 
Shigella spp. are Gram-negative bacteria that infect the intestinal epithelium and are 
major causes of diarrhea, including dysentery. Shigella is transmitted by the fecal-oral 
route and taken up by contaminated food or water. It is endemic throughout the world but 
the main burden of disease is in developing countries. In 2009, the World Health 
Organization (WHO) estimated approximately 125 million cases of shigellosis per year in 
Asia alone (Bardhan et al., 2010).  Ninety-nine percent of all cases occur in developing 
countries and approximately 70% in children younger than 5 years of age (Kotloff et al., 
1999). Current estimates of mortality vary between 108,000 worldwide 
(http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index6.html) and 14,000 in Asia where 
previously 80% of all deaths were estimated to occur. Sixteen serotypes (all 14 S. flexneri, 
S. sonnei, and S. dysenteriae type I) are considered to be of global importance (Zhang et 
al., 2011) with Shigella sonnei being the most common serotype worldwide. 
Among the Shigella serotypes that are epidemiologically more relevant, the investigators 
of the recently published GEMS study, aimed to identify the main causes of moderate to 
severe diarrhea (MSD) in Africa and Asia (Livio et al., 2014) have shown that 8 Shigella 
serotypes are approximately responsible for 87% of the disease. However, they concluded 
that a quadrivalent vaccine containing S. sonnei and 3 serotype/subserotypes of S. flexneri 
(S. flexneri 2a, S. flexneri 3a, and S. flexneri 6) can provide a sufficiently broad coverage 
against Shigella serotypes (up to 65%), which cause the majority of endemic pediatric 
shigellosis in the developing world, and can also provide broad coverage for travelers. 
In target populations, treatment options for shigellosis are limited. Shigellosis can be 
treated with appropriate antibiotics. However, antibiotic resistance is increasing and many 
Shigella isolates are resistant to two or more of the common antibiotics ampicillin, 
chloramphenicol, nalidixic acid, co-trimoxasole. Resistance to third generation 
antibiotics, especially ciprofloxacin, has been reported to be emerging (Zhang et al., 
2011). Still effective antibiotics include ceftriaxone that is administered intramuscularly 
or intravenously and is not easily accessible for people in impoverished communities. 
No vaccine is available. Natural infection (experimental infection or vaccination with 
attenuated Shigella), leads to good protective immunity, but despite the generally high 
genetic conservation between serotypes, the protection is highly specific for the infecting 
serotype. This suggests that the dominant protective antigen is the O antigen (OAg) of the 
lipopolysaccharide (LPS). There have been many attempts to make a Shigella vaccine, 
using inactivated whole cell bacteria either orally or parentally (low efficacy, high 
reactogenicity for parenteral), attenuated live oral vaccines (no vaccine has yet obtained a 
useful balance between attenuation and efficacy), recombinant surface proteins (several 
projects at an early stage), O antigen conjugates (Levine et al., 2007). The latter have 
been the most successful to date with a parenteral S. sonnei and S. flexeneri type 2OAg 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 26 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
conjugates tested in field trials in Israel that achieved 74% efficacy in adults (Cohen et al., 
1997) with one immunization and 71% efficacy in children 3 years of age and older with 
2 vaccinations (Passwell et al., 2003, Passwell et al., 2010). No significant efficacy was 
achieved in younger children in accordance with a very low immunogenicity in the young 
children. As expected for an OAg vaccine, this was highly serotype specific and the S. 
sonnei OAg afforded no protection against infection with S. flexneri nor did a S. flexneri 
2a based OAg conjugate protect against S. sonnei. In addition, to achieve broad-spectrum 
protection against the 16 serotypes that are currently considered to be globally important, 
a multivalent OAg-vaccine will be needed. Therefore, new vaccine development 
approaches are needed. 
GSK Vaccines Institute for Global Health (GVGH) candidate vaccine against shigellosis 
caused by Shigella sonnei (1790GAHB) is based on a parenteral vaccine targeting the 
OAg but using a new platform technology called Generalized Modules for Membrane 
Antigens (GMMA) as a novel delivery system which may be applicable also for other 
vaccines against Gram-negative pathogens. GMMA are naturally shed from the surface of 
Gram-negative bacteria and consist of outer membrane proteins, outer membrane lipids, 
including phospholipids and LPS, and enclosed periplasmic proteins (Beveridge, 1999). 
In the previous literature, GMMA are called outer membrane vesicles (OMV). However, 
this term has also been used for vesicles derived by detergent-extraction of homogenized 
bacteria which are used as vaccines, e.g. to control Neisseria meningitidis type B 
infections in New Zealand (MeNZB) or other broader coverage MenB vaccines 
(Bexsero). In order to clearly differentiate these different types of particles, the name 
‘GMMA’ was introduced for the blebs spontaneously released from the cell surface 
(Berlanda Scorza et al., 2012). The natural arrangement of the outer membrane is 
preserved during the release of GMMA and therefore GMMA allow an optimal exposure 
of the antigens of the outer membrane for recognition by the host immune system. GVGH 
has developed an economic process to purify GMMA in large quantities from high 
density cultures of bacteria genetically modified to increase GMMA production and 
generate a LPS with low endotoxicity, suitable for use in humans. S. sonnei was chosen as 
the proof of concept for the GMMA technology and as a prototype Shigella GMMA 
vaccine since S. sonnei is among the most common serotypes causing dysentery in 
humans.  
A comprehensive review of GVGH 1790GAHB vaccine is contained in the Investigator’s 
Brochure (IB) supplied by GVGH; this document should be reviewed prior to initiating 
the study. 
1.1 
Background 
This GVGH S. sonnei 1790GAHB vaccine has been tested in two Phase 1 trials in 
European adult population: H03_01TP, looking at the intramuscular (IM) administration, 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 27 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
and H03_02TP, looking at the intradermal (ID), intranasal (IN) and IM administration. 
Based on the results from these phase 1 studies, it has been decided to proceed with 
further development using only the IM route of immunization and to test in the proposed 
H03_04TP study two doses selected based on the results from H03_01TP study. The two 
doses have been selected as follows: 25 µg is the lowest dose that in phase 1 induced 
antibody titers comparable to antibodies in a population of convalescent subjects after 
natural infection already after the first vaccination, while 100 µg is tested for two reasons 
i.e.1) a higher dose may be needed to induce high antibody titers in endemic population 
and 2) there is a need to test in African populations the tolerability of a higher dose of 
GMMA that will be ultimately needed in the multivalent vaccine against Shigellosis. 
The proposed H03_04TP trial is the logical continuation of the two Phase 1 studies and is 
aimed to evaluate the safety and immunogenicity profile of 1790GAHB in adults from an 
African country, where shigellosis remains a major health problem.  
The dose regimen tested in phase 1 studies (three doses given 1 month apart) did not 
show any significant benefit from the third dose in terms of immunogenicity, therefore a 
two dose schedule was selected for the current trial. The two dose schedule will allow 
evaluation of the immunogenicity in the endemic population where one dose may be not 
enough to induce the same immunogenicity observed in European population.  
During the two phase 1 trials two subjects of African descent experienced a transient and 
clinically asymptomatic decrease of circulating neutrophils of grade 3 (severe) that was 
finally classified as "benign ethnic neutropenia". In addition, six more subjects 
experienced transient and clinically asymptomatic grade 2 (moderate) neutropenia. 
Although this finding was not associated with any clinical illness, some precautionary 
procedures for enrollment and monitoring of trial subjects have been introduced to protect 
the safety of study subjects (refer to Section 3.7, Procedures Related to Neutropenia).  
The trial will be conducted in compliance with the protocol, GCP and applicable 
regulatory requirement(s). 
1.2 
Rationale 
The purpose of H03_04TP study is to evaluate the safety and the immunogenicity of two 
different doses (25 µg and 100 µg) of the GVGH S. sonnei 1790GAHB vaccine in healthy 
adults in Africa and represents the first step towards testing of the GMMA vaccine in the 
vaccine target population of children from developing countries where Shigellosis is 
endemic. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 28 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2. 
OBJECTIVES 
2.1 
Primary Objective(s) 
Primary Safety Objective(s) 
To evaluate the safety profile of two injections of S. sonnei 1790GAHB vaccine in 
healthy adults in a Shigella endemic country 
2.2 
Secondary Objective(s) 
Secondary Immunogenicity Objective(s) 
To evaluate the immunogenicity profile of two injections of S. sonnei 1790GAHB 
vaccine in healthy adults at 28 days after 1st vaccination and 28 days after 2nd vaccination, 
by measuring the anti-LPS S. sonnei serum IgG. 
2.3 
Exploratory Objective(s) 
This study has no exploratory objectives.

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 29 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
3. 
STUDY DESIGN 
3.1 
Overview of Study Design 
This is a phase 2a, randomized, observer blind, controlled single center study in healthy 
adult women and men healthy volunteers evaluating the safety and immunogenicity of 
two doses of the GVGH vaccine against Shigella sonnei infections (1790GAHB). As no 
vaccine is currently available against shigellosis, the safety profile of the 1790GAHB 
vaccine will be evaluated in comparison to that of two control vaccines, Menveo as 1st 
vaccination and Boostrix as 2nd vaccination. All subjects and blinded study personnel will 
be blinded to treatment throughout the study.  
This clinical trial has been designed to minimize pain, discomfort, fear and any other 
foreseeable risks. During the screening period, subjects giving informed consent will be 
screened for general health status. No pharmacokinetic tests will be performed as 
evaluation of pharmacokinetic properties is not required for vaccines unless new delivery 
systems are employed or when the vaccine contains novel adjuvants or excipients 
(Berlanda Scorza et al., 2012). Subjects who meet all inclusion criteria and none of the 
exclusion criteria, with screening tests within normal values and women of child bearing 
potential with negative pregnancy test will be eligible for enrollment. Female subjects of 
child bearing potential must use birth control measures during study participation. 
A total of 72 eligible subjects will be assigned to one of the three parallel treatment arms 
in a 1:1:1 ratio to receive either the study vaccine dose A (25 µg), the study vaccine dose 
B (100 µg) or the control vaccines as follows: 
Table 3.1-1 Overview of the Study Groups 
 
No. Subjects 
Group A (25 µg) 
24 
Group B (100 µg) 
24 
Group C (Control) 
24 
Total 
72 
Subjects will be randomized to one of the three vaccine groups and all subjects will 
receive two intramuscular vaccinations, four weeks apart. 
Screening/baseline clinical safety labs will take place before Visit 1 (from -28 up to -1 
day). Blood will be obtained as part of the initial screening for hematology, renal, and 
liver function tests, and serological tests for hepatitis B and HIV. In addition, an analysis 
of the urine will be performed. Each randomized subject will have blood collected before 
the 1st and 2nd vaccination, and 28 days after the 2nd vaccination for immunological 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 30 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
testing. Additional blood draws for hematology, renal and liver panels will be obtained 7 
and 28 days after 1st and 2nd vaccination, urine dipstick/urinalysis will be conducted at the 
same time points. All individuals with a neutropenia occurring at any time during the 
study will have additional blood draws to repeat complete blood count on a weekly basis 
until the neutropenia resolves (for classification of neutropenia during the trial, refer to 
Section 3.7, Procedures Related to Neutropenia). 
Subjects will be observed at the clinic for at least 1 hour after each vaccination. In order 
to avoid excluding participants who cannot read and write, safety information (solicited 
local and systemic AE including body temperature measurements and use of 
analgesics/antipyretics) and medications/ vaccinations received beginning in the evening  
following study vaccine administration and daily thereafter through the following 6 days, 
will be recorded by appropriately trained study staff in a Diary Card, following discussion 
with the subject. For this purpose daily home visits will be performed on the day of the 
injection and for 6 days after each injection and a consultation at the vaccination clinic 
will be performed at 7 days after each injection (clinic Visits 2 and 4). 
Any unsolicited AE, serious adverse events (SAEs), all AEs leading to vaccine/study 
withdrawal, reactive arthritis and neutropenia (adverse event of special interest (AESI)) 
and all concomitant medications associated with those events, will be collected for the 
entire study and recorded in the subject’s source document.  
3.2 
Study Period 
Each subject should expect to participate in the study for 2 months, from the time of 
enrolment through the last study visit. 
3.3 
Blinding Procedures 
The identity of the study vaccine and control cannot be concealed as presentations are 
different. 
Therefore an observer blind study design has been chosen: during the study, designated 
unblinded trained and qualified site staff (please see section 5.3) will be responsible for 
preparing the study vaccine or controls out of view of the subject and an unblinded 
nurse(s) or clinician(s) will be responsible for administering the study vaccines to the 
subjects. The unblinded staff will be instructed not to reveal the identity of the study 
vaccines either to the subject or the other investigative site personnel involved in the 
conduct of the trial. The designated unblinded pharmacists, nurse(s) or clinician(s) will 
not take part in evaluating the subject(s) for safety or collect study data after the 
administration of the study vaccine.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 31 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Study vaccines allocations will not be available to the investigator or blinded personnel 
monitoring the trial until after the completion of the trial and final data review. Adherence 
to the randomization list will be verified by a designated and unblinded Study Monitor, 
independent of the staff involved in the regular monitoring of the study, by checking the 
randomization list against the vaccination records maintained at the study site. 
Except in the case of medical necessity, a subject’s treatment should not be unblinded 
without the approval of the Sponsor. In such instance of medical emergency, every effort 
should be made to contact the Sponsor prior to unblinding. If unblinding should occur (by 
either accidental unblinding or emergency unblinding for a serious adverse event) prior to 
completion of the study, the investigator must promptly contact the Sponsor and 
document the circumstances on the appropriate forms. Instructions regarding emergency 
unblinding will be provided to the investigator. 
3.4 
Data Collection 
3.4.1 Data Collected from Subjects 
The following data will be collected from each subject over the duration of their study 
participation: 
 Demographic Information. 
 Post-vaccination immediate reactions. 
 Body temperature. 
 Adverse Events. 
 Medical History. 
 Concomitant Medications. 
All data collected must only be identified using the GVGH Subject ID and Subject code, 
as described in section 5.1.4, Randomization. 
3.4.2 Tools Used for Data Collection 
Data will be recorded in a Subject Diary Card by appropriately trained study staff and 
entered on Case Report Forms (CRFs). 
The subject Diary Card will be the only source document allowed for solicited local and 
systemic adverse events (including body temperature measurements), starting after the 
initial 60 minute post-vaccination period at the clinic. The following additional rules 
apply to documentation of safety information collected in the Diary Card. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 32 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
The Investigator or delegated staff should monitor the Diary Card status throughout the 
study for compliance and any solicited local and systemic adverse events that were of 
concern to the subject. 
1. No corrections or additions to the information recorded by the trained study staff 
within the Diary Card will be allowed after it is delivered to the site. 
2. Any blank or illegible fields on the Diary Card must be described as missing in the 
CRF. 
Case Report Forms 
This study utilizes Case Report Forms (CRFs) to collect study-related data from each 
subject. A qualified site staff member(s) is required to enter subject data in the CRFs in 
English based on the medical information available in each subject’s source record. 
Data should be entered into the CRF in a timely fashion following each subject’s clinic 
visit, study procedure, or home visit. Each subject’s CRF casebook will be compared with 
the subject’s source records by a GVGH-approved study monitor (or designee) over the 
duration of the study in order to ensure data collection accuracy. 
3.5 
Collection of Clinical Specimens 
The following clinical specimens are required to be collected from each subject in this 
study: 
 Blood 
 Urine 
Blood Specimens 
A maximum of 10 mL of blood will be obtained as part of the initial screening. The blood 
will be used for pregnancy testing in females of child bearing potential and for 
hematology, renal and liver function tests, and serological tests for hepatitis B and HIV in 
all subjects as described in synopsis Table 3, Hematological, Haematochemical Blood 
Tests and Urinalysis Table. The safety laboratory assays will be conducted at the Clinical 
Trials Laboratory, Kilifi, Kenya. 
Each randomized subject will have blood collected before the 1st and 2nd vaccination, and 
28 days after the 2nd vaccination for immunological assays. The blood volume will not 
exceed 10 mL at each time point in order to provide the necessary serum volume 
(approximately half of the blood draw volume) for the serology assays.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 33 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Serum samples will be stored frozen below -20ºC. One aliquot of serum will be 
maintained at the KEMRI-Wellcome Trust laboratory. The other aliquots will be shipped 
according to guidelines provided by the sponsor to the laboratories for analysis. The 
serologic assays will be conducted at the GSK Clinical Serology Laboratory, Marburg, 
(Germany) or a delegated laboratory. 
Aliquots of sera will be archived for 15 years both at KEMRI-WT laboratory in Kilifi and 
GSK laboratory in Marburg (Germany) for future research on immunogenicity of the 
Shigella vaccine. Study-related future research may include additional evaluation of 
immunogenicity on Shigella sonnei (i.e. IgM, IgA against the O antigen or IgG against 
other antigens of Shigella sonnei). Non-study related future research may include 
serology on other Shigella serotypes and other bacteria causing infectious diseases in 
developing countries (e.g. Salmonella Typhi, Salmonella Paratyphi, non-typhoidal 
Salmonella, meningitis) to inform development of other vaccines relevant to the 
populations in developing countries. It may not be possible to contact individual 
participants in the future in order to disseminate results obtained from research conducted 
on archived samples. However, these results, if relevant, will be published in open access 
peer-reviewed journals and disseminated to Kilifi county leaders and the community. An 
archival time of 15 years should cover the entire vaccine development time, including the 
possibility to address potential questions from regulators during the registration time. 
Complete instructions for processing, labeling, storage and shipping of samples are 
included in the Clinical Specimen Laboratory Manual provided by sponsor and available 
in the Investigator Site File. 
Additional blood draws of 10 mL for hematology, renal and liver function tests will be 
obtained 7 and 28 days after 1st and 2nd vaccination.  
See section 7, Assessments for additional details. 
The total amount of blood collected over the study period (including the screening) per 
subject will be 80 mL. 
Blood samples must be collected in the appropriate manner, using exclusively materials 
and guidelines supplied by the sponsor. The investigator must ensure that his/her 
personnel and the laboratory(ies) under his/her supervision comply with this requirement. 
The results of safety testing will be recorded in the source document and CRF. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 34 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Urine Specimens 
Urine will be collected for urine dipstick/urinalysis as part of the initial screening, before 
the 2nd vaccination, and 7 and 28 days after the 1st and 2nd vaccination. Urine samples will 
be also used for pregnancy testing in females of child bearing potential before the 1st and 
2nd vaccination, and 28 days after the 2nd vaccination.  
The results of urine dipstick/urinalysis will be recorded in the source document and CRF. 
3.6 
Stopping/Pausing Guidelines 
At the end of the 7 days observation period following 1st vaccination of the initial 18 
subjects, a summary of all safety data (solicited local and systemic AE, unsolicited AE 
and SAE), listings of hematology, blood chemistry and urine dipstick/ urinalysis test 
values and respective clinically significant modifications, if any, will be provided to the 
DSMB. Based on evaluation of the safety data, the DSMB will make a recommendation, 
as to whether the enrollment can be completed or not. Additionally, DSMB will make a 
recommendation, as to whether the enrollment of further subjects could be done using the 
published local normal ranges for neutrophils in Africa (Karita et al., 2009) or should 
instead be continued using the western normal ranges adopted for the first 18 subjects. 
Enrollment for the subsequent subjects will be started immediately after DSMB review 
and confirmation in writing. 
During the course of the study, the occurrence of two cases of marked neutropenia (i.e. < 
0.5 x 109/L), or of febrile neutropenia (i.e., ANC <1.0x109/L associated with fever) will 
result in study hold, unblinding of data by DSMB (but not by the investigators in the site), 
discussion of results with safety management team (i.e., Pharmacovigilance) and final 
decision made in consultation with DSMB, IRB and PI. For additional information, 
please refer to Section 3.7, Procedures Related To Neutropenia 
Independent of the DSMB, GVGH, as a sponsor, retains the right to halt the study at any 
time if there is a safety concern. If the study is prematurely terminated, the sponsor will 
promptly inform Regulatory Authorities and Ethic Committees on the decision of 
stopping the trial and no further enrollment or study immunizations will occur until 
written authorization is provided by the sponsor in conjunction with a recommendation to 
proceed by the DSMB and in consultation with Regulatory Authorities and Ethic 
Committees, as appropriate. 
3.7 
Procedures related to neutropenia 
During the two phase 1 trials with 1790GAHB, two subjects of African descent 
experienced a transient and clinically asymptomatic decrease of circulating neutrophils of 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 35 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
grade 3 (severe) that was finally classified as "benign ethnic neutropenia". In addition, six 
more subjects experienced transient and clinically asymptomatic grade 2 (moderate) 
neutropenia. Although this finding was not associated with any clinical illness, some 
precautionary procedures for enrollment and monitoring of trial subjects were introduced 
to protect the safety of study subjects, including selection of subjects with baseline ANC 
above 1.8x109/L.  
In order to maintain a prudent approach, but, at the same time, to not compromise the 
scientific validity of the clinical trial by selecting participants that are not entirely 
representative of the local healthy population ( if non-local laboratory reference intervals 
are used) a step-wise approach will be adopted for the present trial H03_04TP. More 
specifically, same as in Phase 1 trials, the more conservative western normal ranges will 
be adopted for ANC collected up to 7 days after 1st vaccination of the initial 18 subjects. .  
Subsequently, all safety data from these 18 subjects will be evaluated by the DSMB 
which will make a recommendation as to whether the enrollment and assessment of 
neutropenia during the study of further subjects could be done using the local normal 
ranges published for neutrophils (Karita et al., 2009) and for which a consensus interval 
of 1.0 to 5.3x109/L has been reached, or should be continued using the western normal 
ranges adopted for the first 18 subjects. This is also in consideration of the clinically 
benign nature of the events reported in the phase 1 studies and of the documented lower 
absolute neutrophils counts in healthy African populations (one of the key targets for this 
vaccine) compared to western populations (Badenhorst et al., 1995, Ezeilo, 1972, Lugada 
et al., 2004),     
Therefore, study procedures will be as follows: 
 First subset of 18 subjects (prior to DSMB evaluation of data): 
Subjects with ANC less than 1.8x109/L at screening will not be enrolled in the study. 
All individuals with ANC <1.8x109/L, occurring at 7 days after the first dose, will 
have additional blood draws for complete blood count to be repeated on a weekly 
basis until the neutropenia resolves (ANC ≥ 1.8x109/L). In case the ANC is less than 
0.5x109/L after 1st vaccination, the subject will be immediately discontinued from 2nd 
vaccination and will have the test repeated on a weekly basis until the neutropenia 
resolves. 
 All subjects (after DSMB evaluation of safety data from the initial 18 subjects with 
recommendation to switch to local normal ranges published for neutrophils): 
Subjects with neutropenia defined as ANC less than 1.0x109/L at screening will not be 
enrolled in the study. All individuals with a neutropenia (ANC <1.0x109/L), occurring 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 36 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
at any time during the study 7 days after the first dose, will have additional blood 
draws for complete blood count to be repeated on a weekly basis until the neutropenia 
resolves (ANC ≥ 1.0x109/L). In case the ANC is less than 0.5x109/L after 1st 
vaccination, the subject will be immediately discontinued from 2nd vaccination and 
will have the test repeated on a weekly basis until the neutropenia resolves. 
For classification and grading of severity of neutropenia for the first subset of 18 subjects, 
the criteria of Common Terminology Criteria for Adverse Events (CTCAE) issued by US 
Department of Health and Human Services (version 4.3; 2010) will be adopted. In case 
DSMB endorses the use of local ranges of normality for the second subset of 54 subjects, 
the grading will be modified based on input from DSMB.  All individuals with 
neutropenia either ongoing or with onset at visit 5 (or last study visit) will have additional 
blood draws for complete blood count to be repeated on a regular basis until the 
neutropenia resolves (ANC ≥ 1.0 x109/L or ANC ≥ 1.8x109/L, depending on 
recommendations given by DSMB after evaluation of safety data from the initial 18  
subjects).  
Finally, all cases of neutropenia, regardless of intensity, will be considered as Adverse 
Events of Special Interest (AESI) from a reporting perspective. 
3.8 
Data Monitoring Committee 
A DSMB will be in place to receive from GVGH a summary of all safety data (solicited 
local and systemic AEs, unsolicited AEs and SAEs) and listings of clinically significant 
modifications in hematology, blood chemistry and urine dipstick/ urinalysis test values 
obtained during one week follow-up post-first vaccination of the initial 18 subjects. Based 
on evaluation of the safety data, the DSMB will make a recommendation to GVGH, as to 
whether the enrollment can be completed or not. Additionally, DSMB will make a 
recommendation to GVGH, as to whether the enrollment of further subjects could be 
done using the published local normal ranges for neutrophils in Africa (Karita et al., 
2009) or should instead be continued using the western normal ranges adopted for the 
first 18 subjects. 
In addition to the evaluation of the safety data from the initial 18 subjects, DSMB will be 
consulted for any safety issue that might be reported during the trial. 
The composition of DSMB and the details of all relevant procedures will be documented 
in the DSMB Charter. 
3.9 
Premature Withdrawal from Study 
Subjects may withdraw at any time, or be dropped from the study at the discretion of the 
investigator should any untoward effects occur and/or for safety reasons. In addition, a 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 37 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
subject may be withdrawn by the investigator or the Sponsor if he/she violates the study 
plan or for administrative reasons. The investigator or study coordinator must notify the 
Sponsor immediately when a subject has been withdrawn due to an adverse event. 
The circumstances above are referred to as premature withdrawal from the study, and the 
reason for premature withdrawal should be clearly documented and detailed in the source 
documentation. The investigator should make every attempt to evaluate the subject’s 
safety, including resolution of ongoing AEs, at the time of premature withdrawal. If a 
subject wants to withdraw from the study before all doses are administered or prior to the 
last planned study visit, the subject will be asked to be followed for safety for the duration 
of the study. When a subject withdraws, or is withdrawn, from the study, the procedures 
described in section 5.5.1, Early Termination Visit should be completed if possible. 
The reasons for premature withdrawal from the study include: Adverse event, death, 
withdrawal of consent, lost to follow-up, administrative reason, and protocol deviation. 
These reasons are described in greater detail below. 
Adverse Event 
For any subject withdrawn from study participation prior to the planned Study 
Termination Visit, it is important to determine if an AE was associated with the reason for 
discontinuing the study. This AE must be identified on the AE CRF page by indicating 
“Withdrawn from study due to AE”. Any ongoing AEs at the time of study withdrawal 
must be followed until resolution or stabilization. 
Subjects who develop a serious adverse event (SAE) judged to be possibly or probably 
related to the study vaccine, including hypersensitivity reactions, should not receive 
subsequent vaccination. 
Death 
For any subject withdrawn from study participation due to death, this should be noted on 
the Study Termination CRF page and the associated SAE that led to the death must be 
reported. 
Withdrawal of consent 
The subject can withdraw consent for participation in the study at any time without 
penalty or loss of benefit to which the subject is otherwise entitled. Reason for early 
termination should be deemed as “withdrawal of consent” if the subject withdraws from 
participation due to a non-medical reason (i.e., reason other than AE). If the subject 
intends to withdraw consent from the study, the investigator should clarify if the subject 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 38 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
will withdraw completely from the study or if the subject will continue study participation 
for safety, or a subset of other study procedures. If the subject requests complete 
withdrawal from the study, no further study interventions will be performed with the 
subject. 
Lost to Follow-Up 
For subjects who fail to show up for final visits (clinic or home visits), or for three 
consecutive visits, study staff are encouraged to make at least three documented attempts 
to contact the subject to encourage the completion of study termination procedures. These 
efforts to contact the subject should be recorded in the source document. The termination 
date for the subject to be captured on the Study Termination CRF page is the date of the 
last successful contact (clinic visit or home visits) with the subject. 
Administrative Reason 
Examples for subjects withdrawn from the study due to administrative reason can include: 
Sponsor decision to terminate the study, subject meeting a pre-specified withdrawal 
criterion, subject discontinuation for insurance issues, moving, no time, etc. This reason 
should be noted in the Study Termination CRF page and any ongoing AEs at the time of 
study withdrawal must be followed until resolution/stabilization. 
If the clinical study is prematurely terminated by the Sponsor, the investigator is to 
promptly inform the study subjects and local EC/IRB and should assure appropriate 
therapy and follow up for the subjects. All procedures and requirements pertaining to the 
archiving of study documents should be followed. All other study materials (study 
medication/vaccines, etc.) must be returned to the Sponsor. 
For subjects who are withdrawn from the study due to receipt of an excluded 
medication/vaccination or due to significant protocol non-compliance, this reason should 
be noted in the Study Termination CRF page. 
In studies that involve more than 1 consecutive dose of study vaccine, a separate event is 
“withdrawal of study vaccination”. This event may occur if subjects are expected to 
receive more than 1 consecutive dose of vaccine as part of study participation. The act of 
withholding additional study vaccinations is referred to as withdrawal of study 
vaccination. Subjects may be withdrawn from study vaccination for several reasons 
including but not limited to: AE related to earlier vaccinations, failure to meet inclusion 
or exclusion criteria for revaccination (see section 4.0, Selection Of Study Population), or 
pregnancy. Subjects who are withdrawn from study vaccination should be 
encouraged to continue in the study for safety follow-up and other procedures as 
appropriate until the scheduled termination visit. If the subject is withdrawn from 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 39 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
study vaccination(s) due to adverse event, this event must be linked to the withdrawal 
from vaccination on the AE CRF page 
Protocol Deviation 
A protocol deviation is any change, divergence, or departure from the study design or 
procedures of a study protocol. In general, subjects associated with protocol deviations 
may remain in the study unless continuation in the study jeopardizes the subject’s health, 
safety, or rights. 
Investigators will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact GVGH or its agents, if any, monitoring the 
study to request approval of a protocol deviation, as no authorized deviations are 
permitted. If the investigator feels a change to the protocol would improve the conduct of 
the study this must be considered a protocol amendment, and unless such an amendment 
is agreed upon by GVGH and approved by the IRB/EC and health authorities it cannot be 
implemented.  
Any subject who becomes pregnant during the study, despite the protocol requirement for 
adequate contraception, will not receive further vaccination but should be encouraged to 
continue participating in the study for safety follow-up. The site must complete a paper 
Pregnancy Report CRF (initial report) as soon as possible after learning of pregnancy 
occurrence (see section 7.1.6, Pregnancies for further details). If the subject withdraws 
from the study for any of the above categories except death, the site will obtain 
permission from the subject to continue to remain in contact with her until the outcome of 
the pregnancy is known, even if the outcome is not known until after the subject reaches 
the end of follow-up period. 
Refer to section 3.6, Stopping/Pausing Guidelines and to section 3.7 Procedures related to 
neutropenia for further details in case of neutropenia. 
3.10 
End of Study 
Most clinical trials intended to support the efficacy/immunogenicity and safety of an 
Investigational Product proceed to full completion of planned sample size accrual. 
Evaluation of the primary and/or secondary immunogenicity/efficacy objectives requires 
the testing of biological samples from the study subjects, which can only be completed 
after all samples are collected. The last samples for the analysis of the primary and/or 
secondary objectives will be taken at visit 5. For the purpose of this protocol, end of study 
is defined as the completion of the testing of such biological samples, to be achieved no 
later than 8 months after collection of the last biological sample visit 5. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 40 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
4. 
SELECTION OF STUDY POPULATION 
4.1 
Inclusion Criteria 
1. Individuals ≥18 years to ≤45 years of age on the day of informed consent who are 
resident in the study area and are not planning to leave during the study period. 
2. Individuals who, after the nature of the study has been explained, have voluntarily 
given written consent according to local regulatory requirements, prior to study entry. 
3. Individuals who can comply with study procedures including follow-up1. 
4. Individuals in good health as determined by the outcome of medical history, physical 
examination, hematology, renal function, and liver function tests, urine 
dipstick/urinalysis and the clinical judgment of the investigator.  
5. Males 
Or 
Females of childbearing potential who are using an effective birth control method2 
which they intend to use for the duration of the study 
Or 
Females without childbearing potential (i.e. irrespective of birth control method) 
Prior to receipt of second study vaccination, subjects must be evaluated to confirm that 
they are eligible for subsequent vaccination. If subjects do not meet any of the original 
inclusion criteria listed above, they should not receive additional vaccinations. 
4.2 
Exclusion Criteria 
1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the 
opinion of the investigator, may interfere with the subject's ability to participate in the 
study. 
2. Individuals with any progressive or severe neurological disorder, seizure disorder or 
previous Guillain-Barré syndrome. 
                                                 
1 A subject is considered to be compliant if the Investigator judges that the subject will return for all the 
follow-up visits as scheduled in the study. 
2 The following birth control methods are considered effective: 
- 
Hormonal contraceptive (such as oral, injected or implantable contraceptives) if used for at least 2 
months prior to 1st vaccination 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 41 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
3. Individuals who, in the judgment of the investigator, may not be able to comply with 
all the required study procedures. 
4. Individuals with history of any illness that, in the opinion of the investigator, might 
interfere with the results of the study or pose additional risk to the subjects due to 
participation in the study. 
5. Individuals with history of reactive arthritis. 
6. Individuals with known HIV or hepatitis B virus infection or HIV related disease, 
history of an autoimmune disorder or any other known or suspected impairment 
/alteration of the immune system. Individuals under systemic administration of 
corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to 
screening. 
7. Individuals with a known bleeding diathesis, or any condition that may be associated 
with a prolonged bleeding time. 
8. Individuals with a neutrophil count lower than 1.8 x 109/L (applicable to the initial 18 
subjects) or lower than 1.0 x 109/L (applicable to the additional subjects if approved 
by DSMB) at screening 
9. Individuals with any serious chronic or progressive disease according to judgment of 
the investigator (e.g., neoplasm, insulin dependent diabetes, Type 2 diabetes mellitus, 
hypertension, cardiac, renal or hepatic disease and tuberculosis). 
10. Individuals who have any malignancy or lymphoproliferative disorder. 
11. Individuals with history of allergy to vaccines components or any other allergies 
deemed by the investigator to increase the risk of an adverse event if they were to 
participate in the trial. 
12. Individuals participating in any clinical trial with another investigational product 
within 28 days prior to the screening study visit or intent to participate in another 
clinical study at any time during the conduct of this study. 
13. Individuals who received vaccines containing meningococcal A, C, W, Y or tetanus, 
diphtheria or pertussis antigens within 12 months before screening, or any other 
vaccines within 4 weeks prior to screening in this study or who are planning to receive 
any vaccine within the entire study duration.  
14. Individuals who have received blood, blood products, and/or plasma derivatives 
including parenteral immunoglobulin preparations in the 12 weeks prior to the first 
dose of the study vaccine. 
15. Individuals who are study personnel or immediate family members (parents, children, 
spouse and brothers/sisters) to the personnel conducting this study. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 42 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
16. Individuals with body temperature ≥ 38.0◦C within 3 days of intended study 
vaccination is a reason for delay of vaccination (see section 4.3 Criteria for Delay of 
Vaccination for further details). 
17. Individuals with Body Mass Index (BMI)> 30 kg/m2 
18. Individuals with history of substance or alcohol abuse within the past 2 years. 
19. Women who are pregnant or are breast-feeding, or are of childbearing age who have 
not used (for the two months preceding the 1st vaccination) and are not willing to use 
acceptable contraceptive measures, for the duration of the study. If subjects are 
women of childbearing potential, they must have a negative pregnancy test at 
screening visit and prior to enrollment (visit 1). For the purposes of this study 
acceptable methods of contraception are oral, injected or implantable contraceptives. 
20. Individuals who have a previously laboratory confirmed case of disease caused by S. 
sonnei. 
21. Any condition which, in the opinion of the investigator, may pose an increased and 
unreasonable safety risk to the subject if they participated in the study.  
22. Individuals with a previous history of Benign Ethnic Neutropenia or drug related 
neutropenia 
23. Individuals who have or are likely to require concomitant treatment with neutropenic 
agents 
 
Prior to receipt of second study vaccination, subjects must be evaluated to confirm that 
they are eligible for subsequent vaccination. If subjects meet any of the original exclusion 
criteria listed above, they should not receive additional vaccinations. 
4.3 
Criteria for Delay of Vaccination 
There may be instances when individuals meet all eligibility criteria for vaccination yet 
have a transient clinical circumstance which may warrant delay of vaccination:  
- body temperature elevation [≥38.0° C (≥ 100.4° F) within 3 days prior to intended 
study vaccination] 
- use of antipyretics and/or analgesic medications within 24 hours prior to 
vaccination.  
- Individuals who have received blood, blood products and/or plasma derivatives or 
any parenteral immunoglobulin preparation in the past 12 weeks. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 43 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Under such circumstances, a subject may be considered eligible for study enrolment after 
the appropriate window for delay has passed and inclusion/exclusion criteria have been 
rechecked, and if the subject is confirmed to be eligible. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 44 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
5. 
STUDY PROCEDURES 
The sections that follow provide an overview of the procedures that are to be followed in 
enrolling, evaluating, and following subjects who participate in this clinical study. Visits 
can be either clinic visits or home visits, as specified in the Table below and in the Time 
and Events Table 2. 
Table 5-1 
Study Procedures 
Visit Category 
Procedures 
Pre-vaccination Clinic Visit(s) 
Section 5.1 describes procedures to be followed prior to study 
vaccination: informed consent, screening, enrolment, and 
randomization 
Vaccination Clinic Visit(s) 
Section 5.2 describes procedures to be followed during each 
clinic visit involving vaccination: vaccination, post-
vaccination procedures, and post-vaccination reminders  
Post-vaccination Visit(s)  
Section 5.3 describes follow-up clinic and home visits 
Unscheduled Visit(s) 
Section 5.4 describes possible procedures to be followed at 
unscheduled clinic visit 
Study Termination Visit 
Section 5.5 describes procedures to be followed at the last 
study visit for a subject (may include early termination visit) 
 
5.1 
Pre-vaccination Clinic Visit(s) 
This section describes the procedures that must be performed for each potential subject 
prior to vaccination, including obtaining informed consent, screening, enrolment and 
randomization. 
5.1.1 Informed Consent/Assent 
"Informed consent" is the voluntary agreement of an individual or his/her legal 
guardian(s) to participate in research. Consent must be given with free will of choice, and 
without undue inducement. The individual must have sufficient knowledge and 
understanding of the nature of the proposed research, the anticipated risks and potential 
benefits, and the requirements of the research to be able to make an informed decision. 
Informed consent following local IRB/EC guidance must be obtained before conducting 
any study-specific procedure (i.e., all of the procedures described in the protocol). The 
process of obtaining informed consent should be documented in the subject source 
document in addition to maintaining a copy of the signed and dated informed consent. 

G S K Vacci nes I nstit ute f or Gl o bal Healt h  
 
Pr ot oc ol H 0 3 _ 0 4 T P 
0 3  N O V  1 6  Versi o n 4. 0 
C o nfi de ntial 
P a ge 4 5  of 8 9  
P R O- 0 1 T E M P 0 6 / Atlas N o. 2 9 3 6 2 0 
Versi o n N o. 4 / Versi o n Date: J a n uar y 2 9, 2 0 1 5 
St u d y will be e x plai ne d i n eit her S wa hili or i n E n glis h, w here pr os pecti ve partici pa nts 
ex press a prefere n ce. If a s u bject is u na ble t o rea d, a n i m partial wit ness s h o ul d be prese nt 
d uri n g t he e ntire i nf or m e d c o nse nt disc ussi o n. A n i m partial wit ness is defi ne d as a pers o n 
w h o is i n de pe n de nt fr o m st u d y c o n d u ct, w h o ca n n ot be u nfairl y i nfl ue nce d b y t h ose 
i n v ol ve d wit h t he st u d y, w h o atte n ds t he i nf or me d c o nse nt pr ocess if t he s u bject or t he 
s u bject's le gall y acce pta ble re prese ntati ve ca n n ot r ea d, a n d w h o rea ds t h e i nf or me d 
c o nse nt f or m a n d a n y ot her writte n i nf or m ati o n s u p plie d t o t he s u bject. Aft er t he writte n 
i nf or me d c o nse nt f or m a n d a n y ot h er writte n i nf or mati o n t o be pr o vi de d t o s u bjects, is 
rea d a n d e x plai ne d t o t he s u bject a n d aft er t he s u bject has ver ball y c o nse nt e d t o t he 
s u bject’s partici pati o n i n t he st u d y a n d, if ca p a ble of d oi n g s o, has si g ne d a n d pers o nall y 
date d t he i nf or me d c o nse nt f or m, t he wit ness s h o ul d si g n a n d pers o nall y d ate t he c o nse nt 
f or m. B y si g ni n g t he c o nse nt f or m, t he wit ness att ests t hat t he i nf or mati o n i n t he c o nse nt 
f or m a n d a n y ot her writte n i nf or mati o n was acc uratel y e x plai ne d t o, a n d a p pare ntl y 
u n derst o o d b y, t h e s u bject a n d t hat i nf or me d c o nse nt was freel y gi v e n b y t he s u bject. 
Pre-test c o u nselli n g will be perf or me d f or i n di vi d uals w h o c o nse nt t o HI V testi n g. T h ose 
i n di vi d uals, w h o will be f o u n d t o be HI V p ositi ve, will be als o c o u nselle d p ost-test a n d 
referre d t o t he Mi nistr y of Healt h HI V care ser vices. 
5. 1. 2 
Scree ni n g 
After a n i n di vi d ual has c o nse nte d t o partici pate i n t he st u d y a n d i nf or me d c o nse nt is 
si gne d, t hat i n di vi d ual will be gi ve n a u ni q ue 5- di git Scree ni n g N u m ber (assi g ne d 
seq ue ntiall y b y t he site fr o m  
). T he s u bject’s u ni q ue Scree ni n g N u m b er will be 
d oc u me nte d i n t he Scree ni n g a n d E nr ol me nt l o g. T he eli gi bilit y of t he s u bj ect will be 
deter mi ne d bas e d o n t he i ncl usi o n a n d e x cl usi o n criteria liste d i n secti o n 4, Selecti o n of 
St u d y P o p ulati o n  a n d e v al uate d d uri n g t his scree ni n g pr oce d ure. 
P ri or t o st u d y e nr ol me nt, de m o gra p hic dat a will be c ollecte d fr o m t he s u bj ect, i ncl u di n g 
ge n d er, race, b o d y mass i n de x. 
Me dical hist or y will als o be c ollecte d, i ncl u di n g b ut n ot li mite d t o a n y me dical hist or y 
t hat ma y b e rele v a nt t o s u bject eli gi bilit y f or st u d y partici pati o n s uc h as pri or 
vacci nati o ns, c o n c o mita nt me dicati o ns, a n d pre vi o us a n d o n g oi n g ill nesses or i nj uries. 
Rele va nt me dical hist or y ca n als o i ncl u de a n y me dical hist or y t hat c o ntri b utes t o t he 
u n dersta n di n g of a n a d verse e ve nt t hat o cc urs d uri n g st u d y partici p ati o n, if it re prese nts 
a n e x acer bati o n of a n u n derl yi n g dise ase/ pr e-e xisti n g pr o ble m. 
P P D
Re vie w of s yste ms is a str uct ure d i nter vi e w t hat q ueries t he s u bject as t o a n y c o m plai nts 
t he s u bject has e x perie nce d acr oss eac h or ga n s yst e m. T his will be perf or m e d bef ore 
e nr ol me nt a n d use d t o g ui de p h ysic al e xa mi nati o n. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 46 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
If applicable, prior and concomitant medications or vaccinations taken prior to start of 
study should be collected (refer to section 6.5, Prior and Concomitant Medications and 
Vaccines for further details). 
Collect vital signs, heart rate, respiratory rate, blood pressure, and temperature. Measure 
height and weight. 
Perform pregnancy testing in women of childbearing age (refer to section 3.5, Collection 
of Clinical Specimens for guidance regarding the procedure). Informed consent process 
with any women of childbearing potential will include counseling about pregnancy and 
family planning, including discussion of their commitment to practice acceptable birth 
control measures (defined as oral, injected or implantable contraceptives).Women of 
childbearing potential are defined as a post onset of menarche and pre-menopausal female 
capable of becoming pregnant. This does not include females who meet any of the 
following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 
year earlier, (3) total hysterectomy or (4) post bilateral oophorectomy.    
A general physical examination is to be performed by a qualified health care practitioner. 
“Qualified health care practitioner” refers to any licensed health care professional who is 
permitted by national policy to perform physical examinations and who is identified 
within the Study Staff Signature Log. 
These data will be written in the source document (see section 9.1, Source 
Documentation). 
Approximately 10 mL of blood will be drawn from all subjects for the hematology, renal 
and liver function testing, serological tests for HBV and HIV and pregnancy test (Refer to 
section 3.5, Collection of Clinical Specimens and to synopsis Table 3, Hematological, 
Haematochemical Blood Tests and Urinalysis Table). 
In the event that the individual is determined ineligible for study participation, he/she is 
considered a screen failure. The reason for screen failure must be documented in the 
Screening and Enrolment log. If the individual is determined to be eligible for the study, 
he/she will be enrolled into the study. 
5.1.3 Enrolment 
If an individual is determined to be eligible for study participation, the investigator will 
enroll the subject 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 47 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
5.1.4 Randomization 
Enrolled subjects will be randomized and automatically assigned a unique Subject ID. 
The Subject ID will be the subject’s unique identification number for all CRFs and 
associated study documentation that will be used for duration of the study. After 
randomization, the Screening Number ceases to be used and remains in the Screening and 
Enrolment Log only. 
At randomization, the subject will be assigned also a unique subject code. The subject 
code consists of the 2 letters subject’s initials (the 1st letter of the surname name – 
followed by the 1st letter of the 1st name). 
If for any reason, after signing the informed consent form (ICF), the subject who is 
eligible and enrolled fails to be randomized, this is called a randomization failure and the 
early termination study procedures must be applied. The reason for all randomization 
failures should be recorded in the Screening and Enrolment Log and in the source 
document as specified in the Source Data Agreement (SDA). The information on subjects 
who are randomization failures should be kept distinct from subjects who are screen 
failures, as described in section 5.1.2, Screening. 
If for any reason, after randomization the subject fails to undergo treatment, this is an 
Early Termination and the reason should be recorded in source document as specified in 
the SDA. The information on these Early Termination subjects should be kept distinct in 
the source documentation from randomization failures. 
Screening phase will be performed until 72 subjects are randomized and vaccinated. 
Additional subjects may be randomized into the study at the discretion of the sponsor in 
the case of any subject who is randomized but does not receive any study vaccine. 
Subjects withdrawn or lost to follow up will not be replaced. 
5.2 
Vaccination Clinic Visit(s) 
Vaccination will be performed on day 1 and day 29. 
For studies which have visits for concomitant vaccinations or treatments, see section 6.5, 
Prior and Concomitant Medications and Vaccines for those visit procedures. 
Ensure all serology samples are taken prior to each vaccination. 
After completing the pre-vaccination procedures on day 1, administer the vaccine to the 
subject according to the procedures described in section 6.3, Vaccine Preparation and 
Administration. Observe the blinding procedures described in section 3.3, Blinding 
Procedures. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 48 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Prior to administration of each vaccination, confirm that the subject is eligible for 
additional study vaccinations and does not meet any criteria for delaying additional study 
vaccinations as described in section 4, Selection of Study Population. 
5.2.1 Post-vaccination Procedures 
The following post-vaccination procedures will be performed on day 1 and day 29. 
After vaccination, the subject will be observed for at least 1 hour including observation 
for unsolicited adverse events, solicited adverse events, and body temperature 
measurement. Record all safety data collected during this time in the subject’s source 
document. 
The site should schedule the next study activity (daily home visits) with the subject. 
The subject should be reminded of the next planned study activity. The subject will be 
reminded to contact the site if there are any questions, and to contact the site immediately 
(or as soon as the subject is medically stable) if the subject has a medical condition that 
leads to a hospitalization or an emergency room visit or to a visit to/by a doctor or is of 
concern. 
5.2.2 Post-vaccination Reminders  
Not Applicable 
5.3 
Post-vaccination Visit(s) 
5.3.1 Follow-up Home Visit(s) 
Post-vaccination home visits will be performed daily by a field worker from day 1 (6 
hours after vaccination) to day 7 to check solicited local and systemic adverse events and 
medications/vaccinations received, following discussion with the subject. 
A Diary Card collected in person by study personnel will be used in this study to 
document solicited adverse events. The Diary Card is the only source for collection of 
these data; therefore, it is critical that the trained site staff completes the subject’s Diary 
Card correctly. The appropriate site staff should be trained on how and when to complete 
each field of subject’s Diary Card. 
The appropriate site staff should be trained on how to measure local solicited adverse 
events and body temperature. The trained field workers who will perform the home visits 
will be instructed to direct the subject to the clinic if the event requires medical 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 49 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
supervision. The measurement of solicited local adverse events is to be performed using 
the ruler provided by the site. 
The appropriate site staff should be instructed how to perform body temperature 
measurement using the thermometer provided by the site. The temperature recorded in the 
Diary Card will be the one measured by the site staff during point of contact with subject 
at home. 
Appropriate training should be directed at the site staff who will perform the 
measurements of adverse events and who will enter the information into the subject’s 
Diary Card. The identity of the person who will enter the information into the Diary Card 
must be documented in the subject’s source record and in the study delegation log. Any 
individual that makes entries into the Diary Card must receive training on completion of 
the Diary Card. This training must be documented. 
Whenever possible, the same individual should complete the subject’s Diary Card 
throughout the course of the study. 
5.3.2 Follow-up Clinic Visit(s) 
Safety follow-up clinic visits will be performed 7 days after V1 and V3. 
During the follow-up clinic visit, the subject’s source document and Diary Card will be 
reviewed. No changes to the information recorded by the trained study staff within the 
section of the Diary Card are permissible. For details see sections 3.4.2, Tools Used for 
Data Collection and 5.2.1, Post-vaccination Procedures. The subject will be interviewed 
to determine if any unsolicited adverse events occurred and if any concomitant 
medications or vaccines were taken/received in the time since the last clinic visit. This 
interview will follow a script which will facilitate the collection of relevant safety 
information. The healthcare professional reviewing these data will discuss the symptoms 
(if any) reported by the subject and will determine if any additional diagnoses and/or 
adverse events are present. Adverse events reported by the subject at this follow-up clinic 
visit must be recorded in the subject's source document and on an Adverse Events CRF, 
as specified in section 7.1, Safety Assessment, and not written on the script used for the 
interview. 
Perform a brief symptom-directed physical examination if necessary according to 
symptoms the subject has reported. This is a physical examination that will include an 
examination of organ systems that are relevant to the investigator based on review of the 
subject’s reported adverse events, concomitant medication use. This assessment may 
include: measurement of vital signs, body temperature taken axillary and a check of 
general appearance. The physical assessment must be performed by the investigator or 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 50 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
designee of the investigator, who is qualified to perform a physical assessment in 
accordance with their institutional policy. Corresponding information is documented in 
the subject’s source document and CRF(s). 
At this visit blood sample for safety evaluation and urine sample for urine 
dipstick/urinalysis will be obtained as described in section 3.5, Collection of Clinical 
Specimens 
The site should schedule the next study clinic visit with the subject. The subject will 
receive a reminder of the next planned study activity. The subject will be reminded to 
contact the site if there are any questions and to contact the site immediately (or as soon 
as the subject is medically stable) if the subject has a medical condition that leads to a 
hospitalization or an emergency room visit. 
5.3.3 Safety Follow-up Calls 
Not Applicable 
5.4 
Unscheduled Visits 
An unscheduled visit describes a non-routine study visit triggered by a specific event. 
These could include anticipated or unanticipated adverse events or interventions. 
 All individuals with a neutropenia, occurring at any time during the study, will have 
additional blood draws for complete blood count to be repeated on a weekly basis until 
the neutropenia resolves. If neutropenia occurs at the subject’s last study visit, the 
complete blood count will be repeated on a regular basis until resolution. For 
classification of neutropenia during the trial, refer to Section 3.7, Procedures Related To 
Neutropenia. 
5.5 
Study Termination Visit 
The study termination visit 5 will occur 28 days after 2nd vaccination. The termination 
visit may be a clinic visit or a home visit. The date of termination is the date of the last 
contact (clinic visit or home visit) in which the subject’s health status was assessed or, in 
cases where the subject does not agree to any further safety follow-up, it is the date 
consent is withdrawn. This date should be recorded on the termination CRF page. For 
visit procedures to be performed for a subject whose planned study participation ends 
prematurely, please see section 5.5.1, Early Termination Visit. 
At the clinic visit, the following procedures will be performed:  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 51 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
- 
review of subject’s medical records and source document designed to collect 
solicited AE,  
- 
review of systems, interview of subject to collect unsolicited adverse events, 
medically attended adverse events, AEs leading to withdrawal, SAEs, AESIs, and 
new onset of chronic disease,  
- 
interview of subject to collect concomitant medications/vaccinations,  
- 
symptom-directed physical assessment including measurement of vital signs and a 
check of general appearance,  
- 
Blood sampling for immunogenicity and safety laboratory assessment,  
- 
Urine sample for urine dipstick/urinalysis and pregnancy testing. 
All individuals with neutropenia either ongoing or with onset at visit 5 (last study visit) 
will have additional blood draws for complete blood count to be repeated on a regular 
basis until the neutropenia resolves (for classification of neutropenia during the trial, refer 
to Section 3.7, Procedures Related To Neutropenia). Laboratory results obtained after 
study termination will be maintained in subject medical records and not entered in the 
CRF. 
When the clinical study report is completed, the investigators will share the summary 
results with the participating communities. Town hall and village meetings will be held to 
convey the information and to allow for questions and answers.   
The site will complete the termination CRF page and this will mark the completion of the 
subject’s participation in the study. 
5.5.1 Early Termination Visit 
When a subject is withdrawn from treatment or withdraws from the study, the investigator 
will notify the Sponsor and, when possible, will perform the procedures listed below. The 
reason(s) for the early termination will be included in the subject’s source documentation. 
Early Termination Visits include subjects who were randomized but not treated. 
At the clinic visit or during the home visit, the following procedures will be performed (if 
the Early Termination Visit is a home visit, collect as much information as possible):  
- 
review of subject’s medical records, source document and Diary Card,  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 52 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
- 
review of systems, interview of subject to collect unsolicited adverse events, 
medically attended adverse events, AEs leading to withdrawal, SAEs, AESIs, and 
new onset of chronic disease,  
- 
interview of subject to collect concomitant medications/vaccinations,  
- 
symptom-directed physical assessment including measurement of vital signs and a 
check of general appearance,  
- 
blood sampling for safety laboratory assessment (no blood for immunogenicity 
assessment should be obtained unless this is agreed in advance with the sponsor),  
- 
urine sample for urine dipstick/urinalysis and pregnancy testing. 
All individuals with neutropenia either ongoing or with onset at last study visit will have 
additional blood draws for complete blood count to be repeated on a regular basis until 
the neutropenia resolves (for classification of neutropenia during the trial, refer to Section 
3.7, Procedures Related To Neutropenia). Laboratory results obtained after study 
termination will be maintained in subject medical records and not entered in the eCRF. 
The site will complete the termination CRF page and this will mark the completion of the 
subject’s participation in the study. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 53 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
6. 
TREATMENT OF SUBJECTS 
All vaccines associated with this study are to be stored separately from other vaccines and 
medications in a secure location under appropriate storage conditions with temperature 
monitoring. All vaccines associated with this study must be checked for expiration 
date prior to use. Expired vaccines must not be administered to subjects. 
6.1 
Study Vaccine(s) 
The term ‘study vaccine’ refers to those vaccines provided by the Sponsor, which will be 
evaluated as part of the study objectives. The study vaccines specific to this study are 
described below. 
GVGH S. sonnei (1790GAHB) vaccine 
The investigational agent is the GVGH S. sonnei vaccine. The vaccine consists of S. 
sonnei 1790-GMMA (approximately 200 µg/mL, measured by protein content) adsorbed 
to Alhydrogel (0.7 mg Al3+/mL) in Tris-buffered saline. The vaccine does not contain any 
preservative and is available as a liquid formulation in single dose vials with 0.7 mL of 
injectable solution containing approximately 140 µg of GMMA (as protein content), 
adsorbed onto 0.49 mg Al3+.  
The vaccine will be used at two different antigen doses obtained by bed-side mixing. 
Following dilution with Alhdyrogel (0.7 mg Al3+/mL) in Tris–buffered saline, the volume 
administered will be 0.5 mL for both doses: 
Group A: Each 0.5 mL dose of 1790GAHB will contain approximately 25 μg of GMMA 
total protein and 0.35 mg of Al3+.  
Group B: Each 0.5 mL dose of 1790GAHB will contain approximately 100 μg of 
GMMA total protein and 0.35 mg of Al3+.  
In each group two vaccinations, 28 days apart, will be administered intramuscularly. 
Bed-side mixing instructions will be provided to the investigator and will be located in 
the investigator site file.  
Control vaccines 
Menveo: vaccine indicated for active immunization to prevent invasive meningococcal 
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. The vaccine 
contains no preservative or adjuvant.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 54 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Each 0.5 mL dose of vaccine contains 10 μg MenA oligosaccharide, 5 μg of each of 
MenC, MenY and MenW-135 oligosaccharides conjugated to 32.7 to 64.1 μg CRM197 
protein. 
Boostrix: Vaccine indicated for active booster immunization against tetanus, diphtheria, 
and pertussis. It contains tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis 
antigens (inactivated pertussis toxin [PT], formaldehyde-treated filamentous 
hemagglutinin [FHA] and pertactin). Each antigen is individually adsorbed onto 
aluminum hydroxide.  
For both control vaccines, the Summary of Product Characteristics (SPC) will be 
provided to the investigator and will be located in the investigator site file. 
6.2 
Non-Study Vaccines 
The term ‘non-study vaccine’ refers to those vaccines which will be intentionally given to 
study subjects but not formally included in the analysis of study objectives.  
This protocol does not foresee the use of non-study vaccines. 
6.3 
Vaccine Preparation and Administration 
The investigator or designee will be responsible for oversight of the administration of 
vaccine to subjects enrolled in the study according to the procedures stipulated in this 
study protocol. All vaccines will be administered only by unblinded personnel who are 
qualified to perform that function under applicable local laws and regulations for the 
specific study site. 
Bedside mixing and vaccine administration at the study site will be performed according 
to GVGH instructions and by trained site staff. The site staff responsible for these 
activities will be personnel who are respectively qualified according to applicable laws 
and regulations. GVGH will provide specific procedures and training for these activities. 
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING STUDY VACCINE: 
Prior to vaccination, subjects must be determined to be eligible for study vaccination and 
it must be clinically appropriate in the judgment of the investigator to vaccinate. 
Eligibility for vaccination prior to first study vaccine administration is determined by 
evaluating the entry criteria outlined in protocol sections 4.1, Inclusion Criteria and 4.2, 
Exclusion Criteria. 
Eligibility for subsequent study vaccination is determined by following the criteria 
outlined in section 4.3, Criteria for Delay of Vaccination. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 55 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Study vaccines should not be administered to individuals with known hypersensitivity to 
any component of the vaccines. Standard immunization practices are to be observed and 
care should be taken to administer the injection intramuscularly. Before administering 
vaccine, the vaccination site is to be disinfected with a skin disinfectant (e.g., 70% 
alcohol). Allow the skin to dry. DO NOT inject intravascularly. 
As with all injectable vaccines, trained medical personnel and appropriate medical 
treatment should be readily available in case of anaphylactic reactions following vaccine 
administration. For example, epinephrine 1:1000, diphenhydramine, and/or other 
medications for treating anaphylaxis should be available. 
6.4 
Vaccine Administration Error or Overdose of Vaccine 
Vaccine administration error is defined as receiving a dose of study vaccine that was not 
reconstituted as instructed or administered by a different route from the intended route of 
administration. An overdose of study vaccine (whether accidental or intentional) is 
defined when a dose higher than the recommended dose is administered in one dose of 
study vaccine. 
An overdose would also occur if two doses of the study vaccine are administered within 
half the time of the recommended interval between doses, as defined in the protocol i.e. 
for this protocol, both an overdose and vaccine administration error would occur if receipt 
of more than one dose takes place in a 12 day period. 
Any vaccine administration error or overdose of study vaccine detailed in this protocol 
must be reported as an adverse event, and if the vaccine administration error or overdose 
is associated with a serious adverse event, it must be reported as such within 24 hours to 
the Sponsor. 
6.5 
Prior and Concomitant Medications and Vaccines 
All medications, vaccines and blood products taken or received by the subject within 4 
weeks prior to the start of the study are to be recorded on the Prior and Concomitant 
Medications CRF. 
The use of antipyretics and/or analgesic medications within 24 hours prior to vaccination 
must be identified and the reason for their use (prophylaxis versus treatment) must be 
described in the source document and Concomitant Medications CRF. Use of 
antipyretics/analgesics within 24 hours prior to vaccine administration is a reason to delay 
study vaccination (see section 4.3, Criteria for Delay of Vaccination). 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 56 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Medications taken for prophylaxis are those intended to prevent the onset of symptoms. 
Medications taken for treatment are intended to reduce or eliminate the presence of 
symptoms that are present. 
Concomitant medications include all medications (including vaccines) taken 
by/administered to the subject at and after enrolment and must be documented on the 
Concomitant Medications CRF. 
When recording concomitant medications/vaccines, they should be checked against the 
study entry and continuation criteria in section 4, Selection of Study Population to ensure 
that the subject should be enrolled/continue in the study. 
6.6 
Vaccine Supply, Labeling, Storage and Tracking 
The Sponsor will ensure the following: 
 Supply the study vaccine(s). 
 Appropriate labeling of all study vaccines provided that complies with the legal 
requirements of each country where the study is to be performed. Possibly necessary 
additional labelling of clinical study materials at the study site will be performed 
according to GVGH instructions and by trained site staff who are qualified according 
to applicable laws and regulations. 
The investigator must ensure the following: 
 Acknowledge receipt of the study vaccines by a designated staff member at the site, 
including: 
- 
Confirmation that the vaccines were received in good condition 
- 
Confirmation to the Sponsor of the temperature range during shipment from the 
Sponsor to the investigator’s designated storage location 
- 
Confirmation by the Sponsor that the vaccines are authorized for use. 
 Proper storage of the study vaccines, including: 
- 
Storage in a secure, locked, temperature-controlled location. 
- 
Proper storage according to the instructions specified on the labels. 
- 
Appropriate record keeping and inventory of the study vaccines, including regular 
documentation of adequate storage temperature. 
 Appropriate use of the study vaccines, including: 
- 
Not use of vaccines prior to receipt of authorization for use from the Sponsor. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 57 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
- 
Use only in accordance with the approved protocol. 
- 
Dilution in accordance to bed-side mixing procedure and documentation 
- 
Proper handling, including confirmation that the vaccine has not expired prior to 
administration. 
- 
Appropriate documentation of administration of vaccines to study subjects 
including: 
▪ 
Date, dosage, batch/lot numbers, expiration dates, unique identifying numbers 
assigned to subjects and study vaccines, and time of vaccine administration. 
This information will be maintained in an accountability log that will be 
reviewed by the site monitor. 
▪ 
Reconciliation of all vaccines received from the Sponsor. Reconciliation is 
defined as maintaining records of which and how many vaccines were 
received, which vaccines (and dilution for S. sonnei vaccine) were 
administered to subjects, which vaccines were destroyed at the site, and which 
vaccines were returned to the Sponsor, as applicable. 
 Proper adherence to the local institutional policy with respect to destruction of study 
vaccines. 
 Complete record keeping of vaccine use, wastage, return or destruction, including 
documentation of: 
- 
Copy of the site’s procedure for destruction of hazardous material. 
- 
Number of doses destroyed, date of destruction, destruction code (if available), 
method of destruction, and name of individual performing destruction. 
Vaccines that have been stored differently from the manufacturer’s indications must not 
be used unless the Sponsor provides written authorization for use. In the event that the use 
cannot be authorized, the Sponsor will make every effort to replace the vaccine supply. 
All vaccines used in conjunction with this protocol must be stored separately from normal 
hospital/practice stocks to prevent unintentional use of study vaccines outside of the 
clinical study setting. 
Monitoring of vaccine accountability will be performed by the study monitor during site 
visits and at the completion of the study. 
At the conclusion of the study, and as appropriate during the course of the study, the 
investigator must ensure that all unused study vaccines, packaging and supplementary 
labels are destroyed locally (upon approval from Sponsor) or returned to the Sponsor. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 58 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7. 
ASSESSMENTS 
7.1 
Safety Assessment 
The measures of safety used in this study are based on previous study data. They include 
a close vigilance for, and stringent reporting of selected local and systemic adverse events 
routinely monitored in vaccine studies as indicators of reactogenicity. 
An adverse event (AE) is defined as any untoward medical occurrence in a subject or 
clinical investigation subject administered a pharmaceutical product at any dose that does 
not necessarily have to have a causal relationship with this treatment. Therefore, an AE 
can be any unfavorable and unintended sign (including an abnormal laboratory finding, 
for example), symptom, or disease temporally associated with the use of an 
investigational product, whether or not considered related to the investigational product. 
This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing 
conditions. 
The period of observation for AEs extends from the time the subject signs informed 
consent until he or she completes the specified safety follow-up period (28 days after each 
vaccination) or terminates the study early (whichever comes first). AEs occurring after 
the informed consent form is signed but prior to receiving study vaccine/product will be 
documented as an adverse event and recorded within source document. However, any 
AEs occurring prior to receipt of any study vaccine will be analyzed separately from 
“treatment emergent” AEs (AEs occurring after administration of the first study vaccine). 
Adverse events are collected as either solicited or unsolicited adverse events. Solicited 
events are derived from organized data collection systems, such as Subject interview. 
7.1.1 Solicited Adverse Events 
The term “reactogenicity” refers to solicited signs and symptoms (“solicited adverse 
events”) occurring in the hours and days following a vaccination, to be collected by the 
subject for 7 consecutive days. 
The following solicited adverse events are included in the Diary Card that will be used in 
this study to document solicited adverse events.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 59 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Solicited local adverse events: erythema, induration and pain at injection site. 
Solicited systemic adverse events: headache, arthralgia, chills, fatigue, malaise, myalgia, 
and fever (body temperature measured axillary). 
Other solicited reactions: Use of analgesics/antipyretics, body temperature (measured 
axillary). 
Each adverse event is to be assessed using the scoring system reported below:  
Solicited Local Adverse Events 
Solicited local adverse 
events 
Grade 0 
Absent 
Present - Grading of Severity 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Injection site Erythema 
(Captured as 
measurements in 
millimeters) 
1-24 mm 
25-50 mm 
51-100 mm 
> 100 mm 
Injection site Induration 
(Captured as 
measurements in 
millimeters) 
1-24 mm 
25-50 mm 
51-100 mm 
> 100 mm 
Injection site Pain 
No pain 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Solicited Systemic Adverse Events 
Solicited systemic 
adverse events 
Grade 0 
Absent 
Present - Grading of Severity* 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Headache 
No headache 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Arthralgia 
No 
arthralgia 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Chills 
No chills 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Fatigue 
No fatigue 
No interference 
with activity 
Some 
interference 
Significant; 
prevents daily 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 60 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
with activity 
activity 
Malaise 
No malaise 
No interference 
with activity 
Some 
interference 
with activity 
Significant; 
prevents daily 
activity 
Myalgia  
No myalgia 
Present but does not 
interfere with 
activity 
Interferes with 
activity 
Prevents daily 
activity 
Fever as a 
Body temperature 
(Captured as 
measurements in degrees 
Celsius) 
≤ 37.9 °C 
≥ 38.0 – 38.9°C 
≥ 39.0 – 39.9°C 
≥ 40.0°C 
Axillary Temperature: <35.5 °C to ≥38.0 °C 
Other Solicited Adverse Events 
Other Solicited adverse 
events 
Grade 0 
Absent 
Present - Grading of Severity 
Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Use of 
analgesics/antipyretics 
Categorized as “yes” or “no”  
The study staff must review the data entered into the Diary Card as described in section 
3.4.2, Tools Used for Data Collection and section 5.3.1, Follow-up Clinic Visit(s). 
Note: Any solicited adverse event that meets any of the following criteria must be entered 
into subjects’ source document (see section 9.1, Source Documentation) and also as an 
adverse event on the Adverse Event CRF: 
 Solicited local or systemic adverse event that continues beyond day 7 after 
vaccination. 
 Solicited local or systemic adverse event that leads to a visit to a healthcare provider 
(medically attended adverse event, see section 7.1.3, Evaluation of Adverse Events). 
 Solicited local or systemic adverse event leading to the subject withdrawing from the 
study or the subject being withdrawn from the study by the investigator (adverse event 
leading to withdrawal, see section 7.1.3, Evaluation of Adverse Events). 
 Solicited local or systemic adverse event that otherwise meets the definition of a 
serious adverse event (see section 7.1.4, Serious Adverse Events). 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 61 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.1.2 Unsolicited Adverse Events 
An unsolicited adverse event is an adverse event that was not solicited using the Diary 
Card and that was spontaneously communicated by a subject who has signed the informed 
consent. 
Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses 
requiring hospitalization, or emergency room visit, or visit to/by a health care provider), 
or were of concern to the subject. In case of such events, subjects will be instructed to 
contact the site as soon as possible to report the event(s). The detailed information about 
the reported unsolicited AEs will be collected by the qualified site personnel during the 
interview and will be documented in the subject’s records. 
Unsolicited AEs that are not medically attended nor perceived as a concern by subjects 
will be collected during interview with the subject and by review of available medical 
records at the next visit (see section 5.3, Post-vaccination Visit(s)). 
7.1.3 Evaluation of Adverse Events 
Every effort should be made by the investigator to evaluate safety information reported by 
a subject for an underlying diagnosis and to capture this diagnosis as the event in the AE 
page. In other words, the practice of reporting only symptoms (e.g., “cough” or “ear 
pain”) are better reported according to the underlying cause (e.g., “asthma exacerbation” 
or “otitis media”). 
The severity of events reported on the Adverse Events CRF will be determined by the 
investigator as: 
Mild: 
transient with no limitation in normal daily activity. 
Moderate: 
some limitation in normal daily activity. 
Severe: 
unable to perform normal daily activity. 
The relationship of the study treatment to an AE will be determined by the investigator 
based on the following definitions: 
1. Not Related 
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates an alternative explanation. If the subject has not received the vaccine, the timing 
of the exposure to the vaccine and the onset of the AE are not reasonably related in time, 
or other facts, evidence or arguments exist that reasonably suggest an alternative 
explanation, then the AE is not related. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 62 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2. Possibly Related 
The administration of the investigational vaccine and AE are considered reasonably 
related in time and the AE could be explained by exposure to the investigational vaccine 
or by other causes. 
3. Probably Related 
Exposure to the investigational vaccine and AE are reasonably related in time and no 
alternative explanation has been identified. 
The relationship of the study treatment to an unsolicited AE will be determined by the 
investigator.  
Note: solicited AEs will not be evaluated for relationship to study treatment. Grading for 
severity of solicited local and systemic AEs is described in section 7.1.1, Solicited 
Adverse Events. 
Adverse events will also be evaluated by the investigator for the co-existence of any of 
the other following conditions: 
 “Medically attended adverse event”: an adverse event that leads to a visit to a 
healthcare provider. 
 “New onset of chronic disease” (NOCD): an adverse event that represents a new 
diagnosis of a chronic medical condition that was not present or suspected in a subject 
prior to study enrolment. 
 AEs leading to withdrawal: adverse events leading to study or vaccine withdrawal. 
If solicited or unsolicited adverse events have been reported and the subject indicated that 
the symptoms required medical attendance or were of concern, the subject must be 
contacted for further information. 
When the subject is contacted for any of these reasons, the contact must be documented in 
the subject’s source documentation. 
All AEs, regardless of severity, will be monitored until resolution or until the investigator 
assesses them as chronic or stable. All subjects experiencing AEs - whether considered 
associated with the use of the study vaccine or not - must be monitored until symptoms 
subside and any abnormal laboratory values have returned to baseline, or until there is a 
satisfactory explanation for the changes observed, or until death, in which case a full 
pathologist’s report should be supplied, if possible. The investigator’s assessment of 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 63 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
ongoing Adverse Events at the time of each subject’s last visit should be documented in 
the subject’s medical chart. 
7.1.4 Serious Adverse Events 
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any 
dose results in one or more of the following: 
 Death. 
 Is life-threatening (i.e., the subject was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred); it does not refer to an event 
which hypothetically might have caused death if it were more severe. 
 Required or prolonged hospitalization. 
 Persistent or significant disability/incapacity (i.e., the event causes a substantial 
disruption of a person’s ability to conduct normal life functions). 
 Congenital anomaly/or birth defect. 
 An important and significant medical event that may not be immediately life 
threatening or resulting in death or hospitalization but, based upon appropriate 
medical judgment, may jeopardize the subject or may require intervention to prevent 
one of the other outcomes listed above. 
Adverse events which do not fall into these categories are defined as non-serious. 
It should be noted that a severe adverse event need not be serious in nature and that a 
serious adverse event need not, by definition, be severe. 
Serious adverse events will be captured both on the Vaccines Serious Adverse Event 
(VSAE) form as well as on the AE CRF. All SAEs will be evaluated by the investigator 
for relationship of the event to study vaccine. SAEs that are judged to be possibly or 
probably related to the study vaccine should be reported to the Sponsor as 
related/suspected events. 
The relationship of the study treatment to an SAE will be determined by the investigator 
based on the following definitions: 
1. Related/suspected 
The SAE is judged by the investigator to be possibly or probably related to the study 
vaccine on the AE CRF page (see section 7.1.3, Evaluation of Adverse Events). 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 64 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
2. Not Related 
The SAE is not related if exposure to the study vaccine has not occurred, or the 
occurrence of the SAE is not reasonably related in time, or the SAE is considered 
unlikely to be related to use of the study vaccine, i.e., there are no facts (evidence) or 
arguments to suggest a causal relationship. 
The relationship of the study vaccine to an SAE will be determined by the investigator. 
In addition, SAEs will be evaluated by the Sponsor or designee for “expectedness.” An 
unexpected AE is one that is not listed in the current Summary of Product Characteristics 
or the Investigator’s Brochure or an event that is by nature more specific or more severe 
than a listed event. 
In addition, a pre-existing event or condition that results in hospitalization should be 
recorded on the Medical History CRF. If the onset of an event occurred before the subject 
entered the study (e.g., any pre-planned hospitalization for conditions like cosmetic 
treatments or for non-emergency routine visits for a pre-existing condition), the 
hospitalization would not lead to an AE being classified as serious unless, in the view of 
the investigator, hospitalization was prolonged as a result of participation in the clinical 
study or was necessary due to a worsening of the pre-existing condition. 
7.1.4.1 
Adverse Events of Special Interest 
Adverse events of special interest (AESIs) are predefined adverse events that will be 
specifically highlighted to the investigator and will be summarized separately at the end 
of the study. All AESIs occurring during the study will be categorized and reported as a 
SAE. 
Reactive arthritis (ReA) will be collected and analyzed as an AESI for this study.  
Reactive arthritis is defined as non-purulent joint inflammation that develops in response 
to an infection in another part of the body. Since the inflammation is triggered by a 
previous condition, it is termed “reactive”. Intestinal pathogens that have been associated 
with reactive arthritis include Campylobacter, Salmonella, Yersinia, Clostridium difficile, 
and Shigella. If reactive arthritis is caused by an auto immune response, there is at least a 
possibility that it could be initiated by vaccination of susceptible people with the 
1790GAHB vaccine. 
For diagnosis of ReA, imaging and aspiration are not required (unless clinically 
indicated). 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 65 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Neutropenia, a decrease of circulating neutrophils below the lower limit of the range of 
normality, will be collected and analyzed as an AESI for this study. To this purpose, as 
specified in the study procedures, subjects in this trial will have multiple blood draws for 
monitoring potential episodes of post vaccination neutropenia. For additional information 
on neutropenia, please refer to Section 3.7, Procedures Related To Neutropenia 
7.1.5 Methods for Recording Adverse Events and Serious Adverse Events 
Findings regarding Adverse Events must be reported on an Adverse Events CRF, as 
specified in section 7.1.1, Solicited Adverse Events, and on the VSAE form, if applicable, 
which is part of the Investigator Site File. All findings in subjects experiencing AEs must 
be reported also in the subject's source document. 
All SAEs which occur during the course of the study, whether considered to be associated 
with the study vaccination or not, must be reported within 24 hours of the site becoming 
aware of the event to GVGH or its designee. Specific instructions and contact details for 
collecting and reporting SAEs to GVGH will be provided to the investigator. 
All SAEs are also to be documented on the Adverse Events CRF. Any medication or 
other therapeutic measures used to treat the AE will be recorded on the appropriate 
CRF(s) in addition to the outcome of the AE. 
After receipt of the initial report, representatives of GVGH or its designee will contact the 
investigator if it is necessary to obtain further information for assessment of the event. 
All SAEs must be reported by the investigator to his/her IRB or applicable regulatory 
authorities in accordance with institutional policy/regulatory requirements and adequate 
documentation of this notification must be provided to the Sponsor. 
GVGH or its designee must also comply with the applicable regulatory requirement(s) 
related to the reporting of suspected unexpected serious adverse vaccine reactions (also 
known as SUSARs) to the regulatory authority(ies) and the IRB/EC. If a SUSAR or other 
safety signal relating to use of one of the study vaccines is reported to GVGH or its 
designee, the Sponsor will communicate the information to the investigator and the 
investigator will be responsible for submitting this information to the IRB and other 
relevant authorities. 
7.1.5.1 
Post-Study Events 
Any SAE that occurs outside of the protocol-specified follow-up period and considered to 
be caused by the study vaccine must be reported to GVGH or its designee. These SAEs 
will be processed by GVGH or its designee as during the course of the study, until 6 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 66 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
months after last subject last visit. Instructions and contact details for collecting and 
reporting these suspected SAEs will be provided to the investigator. 
7.1.6 Pregnancies 
To ensure subjects’ safety, each pregnancy in a subject after study vaccination must be 
reported to GVGH or delegate within 72 hours of the site learning of its occurrence. If the 
subject agrees to submit this information, the pregnancy must be followed to determine 
outcome, including spontaneous or voluntary termination, details of the birth, and the 
presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. This follow-up should occur even if intended duration of safety 
follow-up for the study has ended. 
Pregnancy data must be recorded on a Pregnancy Report CRF (initial report) and 
Pregnancy Follow-Up CRF (outcome report) and reported to GVGH or delegate. 
Instructions and contact details for submitting the Pregnancy CRFs will be provided to the 
investigator. 
Any pregnancy outcome meeting the definition of a SAE (see section 7.1.4, Serious 
Adverse Events) must also be reported on the VSAE Report Form. 
7.1.7 Safety Laboratory Measurements 
For list of safety laboratory measurement, refer to synopsis Table 3, Hematological, 
Haematochemical Blood Tests and Urinalysis Table. 
Safety laboratory measurement will be performed as described in Section 3.5, Collection 
of Clinical Specimens.  
Significant alterations in hematology, blood chemistry and urinalysis will be clinically 
assessed by the investigator’s medical judgment based on interpretation of deviations 
from institution’s normal values.  
Any abnormality in laboratory measurements classified as clinically significant must be 
reported in the Adverse Event CRF form. 
If a subject is to have blood drawn and/or urine testing for safety laboratory for repeat 
safety assessment (e.g., in case of markedly abnormal safety laboratory parameter), 
investigator’s medical judgment will be applied concerning values that would trigger 
reanalysis and frequency of repeats.  
Safety laboratory assessments will be performed at the site laboratory, and results of these 
tests will be recorded in the source documents and in the CRF.  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 67 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
7.2 
Efficacy Assessment 
This study has no efficacy measurements. 
7.3 
Immunogenicity Assessment 
The measure of immunogenicity used in this study i.e. IgG enzyme-linked 
immunosorbent assay (ELISA) in sera is standard, widely used and generally recognized 
as reliable, accurate, and relevant (able to describe the quality and extent of the immune 
response). The ELISA methodology used in this study has been adopted based on 
scientific consensus and has been deemed appropriate to describe the immune response 
against Shigella sonnei GMMA in this study. 
Testing will be conducted by a GVGH or designated laboratory in a blinded manner 
towards the treatment arm and the visit. 
The measure of immunogenicity used in this study is IgG ELISA against Shigella sonnei 
OAg. The serologic assays will be conducted on serum samples and will be performed by 
a GVGH or designated laboratory in a blinded manner towards the treatment arm and the 
visit. 
For reference of visits the measurements are taken, refer to section 3.5 and to the Clinical 
Specimen Laboratory Manual.

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 68 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8. 
STATISTICAL CONSIDERATIONS 
8.1 
Endpoints 
8.1.1 Primary Endpoint(s) 
8.1.1.1 
Primary Safety Endpoint(s) 
The safety profile of the two vaccine doses and control(s) will be assessed through 
measurement of the following:  
a. Number and percentage of subjects with solicited local and systemic adverse 
reactions during 7 days following each vaccination. 
b. Numbers and percentage of subjects with deviations from normal ranges of safety 
laboratory data after each vaccination.  
c. Number and percentage of subjects with reported unsolicited adverse events during 
28 days following each vaccination.  
d. Number and percentage of subjects with reported SAEs throughout the study 
duration. 
e. Number and percentage of subjects with reported reactive arthritis or neutropenia 
(AESIs). 
8.1.1.2 
Primary Efficacy Endpoint(s) 
The study does not have primary efficacy endpoint(s). 
8.1.1.3 
Primary Immunogenicity Endpoint(s) 
The study does not have primary immunogenicity endpoint(s). 
8.1.2 Secondary Endpoint(s) 
8.1.2.1 
Secondary Safety Endpoint(s) 
The study does not have secondary safety endpoint(s). 
8.1.2.2 
Secondary Efficacy Endpoint(s) 
The study does not have secondary efficacy endpoint(s), 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 69 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.1.2.3 
Secondary Immunogenicity Endpoint(s) 
The measures of the immunogenicity outcome, (i.e., the anti-LPS S. sonnei serum IgG), 
will include: 
a. IgG Geometric mean concentrations (GMCs) pre-vaccination (Day 1), 28 days after 1st 
vaccination and 28 days after 2nd vaccination, as determined by Enzyme-linked 
Immunosorbent Assay (ELISA), and applicable geometric mean ratios between post- and 
pre-vaccination samples. 
b. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination 
Seroresponse is aimed to define a significant increase in post vaccination samples based 
on the biological performance of this specific serology assay and it is defined as:  
- 
If the baseline value is greater than 50 ELISA Units (EU) then an increase of at 
least 50% in the post-vaccination sample as compared to baseline [i.e. ((Post-vac 
minus baseline)/baseline)100% ≥ 50%] 
- 
If the baseline value is less or equal to 50 EU then an increase of at least 25 EU in 
the post-vaccination sample as compared to baseline [i.e. (post-vac minus 
baseline) ≥ 25 EU] 
c. Number and percentage of subjects with titers post vaccination concentration ≥ 121 
for anti-LPS S. sonnei at 28 days after 1st vaccination and 28 days after 2nd vaccination 
d. IgG Geometric mean concentrations (GMCs) pre-vaccination (Day 1), 28 days after 1st 
vaccination and 28 days after 2nd vaccination by antibody titer at baseline (i.e., above vs. 
below the assay detection limit), as determined by Enzyme-linked Immunosorbent Assay 
(ELISA), and applicable geometric mean ratios between post- and pre-vaccination 
samples. 
e. Number and percentage of subjects with seroresponse for anti- LPS S. sonnei at 28 
days after 1st vaccination and 28 days after 2nd vaccination by antibody titer at baseline 
(i.e., above vs. below the assay detection limit).  
A post vaccination concentration ≥ 121 anti-LPS serum IgG units in the GVGH ELISA 
corresponds to a titer of 1:800 in the ELISA method used by Cohen et al. (Cohen et al., 
1989). This antibody level is the median antibody concentration of a set of 87 
convalescent subjects previously infected by S. sonnei. The value of 121 anti-LPS serum 
IgG units in the Novartis GVGH ELISA was determined by calibration against the Cohen 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 70 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
ELISA (i.e., the GVGH standard serum was tested in Cohen’s lab using the Cohen’s 
methodology) 
8.1.3 Exploratory Endpoint(s) 
8.1.3.1 
Exploratory Safety Endpoint(s) 
The study does not have exploratory safety endpoint(s). 
8.1.3.2 
Exploratory Efficacy Endpoint(s) 
The study does not have exploratory efficacy endpoint(s). 
8.1.3.3 
Exploratory Immunogenicity Endpoint(s) 
Other assays (including serum secretory IgA) might be done to further characterize the 
immune response to the study vaccine. 
8.2 
Success Criteria 
This is a Phase 2a trial and there is no pre-defined success criterion. 
8.2.1 Success Criteria for Primary Objective(s) 
Not applicable. 
8.2.1.1 
Success Criteria for Primary Safety Objective(s) 
Not applicable. 
8.2.1.2 
Success Criteria for Primary Efficacy Objective(s) 
Not applicable. 
8.2.1.3 
Success Criteria for Primary Immunogenicity Objective(s) 
Not applicable. The study does not have primary immunogenicity endpoint(s). 
8.2.2 Success Criteria for Secondary Objective(s) 
Not applicable. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 71 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.2.2.1 
Success Criteria for Secondary Safety Objective(s) 
Not applicable. The study doesn’t have secondary safety objectives. 
8.2.2.2 
Success Criteria for Secondary Efficacy Objective(s) 
Not applicable. The study doesn’t have secondary efficacy objectives. 
8.2.2.3 
Success Criteria for Secondary Immunogenicity Objective(s) 
This is a Phase 2a trial and there are no pre-defined success criteria for secondary 
immunogenicity objectives. 
8.3 
Analysis Sets 
8.3.1 All Enrolled Set 
All screened subjects who provide informed consent and provide demographic and/or 
baseline screening assessments, regardless of the subject’s randomization and treatment 
status in the study and received a Subject ID (where the first two digits identify the site 
number) 
8.3.2 All Exposed Set 
All subjects in the enrolled set who receive a study vaccination. 
8.3.3 Safety Set 
Solicited Safety Set (solicited local and systemic adverse events and other solicited 
adverse events) 
All subjects in the Exposed Set with any solicited adverse event data and/or indicators of 
solicited adverse events (e.g., use of analgesics/antipyretics). 
Unsolicited Safety Set (unsolicited adverse events) 
All subjects in the Exposed Set with unsolicited adverse event data. 
Overall Safety Set 
All subjects who are in the Solicited Safety Set and/or Unsolicited Safety Set. 
Subjects will be analyzed as “treated” (i.e., according to the vaccine a subject received, 
rather than the vaccine to which the subject may have been randomized). 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 72 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.3.4 Full Analysis Set (FAS) Immunogenicity Set 
Full Analysis Set Immunogenicity 
All subjects in the All Enrolled Set who are randomized, receive at least one study 
vaccination and provide immunogenicity data at data at relevant time points. 
- 
Received at least one study vaccination and provide immunogenicity data 28 days 
after 1st vaccination. (FAS 1 - day 28 after 1st vaccination) 
- 
Received at least one study vaccination and provide immunogenicity data 28 days 
after 2nd vaccination. (FAS 2 - day 28 after 2nd vaccination) 
In case of vaccination error, subjects in the FAS sets will be analyzed “as randomized” 
(i.e., according to the vaccine a subject was designated to receive, which may be different 
from the vaccine the subject actually received). 
8.3.5 Per Protocol (PP) Set Immunogenicity Set 
All subjects in the FAS Immunogenicity who: 
 Correctly receive the vaccine (i.e., receive the vaccine to which the subjects is 
randomized and at the scheduled time points). 
 Have no protocol deviations leading to exclusion (see section 8.3.8, Protocol 
Deviations) as defined prior to unblinding. 
 Are not excluded due to other reasons defined prior to unblinding or analysis (see 
section 8.3.8, Protocol Deviations) 
PPS are subsets of FAS and should be always defined even if the objectives do not 
require it. 
Examples for subjects excluded due to other reasons than protocol deviations are: 
- 
Subjects who withdrew informed consent. 
8.3.6 Other Analysis Sets 
Modified FAS 
The differences between FAS and Modified FAS are:  

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 73 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
- 
Subjects who received the same wrong vaccine at the two vaccinations will be 
analyzed in the vaccine the subject actually received (in the FAS they will be 
analyzed according to the vaccine the subject was designed to receive) 
- 
If a subject didn’t receive the vaccination but a blood sample after the vaccination 
visit (where subject didn’t receive the vaccination) was collected then subject will be 
excluded from the immunogenicity analysis for all visits after the vaccination visit. 
8.3.7 Subgroups 
Not applicable. 
8.3.8 Protocol Deviations 
A protocol deviation is any change, divergence, or departure from the study design or 
procedures of a study protocol. A protocol deviation may be a reason to remove data from 
an analysis set at the time of analysis. CSR-reportable protocol deviations will be defined 
as exclusionary from the analysis according to protocol objectives and endpoints, which 
will be specified in the statistical analysis plan. In some cases exclusion of data may be 
due to a reason other than a protocol deviation, e.g. early termination. 
8.4 
Statistical Analysis Plan 
8.4.1 Analysis of Demographic and Baseline Characteristics 
Descriptive statistics (mean, standard deviation, median, minimum and maximum) for, 
age, height and weight and BMI at enrolment will be calculated overall and by vaccine 
group. 
Distributions of subjects by sex and ethnic origin will be summarized overall and by 
vaccine group. 
8.4.2 Analysis of Primary Objective(s) 
8.4.2.1 
Analysis of Primary Safety Objective(s) 
The analysis of safety assessments in this study will include summaries of the following 
categories of safety data collected for each subject: 
 Vaccine exposure. 
 Solicited local and systemic adverse events. 
 Unsolicited adverse events. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 74 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
 Clinical Laboratory Investigations.  
8.4.2.1.1 Analysis of Extent of Exposure 
The frequencies and percentages of subjects with vaccinations will be summarized overall 
and by vaccine group. Data will be tabulated for the All Enrolled Set.  
8.4.2.1.2 Analysis of Solicited Local, Systemic and Other Adverse Events 
All solicited adverse events will be summarized according to defined severity grading 
scales.  
Frequencies and percentages of subjects experiencing each adverse event will be 
presented for each symptom severity. Summary tables showing the occurrence of any 
local or systemic adverse event overall and at each time point will also be presented. 
Post-vaccination solicited adverse events reported from day 1 to day 7 will be 
summarized for the intervals day 1-3, day 4-7, day 1-7 by maximal severity and by 
vaccine group. The severity of solicited local adverse events, including injection-site 
erythema and induration will be summarized according to categories based on linear 
measurement:  25 to 50 mm, 51 to 100 mm, >100mm. 
Injection site pain and systemic adverse events (except fever) occurring up to 7 days after 
each vaccination will be summarized according to “mild”, “moderate” or “severe”. 
Each solicited local and systemic adverse event will also be further summarized as “none” 
versus “any”. 
Implausible measurements (for further definition see statistical analysis plan) will be left 
out of the analysis. 
Use of antipyretics and analgesics will be summarized by frequency by type of use 
(prophylactic versus treatment) and percentage of subjects reporting use.  
Body temperature will be summarized by 0.5 °C increments from 36.0 °C up to ≥40 °C 
and will be broken down according by route of measurement. 
8.4.2.1.3 Analysis of Unsolicited Adverse Events 
This analysis applies to all adverse events occurring during the study, judged either as 
probably related, possibly related, or not related to vaccination by the investigator, 
recorded in AE CRF, with a start date on or after the date of first vaccination. AE starting 
prior to the first vaccination will only be listed. The original verbatim terms used by 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 75 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
investigators to identify adverse events in the CRFs will be mapped to preferred terms 
using the MedDRA dictionary. The adverse events will then be grouped by MedDRA 
preferred terms into frequency tables according to system organ class (SOC). 
All reported adverse events, as well as adverse events judged by the investigator as at 
least possibly related to study vaccine, will be summarized according to SOC and 
preferred term within SOC. These summaries will be presented by vaccination group. 
When an adverse event occurs more than once for a subject, the maximal severity and 
strongest relationship to the vaccine group will be counted. 
Separate summaries will be produced for the following categories: 
 Serious adverse events and adverse events of special interest. 
 Adverse events that are possibly or probably related to vaccine. 
 Adverse event leading to withdrawal. 
Data listings of all adverse events will be provided by subject. In addition, adverse events 
in the categories above will be provided as listed data. 
8.4.2.1.4 Analysis of Safety Laboratory Values 
The investigator must assess all safety laboratory results (see section 7.1.7). Clinically 
significant modifications in blood chemistry, hematology, and urinalysis test values will 
be assessed by medical judgment based on interpretation of deviations from the 
institution’s normal values. 
All laboratory safety data will be analyzed descriptively by vaccine group. Safety 
laboratory data will be shown in a 3 x 3 table by visit using categorization of laboratory 
values of hematological and haematochemical blood tests and urinalysis according to 
institutional normal reference range (below, within, above). 
8.4.2.2 
Analysis of Primary Efficacy Objective(s) 
This study does not include primary efficacy objectives. 
8.4.2.2.1 Statistical Hypotheses 
Not applicable.  
8.4.2.2.2 Analysis Sets 
Not applicable. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 76 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.4.2.2.3 Statistical Methods 
Not applicable. 
8.4.2.3 
Analysis of Primary Immunogenicity Objective(s) 
This study does not have primary immunogenicity objectives. 
8.4.2.3.1 Statistical Hypotheses 
Not applicable. 
8.4.2.3.2 Analysis Sets 
Not applicable. 
8.4.2.3.3 Statistical Methods 
Not applicable. 
8.4.3 Analysis of Secondary Objective(s) 
8.4.3.1 
Analysis of Secondary Safety Objective(s) 
This study does not have secondary safety objectives. 
8.4.3.1.1 Analysis of Extent of Exposure 
Not applicable. 
8.4.3.1.2 Analysis of Solicited Local, Systemic and Other Adverse Events 
Not applicable. 
8.4.3.1.3 Analysis of Unsolicited Adverse Events 
Not applicable. 
8.4.3.1.4 Statistical Hypotheses 
Not applicable. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 77 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.4.3.1.5 Analysis Sets 
Not applicable. 
8.4.3.1.6 Statistical Methods 
Not applicable. 
8.4.3.2 
Analysis of Secondary Efficacy Objective(s) 
This study does not have secondary efficacy objectives. 
8.4.3.2.1 Statistical Hypotheses 
Not applicable. 
8.4.3.2.2 Analysis Sets 
Not applicable. 
8.4.3.2.3 Statistical Methods 
Not applicable. 
8.4.3.3 
Analysis of Secondary Immunogenicity Objective(s) 
8.4.3.3.1 Statistical Hypotheses 
This Phase 2a safety and immunogenicity study is aimed to descriptively evaluate the 
safety and immunogenicity profiles of the study vaccines. No specific hypotheses are 
tested in this study.  
8.4.3.3.2 Analysis Sets 
The modified FAS will be the primary analysis set for the immunogenicity objective. 
8.4.3.3.3 Statistical Methods 
Analysis of continuous variables 
The ELISA concentrations will be logarithmically transformed (base10) (to fulfil the 
normal distribution assumption). GMC will be calculated, with their associated two-sided 
95% CIs, by exponentiating the corresponding log-transformed means and their 95% CI. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 78 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Additionally, within-subject GMRs will be computed for GMTs/GMCs at one month 
after first and second vaccination versus baseline (day 1). The GMRs and 95% CIs will be 
constructed by exponentiating the mean within-subject differences in log-transformed 
titers and the corresponding 95% CIs. 
Analysis of binary variables 
The number and percentages of subjects with seroresponse from baseline and with high 
antibody level after vaccination (i.e. post vaccination antibody level ≥ 121 IgG units in 
the GVGH ELISA), will be summarized. Two-sided 95% Clopper-Pearson CIs for the 
percentages will be computed. 
Titers below the limit of detection will be set to half that limit for the purposes of 
analysis. Missing values of immunogenicity will be excluded from analyses (i.e. 
complete-case analysis) since they are considered missing completely at random, i.e. not 
informative and with no impact on inferences.  
8.4.4 Analysis of Exploratory Objectives 
 Other assays, including serum secretory IgA, might be done to further characterize the 
immune response to the study vaccine. The analysis will be described in the statistical 
analysis plan. 
8.4.4.1 
Analysis of Exploratory Safety Objective(s) 
Not applicable. 
8.4.4.2 
Analysis of Exploratory Efficacy Objective(s) 
Not applicable. 
8.4.4.3 
Analysis of Exploratory Immunogenicity Objective(s) 
Not applicable. 
8.5 
Sample Size and Power Considerations of Primary Objectives 
No formal statistical sample size and power computations are performed since the 
objectives of the study are to descriptively assess the immunogenicity and safety of the 
investigational vaccine. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 79 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
8.6 
Interim Analysis 
 For up to 45 subjects, once they have completed the study, a group unblinded preliminary 
immunogenicity analysis and a blinded interim safety analysis will be performed. 
Individual subject results from preliminary analyses will not be made available to site and 
sponsor personnel until the end of the study. The results of these immunogenicity and 
safety analyses will not impact the conduct of the study, but will inform the planning of 
future studies with the same vaccine.

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 80 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
9. 
SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING 
Study monitoring and auditing will be standardized and performed in accordance with the 
Sponsor’s or delegated contract research organization’s (CRO) standard operating 
procedures and applicable regulatory requirements (e.g., FDA, EMA, and ICH 
guidelines). 
Prior to enrolment of the first study subject, GVGH or delegate will train investigators 
and/or their study staff on the study protocol, all applicable study procedures, 
documentation practices and all electronic systems. CRFs supplied by the Sponsor must 
be completed for each enrolled subject (see section 8.3.1, All Enrolled Set for definition 
of enrolled subject). Documentation of screened but not enrolled subjects must be 
maintained at the site and made available for review by the site monitor. Data and 
documents will be checked by the Sponsor and/or monitor. 
9.1 
Source Documentation 
Prior to the start of the study, the site staff participating in the study conduct will be 
instructed on what documents will be required for review as source documents. The kinds 
of documents that will serve as source documents will be agreed between Sponsor or 
delegate and investigator and designees and specified in the SDA prior to subject 
enrolment. 
In addition, source documentation must include all of the following: subject identification 
(on each page), eligibility and participation, proper informed consent procedures, dates of 
visits, adherence to protocol procedures, adequate reporting and follow-up of adverse 
events, documentation of prior/concomitant medication/vaccines, study vaccine 
receipt/dispensing/return records, study vaccine administration information, any data 
collected by a conversation with the subject and date of completion and reason. 
The subject must also allow access to the subject’s medical records. Each must be 
informed of this prior to the start of the study and consent for access to medical records 
may be required in accordance with local regulations. 
All safety data reported by subjects must be written down in source documents prior to 
entry of the data into CRFs. If there are multiple sources of information (e.g., verbal 
report of the subject, telephone contact details, medical chart) supporting the diagnosis of 
an adverse event, these sources must be identified in the source documents, discrepancies 
between sources clarified, the ultimate diagnosis must be justified and written in the 
source documents, and this diagnosis must be captured in the Adverse Event CRF (AE 
CRF). The AE CRF must also capture which source(s) of information were used to 
determine the adverse event (e.g., subject recall, medical chart). 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 81 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
9.2 
Study Monitoring, Auditing and Source Data Verification 
Prior to enrolment of the first study subject, GVGH or its designee (e.g., a CRO) will 
develop a Clinical Monitoring Plan (or comparable documentation) to specify how 
centralized and/or on-site monitoring, including clinical specimens reconciliation, will be 
performed for the study. Study progress will be monitored by GVGH or its designee as 
frequently as necessary to ensure: 
 that the rights and well-being of human subjects are protected, 
 the reported study data are accurate, complete, and verifiable from the source 
documents and 
 the conduct of the study is in compliance with the current approved 
protocol/amendment(s), GCP and applicable regulatory requirements. 
Contact details for the GVGH team or its designee involved in study monitoring will be 
provided to the investigator. Study data recorded on CRFs will be verified by checking 
the CRF entries against source documents in order to ensure data completeness and 
accuracy as required by study protocol except for those parameters which are specifically 
described in section 7, Assessment being entered directly into the EDC system. 
Data verification may also be performed through a centralized review of data (e.g., 
checking for outliers or other anomalies). Additional documents such as the investigator 
site file, pharmacy records, and informed consent documentation must also be available 
for review if requested. Arrangements for monitoring visits will be made in advance in 
accordance with the monitoring plan, except in case of emergency. 
The investigator and/or site staff must make source documents of subjects enrolled in this 
study available for inspection by GVGH or its representative at the time of each 
monitoring visit and Sponsor audits, when applicable. These documents must also be 
available for inspection, verification and copying, as required by regulations, by officials 
of the regulatory health authorities (e.g., FDA, EMA and others) and/or ECs/IRBs. The 
investigator and study site staff must comply with applicable privacy, data protection and 
medical confidentiality laws for use and disclosure of information related to the study and 
enrolled subjects. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 82 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
10. 
DATA MANAGEMENT 
10.1 
Data Entry and Management 
In this study, all clinical data (including, but not limited to, AE/SAEs, concomitant 
medications, medical history, and physical assessments), safety data, and immunogenicity 
data will be entered onto case report forms (CRFs) in a timely fashion by the investigator 
and/or the investigator’s dedicated site staff. Data entered onto CRFs are stored on a 
secure website. The data collected on this secure website are assimilated into an 
electronic data capture (EDC) system, which is compliant with Title 21 Part 11 policies of 
the Code of Federal Regulations (FDA 1997). The data system includes password 
protection and internal quality checks. The EDC system will be designed and validated by 
the Sponsor prior to activation for data entry by sites. The investigator or designated 
delegate must review data entered and electronically sign the CRFs to verify their 
accuracy. 
Access to the EDC system for data entry or review will require training and distinct 
individual access code assignments to those site staff members who will be entering study 
data and those involved in study oversight who may review study data. Data are collected 
within the EDC system, to which the Sponsor and site monitors have exclusively “read 
only” access. 
10.2 
Data Clarification 
As part of the conduct of the trial, the Sponsor may have questions about the data entered 
by the site, referred to as queries. The monitors and the Sponsor are the only parties that 
can generate a query. All corrections and clarifications will be entered into the EDC 
system and will be identified by the person entering the information, the reason for the 
change, as well as the time of the changes made. If changes are made to a previously and 
electronically signed CRF, the investigator must confirm and endorse the changes. 
10.3 
Data Protection 
GVGH respects the subjects’ rights to privacy and will ensure the confidentiality of their 
medical information in accordance with all applicable laws and regulations. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 83 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
11. 
RECORD RETENTION 
Investigators must retain all study records required by GVGH and by the applicable 
regulations in a secure and safe facility. The investigator must consult a GVGH 
representative before disposal of any study records, and must notify the Sponsor of any 
change in the location, disposition, or custody of the study files. Essential documents 
must be retained for 15 years. “Essential documents” are defined as documents that 
individually and collectively permit evaluation of the conduct of a study and the quality 
of the data produced. These documents should be retained for a longer period, however, if 
required by the applicable national regulatory or institutional requirements.  
These principles of record retention will also be applied to the storage of laboratory 
samples, provided that the integrity of the stored sample permits testing. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 84 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
12. 
USE OF INFORMATION AND PUBLICATION 
GVGH assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov, and in compliance with current regulations. 
GVGH also assures that key results of this clinical study will be posted in a publicly 
accessible database within the required time-frame from the end of study as defined in 
section 3.9, End of Study. 
In accordance with standard editorial, ethical practices and current guidelines of Good 
Publication Practice (Graf 2009), GVGH will generally support publication of multicenter 
studies only in their entirety and not as individual center data. In this case, a coordinating 
investigator will be designated by mutual agreement prior to the start of the study. The 
coordinating investigator will also sign the clinical study report on behalf of the principal 
investigators (CPMP/EWP/2747/00). Authorship will be determined by mutual agreement 
and in line with International Committee of Medical Journal Editors authorship 
requirements. Any formal publication of the study in which contribution of GVGH 
personnel exceeded that of conventional monitoring will be considered as a joint 
publication by the investigator and the appropriate GVGH personnel. 
GVGH must be notified of any intent to publish data collected from the study and prior 
approval from GVGH must be obtained prior to submission for publication. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 85 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
13. 
ETHICAL CONSIDERATIONS 
13.1 
Regulatory and Ethical Compliance 
The study will be conducted in compliance with the protocol, GCP and applicable 
regulatory requirement(s). 
This clinical study was designed and shall be implemented and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations and with the ethical principles laid down in the Declaration of 
Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997). 
For each scheduled study visit (Screening visit and Visit 1 to 5) subjects will be 
reimbursed Kenyan Shillings (KSh) 1,000 per visit as follows: 
- KSh 500 for daily lost wages and time spent at study clinic;  
- KSh 300 for the cost of transportation;  
- KSh 200 for food.  
 
In case of acute illness, subjects will receive free medical care. Subjects who will develop 
chronic conditions will be referred to the respective Ministry of Health clinic for further 
management and follow-up. 
 
13.2 
Informed Consent Procedures 
Eligible subjects may only be included in the study after providing written informed 
consent, as described in section 5.1.1, Informed Consent/Assent. Before the start of the 
study, the investigator will have the informed consent and any other materials that will be 
provided to the subjects reviewed and approved by the IRB/EC. This review and approval 
will be documented and stored with other study documents. The investigator or designee 
must fully inform the subject or legal guardian of all pertinent aspects of the study. A 
copy of the written informed consent will be given to the subject or the designee. The 
subject/designee must be allowed ample time to ask about the details of the study and to 
make a decision as to whether or not to participate in the study. The subject must sign the 
consent form indicating their agreement to participate in the study before any study-
related procedures are conducted. If the subject is unable to read and write, a witness must 
be present during the informed consent discussion and at the time of informed consent 
signature. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 86 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Prior to the start of the study, GVGH will provide to investigators a proposed informed 
consent form that complies with the ICH GCP guideline and regulatory requirements and 
is considered appropriate for this study. Any changes to the proposed consent form 
suggested by the investigator must be agreed to by GVGH before submission to the 
IRB/EC and a copy of the approved version must be provided to the GVGH monitor after 
IRB/EC approval. 
Women of childbearing potential should be informed that taking the study medication 
may involve unknown risks to the fetus if pregnancy were to occur during the study and 
agree that in order to participate in the study they must adhere to the contraception 
requirements indicated in the protocol for the duration of the study. If case of doubts on 
the ability of a subject to adhere to these requirements, that subject should not be allowed 
in the study.  
13.3 
Responsibilities of the Investigator and IRB/EC 
The protocol and the proposed informed consent form must be reviewed and approved by 
a properly constituted IRB/EC before study start. Properly constituted IRB/EC is defined 
in ICH Guideline for Good Clinical Practice E6 (R1), Section 3 (ICH 1997). A signed and 
dated statement that the protocol and informed consent have been approved by the 
IRB/EC must be given to GVGH before study initiation. Prior to study start and at any 
time the protocol is amended during study conduct, the investigator is required to sign a 
protocol signature page confirming his/her agreement to conduct the study in accordance 
with these documents and all of the instructions and procedures found in this protocol and 
to give access to all relevant data and records to GVGH monitors, auditors, GVGH 
Clinical Quality Assurance representatives, designated agents of GVGH, IRBs/ECs, and 
regulatory authorities as required. If an inspection of the clinical site is requested by a 
regulatory authority, the investigator must inform GVGH immediately that this request 
has been made. 
The investigator also responsible for the following: 
 Maintaining a list of appropriately qualified persons to whom the investigator has 
delegated significant study-related duties. 
 Demonstrating the capability of recruiting the required number of suitable subjects 
within the recruitment period. 
 Demonstrating sufficient time and staffing to properly conduct and complete the study 
within the agreed study period. 
 Ensuring that all persons assisting with the study are adequately informed about the 
protocol, the investigational product(s), and their study-related duties and functions 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 87 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
 Ensuring that appropriately trained health care professionals are responsible for all 
study-related medical decisions and for ensuring appropriate medical care of subjects 
experiencing any adverse event related to the study. 
The investigator should not implement any deviation from, or changes of the protocol 
without agreement by the Sponsor and prior review and documented approval/favourable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an 
immediate hazard(s) to study subjects, or when the change(s) involves only logistical or 
administrative aspects of the study (e.g., change in monitor(s), change of telephone 
number(s)). In addition, the investigator, or person designated by the investigator, should 
document and explain any deviation from the approved protocol. 
The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior IRB/IEC 
approval/favourable opinion. As soon as possible, the implemented deviation or change, 
the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be 
submitted: 
(a) to the IRB/IEC for review and approval/favourable opinion, 
(b) to the Sponsor for agreement and, if required, 
(c) to the regulatory authority(ies). 
13.4 
Protocol Amendments 
An amendment is a written description of change(s) to or formal clarification of a study 
protocol which may impact on the conduct of the clinical study, potential benefit of the 
clinical study, or may affect subject safety, including changes of study objectives, study 
design, subject population, sample sizes, study procedures, or significant administrative 
aspects. An administrative change of a study protocol is a minor correction or 
clarification that has no significant impact on the way the clinical study is to be conducted 
and no effect on subject safety (e.g., change of telephone number(s), logistical changes). 
Protocol amendments must be approved by GVGH, health authorities where required, and 
the IRB/EC. In cases when the amendment is required in order to protect the subject 
safety, the amendment can be implemented prior to IRB/EC approval. Notwithstanding, 
the need for formal approval of a protocol amendment, the investigator is expected to take 
any immediate action required for the safety of any subject included in this study, even if 
this action represents a deviation from the protocol. In such cases, GVGH should be 
notified of this action, the IRB/EC at the study site, and, if required by local regulations, 
the relevant health authority) should be informed within 10 working days. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 88 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
14. 
REFERENCE LIST 
Badenhorst, C. J., Fourie, J., Steyn, K., Jooste, P. L., Lombard, C. J., Bourne, L. & 
Slazus, W. 1995. The Haematological Profile Of Urban Black Africans Aged 15-64 Years 
In The Cape Peninsula. East Afr Med J, 72, 19-24. 
Bardhan, P., Faruque, A. S., Naheed, A. & Sack, D. A. 2010. Decrease In Shigellosis-
Related Deaths Without Shigella Spp.-Specific Interventions, Asia. Emerg Infect Dis, 16, 
1718-23. 
Berlanda Scorza, F., Colucci, A. M., Maggiore, L., Sanzone, S., Rossi, O., Ferlenghi, I., 
Pesce, I., Caboni, M., Norais, N., Di Cioccio, V., Saul, A. & Gerke, C. 2012. High Yield 
Production Process For Shigella Outer Membrane Particles. Plos One, 7, E35616. 
Beveridge, T. J. 1999. Structures Of Gram-Negative Cell Walls And Their Derived 
Membrane Vesicles. J Bacteriol, 181, 4725-33. 
Cohen, D., Ashkenazi, S., Green, M. S., Gdalevich, M., Robin, G., Slepon, R., Yavzori, 
M., Orr, N., Block, C., Ashkenazi, I., Shemer, J., Taylor, D. N., Hale, T. L., Sadoff, J. C., 
Pavliakova, D., Schneerson, R. & Robbins, J. B. 1997. Double-Blind Vaccine-Controlled 
Randomised Efficacy Trial Of An Investigational Shigella Sonnei Conjugate Vaccine In 
Young Adults. Lancet, 349, 155-9. 
Cohen, D., Block, C., Green, M. S., Lowell, G. & Ofek, I. 1989. Immunoglobulin M, A, 
And G Antibody Response To Lipopolysaccharide O Antigen In Symptomatic And 
Asymptomatic Shigella Infections. J Clin Microbiol, 27, 162-7. 
Ezeilo, G. C. 1972. Non-Genetic Neutropenia In Africans. Lancet, 2, 1003-4. 
Karita, E., Ketter, N., Price, M. A., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, 
O., Jaoko, W., Mutua, G., Ruzagira, E., Mulenga, J., Sanders, E. J., Mwangome, M., 
Allen, S., Bwanika, A., Bahemuka, U., Awuondo, K., Omosa, G., Farah, B., Amornkul, 
P., Birungi, J., Yates, S., Stoll-Johnson, L., Gilmour, J., Stevens, G., Shutes, E., Manigart, 
O., Hughes, P., Dally, L., Scott, J., Stevens, W., Fast, P. & Kamali, A. 2009. Clsi-Derived 
Hematology And Biochemistry Reference Intervals For Healthy Adults In Eastern And 
Southern Africa. Plos One, 4, E4401. 
Kotloff, K. L., Winickoff, J. P., Ivanoff, B., Clemens, J. D., Swerdlow, D. L., Sansonetti, 
P. J., Adak, G. K. & Levine, M. M. 1999. Global Burden Of Shigella Infections: 
Implications For Vaccine Development And Implementation Of Control Strategies. Bull 
World Health Organ, 77, 651-66. 

GSK Vaccines Institute for Global Health 
 
Protocol H03_04TP 
03 NOV 16 Version 4.0 
Confidential 
Page 89 of 89 
PRO-01 TEMP 06 / Atlas No. 293620 
Version No.4 / Version Date: January 29, 2015 
Levine, M. M., Kotloff, K. L., Barry, E. M., Pasetti, M. F. & Sztein, M. B. 2007. Clinical 
Trials Of Shigella Vaccines: Two Steps Forward And One Step Back On A Long, Hard 
Road. Nat Rev Microbiol, 5, 540-53. 
Livio, S., Strockbine, N. A., Panchalingam, S., Tennant, S. M., Barry, E. M., Marohn, M. 
E., Antonio, M., Hossain, A., Mandomando, I., Ochieng, J. B., Oundo, J. O., Qureshi, S., 
Ramamurthy, T., Tamboura, B., Adegbola, R. A., Hossain, M. J., Saha, D., Sen, S., 
Faruque, A. S., Alonso, P. L., Breiman, R. F., Zaidi, A. K., Sur, D., Sow, S. O., Berkeley, 
L. Y., O'reilly, C. E., Mintz, E. D., Biswas, K., Cohen, D., Farag, T. H., Nasrin, D., Wu, 
Y., Blackwelder, W. C., Kotloff, K. L., Nataro, J. P. & Levine, M. M. 2014. Shigella 
Isolates From The Global Enteric Multicenter Study Inform Vaccine Development. Clin 
Infect Dis, 59, 933-41. 
Lugada, E. S., Mermin, J., Kaharuza, F., Ulvestad, E., Were, W., Langeland, N., Asjo, B., 
Malamba, S. & Downing, R. 2004. Population-Based Hematologic And Immunologic 
Reference Values For A Healthy Ugandan Population. Clin Diagn Lab Immunol, 11, 29-
34. 
Passwell, J. H., Ashkenazi, S., Harlev, E., Miron, D., Ramon, R., Farzam, N., Lerner-
Geva, L., Levi, Y., Chu, C., Shiloach, J., Robbins, J. B., Schneerson, R. & Israel Shigella 
Study, G. 2003. Safety And Immunogenicity Of Shigella Sonnei-Crm9 And Shigella 
Flexneri Type 2a-Repasucc Conjugate Vaccines In One- To Four-Year-Old Children. 
Pediatr Infect Dis J, 22, 701-6. 
Passwell, J. H., Ashkenzi, S., Banet-Levi, Y., Ramon-Saraf, R., Farzam, N., Lerner-Geva, 
L., Even-Nir, H., Yerushalmi, B., Chu, C., Shiloach, J., Robbins, J. B. & Schneerson, R. 
2010. Age-Related Efficacy Of Shigella O-Specific Polysaccharide Conjugates In 1-4-
Year-Old Israeli Children. Vaccine, 28, 2231-5. 
Zhang, W., Luo, Y., Li, J., Lin, L., Ma, Y., Hu, C., Jin, S., Ran, L. & Cui, S. 2011. Wide 
Dissemination Of Multidrug-Resistant Shigella Isolates In China. J Antimicrob 
Chemother, 66, 2527-35.